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Abstract

Atrial fibrillation (AF), the most common and clinically significant heart rhythm disorder,
is characterized by rapid and irregular electrical activity in the upper chambers resulting in
abnormal contractions. Radiofrequency (RF) cardiac catheter ablation is a minimally
invasive curative treatment that aims to electrically correct signal pathways inside the atria
to restore normal sinus rhythm. Successful catheter ablation requires the complete and
permanent elimination of arrhythmogenic signals by delivering transmural RF ablation
lesions contiguously near and around critical cardiac structures. These procedures are
complex and technically challenging and, even when performed by the most skilled
physician, nearly half of patients undergo repeat procedures due to incomplete elimination
of the arrhythmogenic pathways. This thesis aims to incorporate innovative design to
improve catheter stability and maneuverability through the development of robotic
platforms that enable precise placement of reproducibly durable ablation lesions.
The first part of this thesis deals with the challenges to lesion delivery imposed by
cardiorespiratory motion. One of the main determinants of the delivery of durable and
transmural RF lesions is the ability to define and maintain a constant contact force between
the catheter tip electrode and cardiac tissue, which is hampered by the presence of
cardiorespiratory motion. To address this need, I developed and evaluated a novel catheter
contact-force control device. The compact electromechanical add-on tool monitors
catheter-tissue contact force in real-time and simultaneously adjusts the position of a force-
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sensing ablation catheter within a steerable sheath to compensate for the change in contact
force. In a series of in vitro and in vivo experiments, the contact-force control device
demonstrated an ability to: a) maintain an average force to within 1 gram of a set level; b)
reduce contact-force variation to below 5 grams (2-8-fold improvement over manual
catheter intervention); c) ensure the catheter tip never lost contact with the tissue and never
approached dangerous force levels; and importantly, d) deliver reproducible RF ablation
lesions regardless of cardiac tissue motion, which were of the same depth and volume as
lesions delivered in the absence of tissue motion.
In the second part of the thesis, I describe a novel steerable sheath and catheter robotic
navigation system, which incorporates the catheter contact-force controller. The robotic
platform enables precise and accurate manipulation of a remote conventional steerable
sheath and permits catheter-tissue contact-force control. The robotic navigation system was
evaluated in vitro using a phantom that combines stationary and moving targets within an
in vitro model representing a beating heart. An electrophysiologist used the robotic system
to remotely navigate the sheath and catheter tip to select targets and compared the accuracy
of reaching these targets performing the same tasks manually. Robotic intervention resulted
in significantly higher accuracy and significantly improved the contact-force profile
between the catheter tip and moving tissue-mimicking material.
Our studies demonstrate that using available contact-force information within a robotic
system can ensure precise and accurate placement of reliably transmural RF ablation
lesions. These robotic systems can be valuable tools used to optimize RF lesion delivery
techniques and ultimately improve clinical outcomes for AF ablation therapy.

Keywords
Catheter Ablation, Catheter Navigation, Radiofrequency Ablation, Contact-Force Control,
Robotic Catheter Navigation System, Mechatronics, Linear Control Systems

iii

Summary for Lay Audience

Atrial Fibrillation (AF) is a common heart rhythm disorder often treated using catheters
inserted in the heart to “burn” the tissue responsible for the arrhythmia (i.e. to make
lesions). Radiofrequency (RF) catheter ablation strategies to treat AF are complex,
technically challenging, and require a high degree of skill and physical effort. Furthermore,
the motion of the heart as it beats and the patient breathes can affect the contact the catheter
tip makes with the heart during the therapy delivery. This makes it very difficult for the
physician to deliver lesions effectively. Because of these problems, it is not uncommon
that lesions are delivered inadequately, leaving untreated tissue that can result in the
recurrence of AF symptoms. Currently, nearly half of all patients return for a second
procedure.
To avoid repeat procedures, ablation lesions must be precisely placed in specific locations
within the heart chamber – lesions must be adjacent to one another and share a common
border. Additionally, these lesions must be reliably durable and cover the entire heart-wall
thickness. One key element that governs lesion production is stable contact force between
the catheter tip and heart tissue. With the advent of force-sensing ablation catheters,
physicians can monitor the amount of force the catheter makes with the tissue in real-time.
However, physicians are limited in controlling the force and have no way to improve force
stability and keep it constant during RF delivery.
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My thesis describes the development and evaluation of two novel robotic technologies
designed to address these problems. Specifically, I introduce the Catheter Contact-Force
Controller (CFC) and the Steerable Sheath and Catheter Robotic Navigation System (SSCRNS). These platforms are used in conjunction with standard, commercially available
ablation instruments to provide automated catheter-tissue contact-force control and precise
remote catheter navigation. I discuss their design and development as well as how these
systems performed on a lab-bench and in pre-clinical studies. I show that the CFC is
effective in stabilizing the force during lesion delivery, resulting in uniform lesions despite
the presence of motion. Use of the SSC-RNS led to improved location accuracy of catheter
navigation compared to manual procedures.
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Introduction and Background

This introductory section provides a brief overview of relevant background information
relating to the research described in the following chapters. This section also describes
atrial fibrillation, cardiac catheter ablation, the current state-of-the-art tools and
technologies used in the clinic. The proposed robotic systems designed to address the
current challenges associated with current catheter ablation strategies are also discussed.

1.1

Atrial Fibrillation

Atrial fibrillation (AF), the most common and clinically significant cardiac arrhythmia, is
a heart rhythm disorder characterized by chaotic electrical activity in the upper chambers
(atria) of the heart. False electrical signals are generated from different parts within the
atria causing abnormal contractions, resulting in a rapid and irregular heartbeat that can
occur in episodes or last permanently [1]. During an AF episode, a surface
electrocardiogram (ECG) will typically illustrate an irregular R-R interval and the absence
of a distinct P-wave, as illustrated in Figure 1.1 [2, 3]. AF is typically categorized as either:
paroxysmal defined as recurrent that resolves within seven days; persistent defined as
continuous AF that is sustained beyond seven days; long-standing persistent defined by
continuous AF sustained beyond 12 months; or, permanent if treatment has failed or has
been discontinued [4].
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Figure 1.1. In comparison to a normal sinus rhythm A, a surface ECG
of AF B will illustrate an irregular R-R interval and the absence of a
distinct P-wave (red).

In North America, Europe, and Asia, the current estimated prevalence of AF is between
1% to 4% [5, 6]. In the ATRIA study, within a large and ethnically diverse population, they
found that 1% of all adults were diagnosed with AF, and nearly 4% of individuals 60 years
and older and 9% of individuals 80 years or older being diagnosed [7]. In addition to
increasing age, the probability of developing AF is also influenced by inherited and
acquired risk factors [8, 9]. Current estimates reveal that globally, 33 million people have
some form of AF [10]. Reflecting the increasing proportions of the elderly, this number is
projected to increase 2-4-fold by 2050 [7, 11, 12].
The healthcare burden associated with AF has increased and is expected to continue rising.
In the United States, AF accounts for more than 479,000 hospitalizations yearly and has
contributed to more than 130,000 deaths [13]. AF has been reported to increase the annual
healthcare cost by USD 8,705 per patient resulting in between USD 6B and USD 26B per
year in additional US healthcare costs [14]. In Canada, each AF patient costs CAD 6,718
attributing to CAD 815M [15]. The reported costs are based on databases collected between
2011 and 2013 and likely have increased significantly since its reporting. AF already has
demonstrated tremendous implications on the global economy and public health [16] and
this situation is rapidly becoming worse.
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Clinically, the most critical complication associated with AF lies in the risk of cardiac
thrombus formation. Because of this, AF is a strong independent risk factor for embolic
strokes [17-19]. On average, AF increases the risk of stroke 5-fold [20], and strokes of AFrelated etiology are twice as likely to be fatal in comparison to non-AF related strokes [21].
Estimates show that AF causes one-third of all strokes after the age of 60. In addition to
age above 60, other significant risk factors of AF-related stroke include female sex, prior
stroke, congestive heart failure, diabetes, and hypertension [22, 23].
The root causes of AF are unclear, but many concepts explaining its mechanism have been
speculated: multiple re-entrant wavelets, rapidly discharging automatic foci, and a single
re-entrant circuit with fibrillatory conduction [1]. Substantial progress has been made in
understanding and defining the mechanisms underlying AF initiation and progression [24,
25]. It was recognized that AF is triggered or maintained by rapidly firing foci entering the
left atrium (LA) originating from the cardiac muscle cells extending within the walls of the
pulmonary veins (PVs). To this end, AF can be treated permanently with local catheter
ablation near the PVs [26, 27].

1.2

Catheter Ablation

Cardiac catheter ablation is a minimally invasive curative treatment that aims to isolate the
PVs from the atria electrically. Radiofrequency (RF) energy is delivered to cardiac tissue
using an electrophysiology ablation catheter, resulting in the production of an ablation
lesion.
A catheter ablation procedure begins with a small incision made in the groin, allowing a
guidewire to be advanced to the right side of the heart via the femoral vein. A trans-septal
puncture, guided by fluoroscopy and ultrasound, is performed through the fossa ovalis to
gain access to the left atrium. An RF ablation catheter can then be introduced and
manipulated within the cardiac chamber (Figure 1.2). Using a variety of modalities and
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catheter navigation technologies (such as fluoroscopy and electromagnetic guidance), an
electrophysiologist (EP) manipulates the catheter to specific targets in the LA and delivers
numerous contiguous RF “applications” into the tissue.

Figure 1.2. The catheter is introduced into the left femoral vein and fed
up to the right atrium (RA) via the inferior vena cava (IVC). A transseptal puncture through the fossa ovalis (FO) allows the catheter to be
introduced into the left atrium (LA) and deliver RF ablation lesions near
the pulmonary veins (PV). The right and left ventricles (RV and LV,
respectively) are not illustrated. This line drawing was adapted from
Calkins et al. [1].

An ablation catheter is a long and flexible medical device consisting of a proximal handle,
which allows the EP to insert, withdraw, and rotate an RF electrode tip within the patient’s
heart. A deflection mechanism on the handle applies tension to pull-wires within the
catheter lumen resulting in the deflection (or bending) of the catheter tip along one, two,
or four orthogonal angles, as illustrated in Figure 1.3.
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Figure 1.3. An ablation catheter consists of a proximal handle connected
to a long and flexible tube, which houses various lumens, electrical
wires, and pull-wires. An operator can insert, withdraw, and rotate an RF
electrode (located at the very tip of the catheter) to make contact with
cardiac tissue and deliver RF energy. A uni- or bi-directional mechanism
on the handle deflects the distal tip (shown in red). The catheter tip
incorporates electromagnetic location sensors, and electrodes used for
delivering RF energy, recording intracardiac ECG, and cardiac pacing.
Ablation catheters also include an irrigation line, which allows saline to
be pumped continuously to cool the electrode during RF delivery.

Precisely placing transmural (across the thickness of the tissue) ablations lesions near the
PVs blocks the electrical signals from disturbing the normal sinus rhythm of the heart. A
common strategy employed in AF ablation is to deliver contiguous lesions encircling the
ostia of the PVs. This procedure is known as pulmonary vein isolation (PVI), whose goal
is to electrically isolate the left and right pairs of PVs from the LA [1]. The circumferential
ablation lesions performed during PVI can be followed with additional ablation sets, as
illustrated in Figure 1.4.
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Figure 1.4. Line illustration represents the LA from the posterior
perspective. PVI requires the precise placement of contiguous
circumferential ablation lesions encircling the right and left PV pairs
(red). The left PV pair includes left superior and inferior pulmonary
veins (LSPV and LIPV, respectively), while the right PV pair consists of
the right superior and inferior pulmonary veins (RSPV and RPIV,
respectively). Other standard ablation lines include: a roof line
connecting the left and right circumferential lesions (purple) and a
corresponding inferior ablation line (yellow) resulting in a complete
isolation the posterior wall; linear lesions between each PV pair (blue);
and a mitral isthmus ablation line connect the left PV pair with the mitral
valve (green). This line drawing was adapted from Calkins et al. [1].

To facilitate catheter navigation, modern catheter labs are equipped with electroanatomical mapping (EAM) systems, which have led to a paradigm shift in treating patients
with cardiac arrhythmia. EAM systems are used to define the mechanisms of arrhythmias,
design ablation strategies, guide ablations, and improve safety by identifying critical
cardiac structures. While manipulating the catheter in the cardiac chamber, its position and
orientation are monitored by a low-field magnetic generator, which locates electromagnetic
sensors incorporated within the catheter tip with sub-millimetre accuracy (Figure 1.5). In
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addition to the primary ablation catheter, EPs can use a mapping catheter (taking the form
of a lasso or paintbrush) to capture the 3D anatomical structure of the heart and determine
the ECG at any mapped point in the cardiac chamber. By gating the acquisition of points
to the cardiac electrical activity, points that represent both location and its corresponding
electrical activity are acquired. A 3D representation is constructed and displayed to the EP.
EAM systems allow for further understanding of arrhythmias and increase the safety,
efficacy, and efficiency of catheter ablation, which has helped decrease procedural
complexity and procedure time [28, 29].
Despite decades of intensive research and innovation, resulting in an arsenal of tools
available to the EP, long-term results of catheter ablation demonstrate a high rate of
recurrence following the first procedure. Early recurrences of AF, occurring after a 3month blanking period post-ablation, have been reported in up to 50% to 70% of patients
[30-33]. The low efficacy rate of first-procedure clinical success is likely due to the
inability to create transmural and durable lesions in a contiguous fashion, ultimately
resulting in the reconnection of the PVs with the LA. In these cases, a repeat procedure is
performed in an attempt to re-isolate the PVs. With multiple procedures, the long-term
success rate can be improved to 80% overall. It has been reported that, on average, each
AF patient undergoes 1.5 ablation treatment to restore normal sinus rhythm [33].
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Figure 1.5. A typical modern EP lab is equipped with an EAM system
which captures the location of the catheter tip using an electromagnetic
field generator located under the chest of the patient A. Other equipment
includes an RF generator and irrigation pump, a system for recording
ECG signals, and fluoroscopic x-ray system (not shown). The EAM
system is on display in front of the EP B. The EP can track the position
of the tip of the ablation catheter (green arrow) in relation to a map of
the patient’s cardiac chamber and monitor the real-time catheter-tissue
contact force (green square) between the tip and moving cardiac tissue.
An additional mapping catheter (orange arrow), in the form of a
paintbrush, is used to collect intracardiac ECG. The EAM system is also
used to plan and guide ablation lines (white arrow) and track the
locations of previously delivered lesions (red arrows).
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Non-ablative strategies to treat AF includes the use of antiarrhythmic drugs. Three
prospective randomized clinical trials have examined the efficacy of ablation as the first
treatment versus antiarrhythmics [34-36]. A meta-analysis summarizing those trials [37],
concluded that ablation was associated with significantly higher freedom from long-term
AF recurrence in comparison to the pharmacological counterpart and provided the evidence
to support AF ablation as first-in-line therapy. In the recent CABANA trial [38], involving
over 2200 patients, they also demonstrated an association with lower AF recurrence rate
using catheter ablation over drug therapy. The Cox-Maze procedure, an open-heart surgical
approach to permanently treat AF, requires a cardiac surgeon to place a series of epicardial
incisions (in a similar fashion to RF ablation) to interrupt the abnormal AF signals
permanently. This procedure is routinely practiced and recommended at the time of
simultaneous mitral and aortic valve operations and coronary artery bypass grafting.
Although this thesis focuses on AF, it is important to recognize that RF catheter ablation
is used to treat other forms of supraventricular arrhythmias, such as atrial flutter and
atrioventricular nodal re-entrant tachycardia, which require ablation in the RA, as well as
ventricular tachycardia, which requires ablation in the LV.

1.2.1

Biophysics of Radiofrequency Lesion Formation

Radiofrequency energy is created by using alternating electrical current to generate an
ablation lesion by electrical heating the cardiac tissue. Thermal energy deposited into the
tissue is used to destroy the arrhythmogenic substrates by heating them to a lethal
temperature; the 50°C isotherm determines the boundary of the lesion where tissue injury
is irreversible. As electrical current passes through the tissue, the voltage drops, and heat
is produced; this is called resistive heating. RF current is primarily delivered in a unipolar
fashion with completion of the electrical circuit through an indifferent electrode placed on
the skin (Figure 1.6). Typically, 500 to 750 kHz is used for efficient tissue heating while
avoiding stimulating cardiac muscle and nerves.
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Figure 1.6. Circuit path for RF catheter ablation. Blood pool resistance
is about half of that than cardiac tissue. Out of the 50 W of energy
delivered from the catheter, only 5 W is deposited in the tissue because
of power loss caused by the lower resistance (and impedance) of the
blood pool. The amount of power delivered into the tissue is based on
the amount of electrode surface in contact with the tissue, which is a
function of electrode size, the orientation catheter in relation to the tissue
surface, and the amount of electrode-tissue contact force. This
illustration has been adapted from Huang & Miller [39].

Resistive heating decreases proportionally with the distance from the electrode to the fourth
power. As a result, only a narrow rim of tissue in contact with the catheter electrode
(approximately 2-3 mm) is heated. The majority of lesion production (and deep tissue
heating) is a result of passive thermal conduction (Figure 1.7). Tissue temperature at any
given distance from the electrode increases exponentially with proximity to the electrode.
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The formation of coagulum at the electrode-tissue interface occurs when the temperatures
exceed 100°C. As the blood and tissue in contact with the electrode begin to boil, denatured
proteins stick to the surface of the electrode. Because coagulum electrically insulates the
surface of the electrode, a concentration of power occurs over a reduced surface area. This
positive feedback loop can cause a complete encasement of the electrode with coagulum
within seconds. Modern RF generators use sharp increases in impedance, associated with
coagulum encasement, to shut off RF energy. The formation of coagulum can cause micro
embolisms, which have been shown to cause cerebral embolic lesions [40-42].
When deep tissue layers exceed 100°C, intramuscular water begins to boil and cause a
sudden buildup of steam. High pressure is released, which can be heard or felt as a steampop [43]. Damage caused by steam pops ranges from superficial endocardial craters to fullthickness myocardial tears resulting in cardiac perforation and tamponade.
Active electrode irrigation is used to mitigate the effects of the electrode and tissue
overheating. Continuous saline irrigation bathes and cools the RF electrode and superficial
tissue layers (Figure 1.7), thereby allowing for longer RF application times and optimal
RF power delivery, resulting in larger lesions. Modern catheters are designed with either
closed-loop or open irrigation systems (catheter photographed in Figure 1.3 uses an open
system). Illustrated in Figure 1.5A, an irrigation pump – triggered with the RF generator
– continuously pumps saline through to the electrode through the irrigation port of the
catheter.
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Figure 1.7. Drawing of RF catheter ablation on tissue demonstrating
resistive and conductive heating. Continuous irrigation cools the
electrode and tissue surface, allowing larger lesions to be formed by
prolonging ablation time. Additional heat is lost passively through the
blood pool (convective) and cardiac tissue (perfusive). This illustration
has been adapted from Huang & Miller [39].

Several factors influence ablation lesion size includes: RF power, duration of RF energy
delivery, electrode-tissue contact force, tissue composition, electrode temperature, peak
tissue temperature, convective cooling, electrode size, ablation circuit impedance,
electrode orientation, electrode geometry, electrode material, and characteristics of RF
power. Electrode-tissue contact force is a novel concept and has emerged as a critical factor
in RF catheter ablation – this thesis heavily focuses on this concept. For this reason, it is
essential that thorough comprehension of catheter-tissue contact force is acquired.

1.2.2

Role of Contact Force in RF Catheter Ablation

Successful catheter ablation requires the complete and permanent elimination of
arrhythmogenic substrates by delivering ablation lesions that are reliably transmural
without collateral injury to other cardiac structures. RF energy creates resistive heating of
the tissue that is in direct contact with the electrode tip, and therefore, sufficient catheter-
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tissue contact is essential [44]. A major determinant of lesion size and depth is the amount
of contact force (CF) between the catheter tip electrode and moving tissue. Greater CF
increases lesion size by improving electrical coupling between the electrode and tissue.
This increases the electrode surface area in contact with the tissue and reduces the shunting
of current to the blood pool. Additionally, greater CF prevents the electrode from sliding
with cardiac motion. To this end, manufacturers have developed ablation catheters with a
force sensor integrated into the distal tip to measure real-time catheter-tissue CF during
mapping and RF ablation. These force-sensing ablation catheters detect forces in 3D with
high resolution (< 1 gram [g]) and display it visually on the EAM system (Figure 1.5). A
large-scale clinical study has shown that force-sensing ablation catheters reduce gaps
between adjacent lesions, steam pops, cardiac perforation, thrombus formation, and
fluoroscopy time, while at the same time improving lesion formation and reducing AF
recurrence rates [45].
Ablations lesions delivered with low levels of CF are superficial, increase the risk of
intermittent contact (occasional complete loss of contact) is correlated with sites of PV
reconnection [46-49]. In contrast, excessive CF is associated with deep tissue heating,
increase the risk of steam-pop, perforation, thrombus formation, and collateral tissue
damage to structures outside the heart, such as esophageal, pulmonary and phrenic nerve
injury [50-56].
In an attempt to optimize durable PVI, clinical studies have provided CF guidelines.
Notably, the EFFICAS II study (investigating 24 patients) demonstrated isolation of the
PV using a CF target of 20 g, ranging between 10 g and 30 g, with a minimum Force-Time
Integral (FTI, defined as the under the contact-force curve with respect to time [44]) of 400
grams-seconds (gs) [57]. In addition to the overall average CF, CF variability (or stability)
is thought to be an essential parameter in determining RF lesion formation [44]. The
SMART-AF trial, investigating 172 patients, showed an increase in clinical success when
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more time was spent within a pre-defined CF range (i.e., reduced CF variability) [58].
Specifically, investigators who stayed within a selected CF range more than 80% of the
time during RF applications were more than four times more likely to have clinical success
in comparison to those who did not. The study concluded that there is a non-linear
relationship between CF and clinical success and that CF stability with sufficient average
CF, rather than merely achieving higher average CF, is the key to creating durable ablation
lesions. Contact quality (which includes catheter stability, cardiorespiratory motion and
catheter drift), rather than absolute CF alone, has emerged as a critical element that governs
lesion size and ablation outcomes. A meta-analysis summarizing all randomized controlled
trials of CF ablation in AF (TOCATTA [59], EFFICAS I [45], EFFICAS II [57], SMARTAF [58], and TOCCASTAR [60]) reports ideal clinical outcomes appear when modest CF
is reached while consistently staying within the CF target range during ablation [61].
Smaller clinical studies have looked at further quantifying CF variability to provide more
context in lesion production and clinical success. Ullah et al. [62] demonstrated that lesions
delivered with variability over 5 g are associated with a lower impedance drop (a surrogate
for poor lesion production), despite delivering the same FTI. Additionally, Makimoto et al.
[63], demonstrated that the relationship between the average and standard deviation of CF
(relative standard deviation [RSD] or the coefficient of variation) correlates with PV
reconnection. They show that ablation segments along the circumferential ablation lines
delivered with lower average force and high variability are prone to form reconnection
gaps. For instance, in the anterior portions of the left PVs, where the most frequent
reconnection gaps are found, not only was the average CF low, but the variability was also
very high (Figure 1.8). Additionally, although the roof and posterior segments of the right
PVs have a typically adequate average CF, they have a high CF variability resulting in a
high RSD – this may be the reason why reconnection gaps are found in these locations [64,
65]. This notion reinforced by Kumar et al. [66], where they demonstrated that the CF
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variability was higher at the sites of reconnection than at non-reconnected sites. RF
applications delivered with high CF variability result in lesions 30%-60% smaller in
volume compared to constant CF, despite being delivered with the same power, duration,
and maximum force [44]. The larger the dynamic range of CF, the less likely the lesion
would reach an appropriate FTI and the longer the required duration of RF application. All
these data suggest that CF variability, in addition to average CF, plays a vital role in durable
ablation production.
In clinical practice, it is virtually impossible to reliably maintain stable CF between the
catheter tip and moving tissue. Thousands of RF applications across hundreds of patients
have been analyzed. In one study (+1600 RF applications across 22 patients), the average
force among the interquartile range is between 6 g and 40 g [67]. In another study (+1400
RF applications across 20 patients performed by two operators), showed that one-in-five
RF applications were delivered sub-optimally with less than 5 g on average, despite
attempts to “optimize” CF [68]. In a final study (+900 RF application across 20 patients),
19% of RF applications were delivered with a variability of less than 10 g, while the rest
remained highly variable greater than 20 g, despite further attempts to optimize CF [69].
Furthermore, average CF and variability also significantly differ depending on whether or
not the patient is in sinus rhythm as well as anatomical regions within the LA [63, 67, 68,
70].
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Figure 1.8. Maps of average CF A and relative standard deviation
(RSD=[SD/Mean]∗100%) B acquired in partial segments along
circumferential ablation lines during PVI. Areas of RSD over 40% are
typically associated with regional locations where reconnection gaps
occur. RSD regions less than 30% are generally non-problematic.
Average CF was higher in the roof and posterior segments of LSPV and
RSPV and lower in the anterior portion of the left PVs. Furthermore, roof
and posterior segments of the RIPV and the anterior segment LSPV,
RSD was significantly higher as compared to the other sections,
implying a higher risk of reconnection. Figure created based on data
from Makimoto et al. [63].

Systolic-diastolic cardiac motion and respiration are the primary contributors to variability
in CF [66, 67, 69]. Given the need to minimize tissue movement to improve CF stability,
techniques have been introduced clinically, which aim to decrease the amplitude of cardiac
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and respiratory motion by increasing their corresponding frequencies. For example, rapid
atrial pacing (increasing heart to over 120 BPM) improves catheter stability in the presence
of cardiac motion [71]. However, the improvement in CF variability is minimal (less than
1 g) and is dependent on regional lesion location within the LA. Furthermore, patients can
be sensitive to prolonged periods of rapid atrial pacing resulting in a quick drop in blood
pressure. High-frequency jet ventilation (HFJV) which increases the ventilation rate to 100
cycles/minute, or inducing patient apnea (breath-hold) can be used to eliminate CF
variability caused by respiratory motion [66, 72, 73]. HFJV may not be suitable for many
patients due to adverse effects [74, 75]. Importantly, HFJV and apnea induction requires
general anesthesia, which relies on the availability of an anesthesiologist and the protocol
of the center where the procedure is performed. Problems associated with general
anesthesia include increased risk of atrial-esophageal fistula, although this is extremely
rare [76]. Among the Heart Rhythm Society and European Heart Rhythm Association
expert consensus, approximately 70% routinely employ general anesthesia (and apnea
induction) for AF cases, and only 8% reported the use of HFJV [1].
As RF catheter ablation extends to more and less experienced operators, clinical success
will continue to vary centre-to-centre. This is further exacerbated by the variety of tools
and technologies at the electrophysiologist’s disposal. With limited methods to mitigate
the effect of excessive cardiorespiratory or patient motion, it is virtually impossible for EPs
to reliably meet any CF guidelines outlined by these reported clinical studies. It is evident
that there is a clear need for new technology to control catheter-tissue CF to optimize pointby-point RF ablation technique. Controlling for catheter-tissue CF and its effect in lesion
production is a principal component of this thesis.

1.3

State-of-the-Art Commercial Technology

This section presents tools and technologies routinely employed for AF ablation
procedures. Emerging technologies, tools, and approaches such as cryoablation, laser and
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ultrasound ablation, balloon-based single-shot catheters, and electroporation are not
addressed. This section is limited to existing commercial technologies – relevant to the
context of this thesis – utilized in point-by-point RF catheter ablation strategies.

1.3.1

Electro-Anatomical Mapping Systems

Modern EP labs incorporate an EAM system, which is used to track the position of an
ablation catheter tip in relationship to an electro-anatomical map of the patient’s cardiac
chamber. EAM systems record and display electrical activation related to the anatomical
location of the recorded sites, which help diagnose and guide ablation procedures.
Innovative catheter technologies, specifically robotic technologies, are typically
incorporated with EAM systems. For this reason, it is essential that a basic comprehension
of EAM systems is acquired. To this end, three commercially available EAM systems
routinely used in the clinic are described in this section.

1.3.1.1

CARTO® 3 Catheter Mapping System

The CARTO® 3 System (Biosense Webster, Irvine, CA) [77] is an advanced mapping
technology that utilizes electromagnetic tracking to create real-time 3D maps of a patient’s
cardiac structures. The system is designed to help electrophysiologists navigate the heart
by generating an accurate 3D map, as well as track the location and orientation of catheters
in the heart during ablation therapy.
CARTO® is based on three foundations: ECG, location, and mapping. The ECG subsystem
receives body surface and intracardiac ECG, which are filtered, presented and recorded
with CARTO®. To ensure that catheter tracking is not influenced by human conductivity,
CARTO® uses an electromagnetic field generator, consisting of three magnetic coils, to
track the electromagnetic sensors on the tip of the catheter (Figure 1.9), as well as locations
from six patches attached to the patient (three on the back and three on the chest). Lastly,
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CARTO® mapping technology is used to build maps of the heart chambers by combining
the precise location and ECG data.
The base CARTO® system can be equipped with optional software modules for differing
clinical needs. Some of these modules include force-sensing ablation catheter
(SMARTTOUCH™ Module); computed tomography (CT) and magnetic resonance
imaging (MRI) image integration and registration (CARTOMERGE®); and remote
catheter magnetic navigation (RMT Module) [77].

Figure 1.9 Illustration demonstrating electromagnetic tracking of the
catheter tip. Three coils, suspended under the patient’s chests beneath the
EP table, emit a low-level magnetic field represented by colour-coded
hemispheres. A 6 degree-of-freedom electromagnetic sensor within the
tap of the mapping or ablation catheter, measures the field strength from
each coil. The relative position to each coil is then triangulated to
determine the relative position and orientation of the catheter tip.
Illustration adapted from Bhakta et al. [78].

1.3.1.2

EnSite Precision™ Cardiac Mapping System

The EnSite Precision™ Cardiac Mapping System (Abbott Laboratories, Minneapolis, MN)
[79] is a 3D cardiac mapping system with features similar to that of CARTO® such as
catheter tracking, mapping and recording ECG with expanded optional software modules.
The distinguishing technical difference between the two systems is that the EnSite
Precision™ system combines impedance-based and electromagnetic-based tracking
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technologies to enable navigation and accurate tracking of both conventional catheters
(open to 3rd-party manufacturers) and sensor-enabled catheters. EnSite Precision™ is an
open-platform system that compliments both tracking technologies.
Over the past two decades, the CARTO® and EnSite Precision™ have dominated this
market and have been used in thousands of clinical studies worldwide, demonstrating its
efficacy in treating several forms of cardiac arrhythmia. PVI procedures guided by either
of these systems have been shown to yield similar clinical outcome [80]. The widespread
use of these systems is associated with higher success rates, shorter fluoroscopy and
procedure times, and accurate visualization of the cardiac chambers.

1.3.1.3

RHYTHMIA HDx™ Mapping System

A third system – the RHYTHMIA HDx™ Mapping System (Boston Scientific,
Marlborough, MA) [81] – is similar to the EnSite Precision™ system whereby it utilizes
both electromagnetic-based and impedance-based catheter tracking technology. Although
this system holds a smaller percentage of the market, in comparison to CARTO ® and
EnSite Precision™, it does stand out by providing a unique mapping catheter. The
INTELLAMAP ORION™ mapping catheter is capable of generating a rapid ultra-highdensity ECG map of the patient’s cardiac chamber [81]. This unique catheter has been
shown to improve long-term success in comparison to procedures guided by CARTO® or
EnSite Precision™ [82]. The RHYTHMIA HDx™ and INTELLAMAP ORION™ are
effective for treating various forms of cardiac arrhythmia, as demonstrated in several preclinical and clinical studies [83-92].
Unfortunately, unlike their competitors, to date, Boston Scientific does not provide an
ablation catheter capable of detecting real-time contact force measurements. Several
patents granted to Boston Scientific in 2017 describe a catheter capable of detecting
catheter-tissue CF [93-96], suggesting that such a catheter will soon be available.
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Force-Sensing Ablation Catheters
THERMOCOOL® SMARTTOUCH™ Catheter

The THERMOCOOL® SMARTTOUCH™ Catheter (Biosense Webster, Irvine, CA) [77]
is an ablation catheter that measures the CF between the catheter tip and moving tissue. A
precision spring located just proximal to the ablation tip electrode is affixed to an
electromagnetic transmitter coil (distal to the spring), which emits a magnetic field. Three
additional electromagnetic coils (positioned circumferential proximal to the spring)
generate an electrical current proportional to the micro-deflection caused by an applied
force to the catheter tip (Figure 1.10). A proprietary algorithm computes a 3D force vector
at approximately 20 Hz and displays both magnitude and direction continuously on the
CARTO® 3 System [97].

Figure 1.10. Photograph of THERMOCOOL® SMARTTOUCH™ forcesensing ablation catheter tip A. A precision spring is affixed to a
transmitter coil emits a magnetic field. Three electromagnetic receiver
coils generate an electrical current proportional to the deflection caused
by force applied to the tip (blue arrow) B.
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electrophysiology catheter features, such as an RF electrode tip, location sensors, ECG
mapping and pacing as well as a saline irrigation port. The THERMOCOOL ®
SMARTTOUCH™ catheter was the first catheter with force-sensing technology to be
approved by the U.S Food and Drug Administration (FDA) for use in cardiac ablation
therapy.

1.3.2.2

QDOT MICRO™ Catheter

The QDOT MICRO™ Catheter (Biosense Webster, Irvine, CA) [77] is the next generation
force-sensing ablation catheter developed by Biosense Webster (Figure 1.11). In addition
to force-sensing technology, the new catheter incorporates three micro-electrodes
embedded at the distal circumference within the standard distal RF electrode. Each
acquired point within CARTO® records four intracardiac electrograms: one from the
standard electrodes and three from the micro-electrodes. This design allows for recording
an ECG from a small tissue area, which has been shown to improve mapping resolution
and diagnosis of electrograms while limiting the need for and cost associated with the use
of separate mapping catheters [98]. The QDOT MICRO™ also incorporates six
thermocouple temperature sensors (three proximal and three distal) embedded 75
micrometres underneath the surface of the RF electrode’s metal shell. The symmetrical
distribution of thermocouples is optimized to monitor temperature at all orientations the
catheter makes to the tissue (defined as catheter-tissue incidence angle), resulting in more
accurate temperature readings from parts of the RF electrode in contact with the tissue. In
contrast, conventional catheters average the tip temperature, which is diluted by the cooler
parts of the tip that are not touching the tissue and the effects of blood and irrigation.
The incorporation of accurate local temperature monitoring allows for safe delivery of an
emerging RF technique, which uses high-power RF ablation. The proposed benefit of this

23

Introduction and Background

approach is to reduce the effects of lesion-to-lesion variability that result in reconnection
gaps. Several pre-clinical studies have shown to improve linear continuity, the delivery of
transmural ablation lesions, shorter ablation time, feasibility and safety. [99-101]

Figure 1.11. Line illustration of the tip of the QDOT MICRO™. The
novel force-sensing ablation catheter incorporates (1) six thermocouple
temperature sensors underneath the surface of the RF electrode for
improved temperature monitoring of the tissue surface; (2) three microelectrodes for high-resolution intracardiac EC mapping; and (3) an
improved tip irrigation system.

1.3.2.3

TactiCath™ Quartz Contact Force Ablation Catheter

The TactiCath™ Quartz Contact Force Ablation Catheter (Abbott Laboratories,
Minneapolis, MN) [79] contains a force sensor consisting of a deformable body and three
optical fibres [102]. Infrared light (emitted through the proximal end of the optical fibres)
travels through the catheter towards a cavity within the catheter tip (Figure 1.12). The
incoming light is bounced back and forth between two parallel reflective mirrors within the
cavity, resulting in reflected light with different wavelengths creating interference patterns.
When force is applied, the cavity length changes (on the order of nanometers) resulting in
a proportional change in the interference pattern. The reflected light is returned through to
the proximal handle by three optical fibres symmetrically distributed around the cavity. A
CF vector (magnitude and direction) is calculated and displayed on the EnSite Precision™
Cardiac Mapping System (Abbott Laboratories, Minneapolis, MN) [46].
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Figure 1.12. Photograph of TactiCath™ force-sensing ablation catheter
tip A. The force sensor consists of a deformable body and three optical
fibres. When force is applied to the tip (blue arrow), a cavity within the
deformable body reflects infrared light (indicated in red) with an
interference pattern proportional to the change in force B.

The accuracy and precision of TactiCath™, as well as its safety and effectiveness in ablation
procedures, have been investigated in several studies [45, 46, 57, 103]. The TactiCath™
was shown to have improved accuracy over the THERMOCOOL® SMARTTOUCH™
catheter, specifically while the catheter is in an orientation parallel to the tissue (i.e.
delivering “linear” lesions) [104].

1.3.3

Steerable Sheaths

A steerable guiding sheath is a widely used tool available to the EP during ablation
procedures. Used in conjunction with ablation catheter, steerable sheaths have been shown
to improve maneuverability and stability of the ablation catheter, as well as enhance contact
between the catheter tip and cardiac tissue during lesion production [105-109].
Incorporating a steerable sheath has also been shown to increase first-procedure clinical
success rates over its non-steerable counterpart [110].

25

Introduction and Background

The Agilis™ NxT Steerable Introducer (Abbott Laboratories, Minneapolis, MN) [79] is the
world’s most commonly used steerable sheath. The handle of the Agilis ™ consists of a
hemostatic seal and side-port irrigation line proximal to the handle. An ablation catheter
can be inserted into the hemostatic seal and entirely fed through the hollow braided shaft
of the sheath (Figure 1.13). The bi-directional deflection mechanism located on the handle
allows the EP to deflect the distal tip of the sheath bi-directionally up to 180°.

Figure 1.13. Photographs of a force-sensing ablation catheter in
conjunction with the Agilis™ steerable sheath A, and their corresponding
tips B. The operator now can insert, withdraw, rotate, and deflect both
the catheter and sheath independently from one another.

The steerable sheath provides additional degrees-of-freedom associated with catheter
manipulation. The EP now can insert, withdraw, rotate, and deflect both the catheter and
sheath independently from one another, which allows the EP to reach extended targets and
manage complex anatomy. In practice, however, catheter manipulation primarily involves
manipulating the steerable sheath (insertion, withdrawal, rotation, and deflection) and only
inserting or withdrawing the catheter to change the amount of CF the catheter tip applies
to the cardiac tissue (Figure 1.14). This approach is popular among recently trained
electrophysiologists and residents entering the field.
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Figure 1.14. Photographs of the steerable sheath handle A, and the
catheter and sheath tips B. Manipulation primarily involves in
manipulating the steerable sheath includes rotation (blue), insertion and
withdrawal (green) and deflection (red). By inserting and withdrawing
the catheter through the sheath (purple), the operator can adjust the
amount of applied force the electrode tip exerts on the tissue.

The MOBICATH® Sheath (Biosense Webster, Irvine, CA) and Vizigo™ Bi-Directional
Guiding Sheath (Biosense Webster, Irvine, CA) are steerable sheaths developed by
Biosense Webster, which have the similar operation as the Agilis ™. Vizigo™ incorporates
electromagnetic sensors incorporated at the distal tip, which allows the sheath tip to be
visualized by CARTO® and display its position and orientation within the EAM systems.
The Vizigo™ is the first commercially available steerable sheath that provides this
capability.

1.3.4

Remote Catheter Navigation Systems

Ablation strategies to treat cardiac arrhythmia are complex, technically challenging, and
require a high degree of skill and physical effort. To address these challenges, remote
catheter navigation systems, utilizing both robotic and magnetic actuation technologies,
have been developed and introduced clinically. Robotic and magnetic navigation systems
(RNS and MNS, respectively) are appealing because they provide remote precise catheter
navigation and have ancillary benefits, such as reducing fluoroscopic x-ray radiation
exposure and the risk to the physician of developing orthopedic problems related to
prolonged use of protective lead aprons. This section will describe four remote catheter
navigation technologies developed for clinical use.
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Amigo™ Remote Catheter System

The Amigo™ Remote Catheter System (Catheter Precision, Mount Olive, NJ) [111]
comprises of a robotic arm attached to the rails of a standard electrophysiology table and
is positioned above the patient’s legs when in use. A conventional RF ablation catheter is
inserted into the patient before being loaded into the Amigo™. The RNS is operated by a
wired hand-held remote-control device that looks similar to the proximal handle of a
conventional catheter. The remote control, which may be used up to 30 m away from the
patient, provides full-range manipulation: inserting; withdrawing; rotating and deflecting
the tip of the catheter. The Amigo™ does not incorporate separate workstations, monitors,
or other hardware and introducing it into the catheter lab does not require additional room
construction. The open platform approach of the system is designed to accommodate a
range of commercially available catheters; however, the robotic system is only compatible
with a few catheters manufactured by either Biosense Webster or Boston Scientific.
The Amigo™ underwent its first clinical trial to evaluate its performance and safety in
mapping the right side of the heart [112]. In the following years, several clinical studies
have demonstrated that the Amigo™ can perform safe and effective right atrial ablation, as
well as left atrial mapping and pulmonary vein isolation comparable to the standard
approach [113-116]. The Amigo™ has a short learning curve and significantly reduces
fluoroscopic x-ray radiation exposure to the operator. A drawback of the system is the lack
of a steerable sheath limiting the manoeuvrability and stability of the catheter tip.

1.3.4.2

Sensei® X Robotic System

The Sensei® X Robotic System (Hansen Medical, Mountain View, CA) [117] provides
robotic steering of two concentric sheaths (14 Fr outer and 10.5 Fr inner), through which
any conventional ablation catheter can be inserted. The assembly is manipulated within the
heart by a robotic arm positioned over the patient’s legs and fixed to the rails of a standard
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electrophysiology table. The Sensei® is controlled within a separate console workstation
positioned in the control room, which provides a 3D joystick and visual feedback to the
EP. Manipulating the ball-like joystick changes the applied tension to the pull-wires
embedded within the inner and outer steerable sheaths, resulting in a broad range of motion
in any direction. If the EP uses the Artisan® X Control Catheter (Hansen Medical,
Mountain View, CA), the incorporated force sensor within the catheter shaft detects realtime perpendicular contact-force between the catheter tip and moving tissue. This
information is provided visually to the physician as well as through their IntelliSense ® Fine
Force (Hansen Medical, Mountain View, CA) haptic technology.
Although the Sensei® can be used with virtually all commercially available EAM systems,
their CoHesion™ 3D Visualization Module (Hansen Medical, Mountain View, CA)
specialized software was developed for robotic integration, 3D visualization, mapping and
tracking with the EnSite™ Prevision Cardiac Mapping system (Abbott Laboratories,
Minneapolis, MN).
In early clinical use, the initial concern regarding the Sensei® system was the increased risk
of perforation [118, 119]. However, more recent reports have demonstrated the feasibility
of performing PVI without major complications [120, 121]. Unfortunately, the huge transseptal outer sheath limits access to critical cardiac structures such as the left ventricle and
coronary sinus [122], which significantly limit the application of the Sensei® system to
atrial ablation.
In 2016, Hansen Medical was acquired by Auris Health, a medical device company that
develops a bronchoscopic robotic navigation system. Since the acquisition, Auris has
terminated the Sensei® platform and incorporated the technology into its platform.
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NIOBE™ Magnetic Navigation System

The NIOBE™ Magnetic Navigation System (Stereotaxis, St. Louis, MO) [123] is the most
widely used remote navigation system with more than 100 active hospital installations, 300
physicians and 9,000 procedures performed annually. NIOBE ™ consists of two
neodymium-iron-boron permanent magnets positioned on both sides of a standard
electrophysiology table, creating a uniform magnetic field (0.08 Tesla [T]) across the
patient’s chest [124-126]. A specialized ablation catheter, which incorporates three small
magnets affixed to the distal tip, is navigated to target locations by first manipulating the
magnetic field orientation. This is done by computer-aided mechanical movements of the
external permanent magnets. The distal portion of the magnetic catheter becomes aligned
with the new orientation of the magnetic field. The Cardiodrive ® (Stereotaxis, St. Louis,
MO) electromechanical unit is used to position the catheter along the magnetic field. Once
the catheter is inserted into the patient’s cardiac chamber and loaded into the Cardiodrive®
unit, all further manipulation can be done remotely from a control room utilizing a joystick,
keyboard, or mouse control. NIOBE™ also has functional automation software designed to
allow for automatic movement of the catheter to specific points, along with defined paths,
in a preprogrammed motion [123].
The weak magnetic field in conjunction with a soft and flexible catheter provides unique
capabilities and benefits, as demonstrated in clinical use: (1) increased precision with
catheter movement and control; (2) reduce the risk of intermittent contact; and (3)
decreased risk of cardiac perforation due to the compliant nature of the catheter [127].
However, whether these benefits translate to improved clinical success remains to be
determined, as clinical trials of patients undergoing PVI guided by NIOBE™ versus the
manual approach has reported mixed results [118, 125, 126, 128, 129].
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The NIOBE™ system also has several shortcomings, which include: (1) incredible costs
associated with the system and room construction; (2) installation of the system in existing
catheter laboratory requires special room shielding and additional regulation because of the
additional permanent magnetic field; (3) since the magnetic fields are changed by
mechanical movements, a large delay occurs between designation of magnetic field vector
and catheter movement within the heart; (4) risk of interference with patients implanted
with a cardiac defibrillation device; (5) the only EAM compatible with NIOBE ™ is
CARTO®; (6) the magnetic catheter cannot detect catheter-tissue CF; and importantly (7)
due to the weak magnetic field strength the NIOBE™ system has been scrutinize by its
users that it cannot reach adequate levels of catheter-tissue CF [122, 130, 131]. Described
in detail in previous sections, insufficient CF results in ineffective lesion production
correlates with reconnection gaps.

1.3.4.4

Catheter Guidance Control and Imaging

The Catheter Guidance Control and Imaging (CGCI, Magnetecs, Inglewood, CA) [132] is
a non-commercial MNS that uses eight electromagnets affixed semi-spherically around the
patient’s chest generating a dynamic 15 cm3 magnetic field within the heart [122]. The
CGCI can navigate a specialized magnetic catheter by manipulating the field strength,
orientation and gradient in near real-time. Similar to NIOBE™, the CGCI uses an
electromechanical unit to advance and retract the catheter along the magnetic field vector.
The CGCI has a maximum field strength of (0.16 T) resulting in a stronger field gradient
(0.7 T/m). The stronger field gradient results in a maximum perpendicular force of 25 g;
however, this has yet to be validated. The EP manipulates the catheter from a workstation
manually, using a joystick to guide the catheter, or automatically, whereby the physician
selects a target on display and the CGCI system plans the path and automatically moves
the catheter accordingly.
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The initial data collected from animal studies using the CGCI are promising [133];
however, clinical data are lacking. A 2010 clinical trial involving five patients was
performed and published [134] and a second and third round of patients involving another
74 patients performed in 2011 [132]. In 2014, a third CGCI installation commenced a
multi-site randomized study of paroxysmal AF ablation procedures with 100 patients. The
results from this clinical trial will provide further validation and outline a path to FDA
clearance [132].

1.4

Robotic Catheter Systems in Academia

Several robotic systems for remotely manipulating catheters during cardiovascular
intervention have been developed in academia. These include systems for remotely
positioning catheters guidance by different medical imaging modalities as well as
improving lesion production. A brief overview of these projects is discussed in this section.
The robotic catheter system proposed in this thesis is inspired mainly by the design
approach of earlier work in our group. Thakur et al. developed a 2 degrees-of-freedom (2DOF) RNS designed for remote navigation during fluoroscopically guided catheterization
[135-137]. The design of the system attempted to take advantage of the EP’s already
acquired dexterous skill of the catheter. The preliminary work defined velocities and
accelerations of a catheter, manipulated by an EP, during catheter intervention [138]. The
system was then further improved by Tavallaei et al. whereby the group developed a 3DOF RNS designed to be compatible with MRI guidance [139-141]. The group developed
and evaluated a novel RNS capable of remotely manipulating a catheter within the bore of
an MRI scanner using non-ferromagnetic ultrasonic motors.
Cercenelli et al. [142] designed and developed a versatile RNS for remote navigation of a
standard ablation catheter. Entitled CathROB, the RNS is impressively compact has builtin features including automatic catheter repositioning and a force-sensing mechanism
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designed for haptic applications. The system has been evaluated in vitro and in vivo using
an animal model.
Several other groups have developed robotic devices to address problems relating to
various intracardiac interventions. Notably, Dr. R. Howe’s group has developed a catheter
RNS to assist with intracardiac mitral valve annuloplasty [143, 144]. This project included
concepts of remote catheter manipulation and force control of a surgical instrument within
a beating heart. The group also developed an open-source 3D-printed force sensor with an
integrated RF electrode tip [145]. This custom force sensor, fixed to a catheter tip, was
used to develop and evaluate a robotic system enabled with CF control of the electrode tip
with moving tissue [146].
Khoshnam et al. undertook attempts to improve catheter-tissue CF using robotic platforms.
The group developed a method to estimate CF of a catheter without an incorporated force
sensor. The catheter tip was modelled as a large deflection beam to derive a loaddisplacement relationship of the curvature of the catheter tip caused by an applied external
force [147, 148]. Based on this preliminary work, a robotic system was developed to enable
CF control and tested on a lab-bench setup [149].
The projects discussed in this section have highlighted important aspects relating to remote
catheter manipulation and CF control. The knowledge obtained from these projects
contributed to the overall design, architecture, and engineering approach used to develop
and test the robotic platforms proposed in this thesis.

1.5

Design Approach of Proposed Robotic System

In this thesis, a novel RNS is proposed, designed to enable remote catheter navigation and
CF control between the catheter tip and moving tissue. An operator uses an interface to
robotically navigate a remote catheter tip to a target location within a moving cardiac
chamber. Before the RF application, the operator can employ force control mechanism that
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would advance the catheter and automatically adjust its position in order to maintain
catheter-tissue CF at the desired force set by the operator.
The proposed RNS will enable remote manipulation of conventional commercially
available force-sensing ablation catheters permitting access to all cardiac chambers and
preserving compatibility of existing EAM systems. The RNS will provide improved
catheter tip stability and manoeuvrability in real-time, while at the same time reducing the
learning curve by providing an intuitive method of controlling the robotic system. Lastly,
but importantly, the proposed RNS will allow the EP to deliver reliably transmural RF
ablation lesions by providing the capability to control CF between the catheter electrode
tip and moving tissue.
The design of the proposed RNS was inspired by the observation of modern RF catheter
intervention in the EP lab and independent interviews with electrophysiologists and clinical
staff. A series of formative studies were performed to acquire basic comprehension of
manual catheter manipulation techniques. Several EPs, with a variety of clinical
experience, participated in an in vitro phantom-based formative study. Based on these data,
it was observed that most EPs navigate a catheter tip to targets within the cardiac chamber
primarily using a steerable sheath. Once preliminary contact is made, the EP then inserts
or withdraws the catheter through the sheath until an acceptable CF is experienced on the
electrode tip. Conventional catheter manipulation technique is illustrated in Figure 1.14.
After observing that the CF is adequate and safe, an RF application would be initiated, and
an ablation lesion would be delivered into the tissue. This process would be repeated
contiguously encircling the PVs and other necessary cardiac structures.
The proposed RNS will reproduce the same manipulation technique described above, by
providing remote control of a force-sensing ablation catheter in conjunction with a
steerable sheath. The Steerable Sheath and Catheter Robotic Navigation System (SSC-
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RNS) will allow for full-range manipulation of a conventional steerable sheath (insertion,
withdrawal, rotation, and deflection) in 3-DOF and permit coaxial displacement of the
catheter (insertion and withdrawal) within the sheath in 1-DOF. This design allows for CF
control by autonomously displacing the catheter within the sheath to ensure that the CF of
the catheter tip is always maintained at the set level. An overview of the proposed
architecture is illustrated in Figure 1.15. Various microcontroller-based electronics within
the SSC-RNS receive data wirelessly from an input device and process numerous control
algorithms, based on linear control theory, to generate proportional control signals. The
robotic systems’ numerous motors actuate the steerable sheath and catheter (mounted
within the SSC-RNS), replicating the motion of the input device. Furthermore, the SSCRNS continuously receives wireless real-time CF measurements provided by an EAM
system (connected to a corresponding force-sensing ablation catheter) and processes a
predictive control algorithm and generate a control signal that positions the catheter within
the sheath under closed-loop CF control.
The robotic system of the SSC-RNS uses an electromechanical mechanism for cathetertissue CF control. This device was initially designed, developed and evaluated
independently from the SSC-RNS. The compact device aptly named the Catheter ContactForce Controller (CFC) was then incorporated into the SSC-RNS platform, further
enabling remote navigation of the steerable sheath.
The SSC-RNS is controlled remotely by an intuitive input device that is designed to utilize
the dextrous skills and hand-eye coordination of a trained EP. The input device is fitted
with encoders and electronics to capture the motion (insertion, withdrawal, rotation, and
deflection) of a repurposed steerable sheath handle and wirelessly transmit the data to the
robotic system. Manipulation of the input device results in direct robotic manipulation of
a remote steerable sheath and catheter in real-time. The input device also provides a user
interface enabling the operator to select navigation and force control parameters.
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Figure 1.15. A block diagram describing the architecture of the proposed
SSC-RNS. An EAM system tracks the location of the tip of a forcesensing ablation catheter within a patient’s cardiac chamber and
monitors its CF between the catheter tip and moving cardiac tissue. The
EP then manipulates an input device, which captures the desired motion
to be replicated a robotic system. The robotic system wirelessly receives
position data from the input device and real-time CF measurements from
the EAM (indicated in blue). The robotic system actuates a remote
steerable sheath and force-sensing catheter (within the patient) according
to the changes in the position of the input device. Furthermore, the
robotic system can enable CF control between the catheter tip and
moving cardiac tissue employed by the input device.

In a clinical setting, the distal tip of the catheter and sheath would be first manually
introduced into the patient’s cardiac chamber. The proximal handles of both the catheter
and sheath would then be mounted into the SSC-RNS. The operator would then sit
comfortably at the workstation of the EAM system with the input device, thereby
decreasing fluoroscopic exposure and operator fatigue. Guided by the EAM system, the
operator would use the SSC-RNS to navigate the catheter tip to the desired location and
engage the catheter tip and the moving tissue. The force controller set to the desired level
(typically between 10 g and 20 g), would be employed resulting in a CF profile with low
variability. An RF application would then be delivered before continuing to the adjacent
target. Point-by-point ablation would continue until the therapy is completed.

1.6
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This introductory chapter provided a description of AF and modern catheter-based
therapeutic techniques, along with a brief overview of state-of-the-art commercial tools
and technology relating to RF catheter ablation. Because this thesis is presented in an
“integrated article format” the remaining body chapters represent publications that are
either published, accepted for publication, or in preparation for submission, and inevitably
some duplication of the introductory material is present. Efforts have been made to link the
independent papers as much as possible.
This introductory chapter provided a description of AF and modern catheter-based
therapeutic techniques. A brief overview of the current state-of-the-art commercial tools
and technology relating to RF catheter ablation was also described. This chapter also
discussed the benefits and limitations of commercial remote navigation systems as well as
novel technologies developed in academia. The outline of this thesis and the corresponding
contributions in each chapter are as follows.
Chapter 2 describes the design, development, and lab-bench evaluation of a novel device,
designed by me, enabling catheter-tissue CF control. A custom-built linear motion stage,
capable of reproducing clinically relevant motion, was used to evaluate the force control
performance of the CFC. CF profiles of a catheter engaging with tissue-mimicking material
were recorded with and without the use of the CFC (representative of manual intervention).
Manual and CFC-assisted CF profiles were compared with one another. A version of this
chapter, entitled “Design and Evaluation of a Catheter Contact-Force Controller for
Cardiac Ablation Therapy,” has been published in IEEE Transactions on Biomedical
Engineering (vol. 63, no. 11, pp. 2301-2307, 2016).
Chapter 3 further evaluates the CFC in vitro to examines its impact on RF lesion
production. CFC-assisted RF ablation lesions were delivered to moving tissue at different
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clinically relevant force levels and were compared to lesions delivered in tissue in the
absence of motion. CFC-assisted ablation lesions were also compared to lesions without
force control representing manual catheter intervention. Furthermore, the CFC was also
tested in vivo in a pig model to evaluate its force control performance in a beating heart. A
version of this chapter, entitled “Eliminating the effects of motion during radiofrequency
lesion delivery using a novel contact-force controller,” has been accepted for publication
to the Journal of Cardiovascular Electrophysiology.
The work in Chapter 4 incorporates the CFC technology into a robotic platform that enables
remote navigation of the steerable sheath and force-sensing ablation catheter. In a labbench study, an operator robotically navigated a remote catheter tip to stationary and
moving targets within a contractile motion phantom. The operator employed the force
controller on moving targets to a set amount of force. Catheter tip-target accuracy and
force-controlled profiles were compared to a repeat experiment where the tasks were
performed manually. A version of this chapter, entitled “Remote catheter navigation and
contact-force control: design and evaluation of a novel steerable sheath and catheter
robotic navigation system,” is in preparation for submission to IEEE Transaction on
Biomedical Engineering.
Chapter 5 provides a summary of the accomplishments and contributions of the thesis,
followed by suggestions for future work that uses the CFC to improve understanding of the
effects of contact force on lesion production and translation of the device into clinical use.

1.7

References

38

1.7

References

[1]

H. Calkins et al., "2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus
statement on catheter and surgical ablation of atrial fibrillation," Heart Rhythm, vol.
14, no. 10, pp. e275-e444, 2017

[2]

H. Calkins et al., "2012 HRS/EHRA/ECAS expert consensus statement on catheter
and surgical ablation of atrial fibrillation: recommendations for patient selection,
procedural techniques, patient management and follow-up, definitions, endpoints,
and research trial design: a report of the Heart Rhythm Society (HRS) Task Force
on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership
with the European Heart Rhythm Association (EHRA), a registered branch of the
European Society of Cardiology (ESC) and the European Cardiac Arrhythmia
Society (ECAS); and in collaboration with the American College of Cardiology
(ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm
Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the
governing bodies of the American College of Cardiology Foundation, the American
Heart Association, the European Cardiac Arrhythmia Society, the European Heart
Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart
Rhythm Society, and the Heart Rhythm Society," Heart Rhythm, vol. 9, no. 4, pp.
632-96 e21, 2012

[3]

A. J. Camm et al., "Guidelines for the management of atrial fibrillation: the Task
Force for the Management of Atrial Fibrillation of the European Society of
Cardiology (ESC)," Europace, vol. 12, no. 10, pp. 1360-420, 2010

[4]

C. T. January et al., "2014 AHA/ACC/HRS guideline for the management of
patients with atrial fibrillation: a report of the American College of
Cardiology/American Heart Association Task Force on Practice Guidelines and the
Heart Rhythm Society," J Am Coll Cardiol, vol. 64, no. 21, pp. e1-76, 2014

[5]

H. Zulkifly, G. Y. H. Lip, and D. A. Lane, "Epidemiology of atrial fibrillation," Int
J Clin Pract, vol. 72, no. 3, p. e13070, 2018

[6]

G. Y. H. Lip, C. M. Brechin, and D. A. Lane, "The global burden of atrial
fibrillation and stroke: a systematic review of the epidemiology of atrial fibrillation
in regions outside North America and Europe," Chest, vol. 142, no. 6, pp. 1489-98,
2012

[7]

A. S. Go et al., "Prevalence of diagnosed atrial fibrillation in adults: national
implications for rhythm management and stroke prevention: the AnTicoagulation
and Risk Factors in Atrial Fibrillation (ATRIA) Study," Jama, vol. 285, no. 18, pp.
2370-5, 2001

[8]

A. Alonso et al., "Simple risk model predicts incidence of atrial fibrillation in a
racially and geographically diverse population: the CHARGE-AF consortium," J
Am Heart Assoc, vol. 2, no. 2, p. e000102, 2013

39

Introduction and Background

[9]

S. A. Lubitz et al., "Association between familial atrial fibrillation and risk of newonset atrial fibrillation," Jama, vol. 304, no. 20, pp. 2263-2269, 2010

[10]

S. S. Chugh et al., "Worldwide epidemiology of atrial fibrillation: a Global Burden
of Disease 2010 Study," Circulation, vol. 129, no. 8, pp. 837-47, 2014

[11]

S. Colilla, A. Crow, W. Petkun, D. E. Singer, T. Simon, and X. Liu, "Estimates of
current and future incidence and prevalence of atrial fibrillation in the U.S. adult
population," Am J Cardiol, vol. 112, no. 8, pp. 1142-7, 2013

[12]

P. P. Kneeland and M. C. Fang, "Trends in catheter ablation for atrial fibrillation in
the United States," J Hosp Med, vol. 4, no. 7, pp. E1-5, 2009

[13]

M. Writing Group et al., "Executive Summary: Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association," Circulation, vol.
133, no. 4, pp. 447-54, 2016

[14]

M. H. Kim, S. S. Johnston, B. C. Chu, M. R. Dalal, and K. L. Schulman,
"Estimation of total incremental health care costs in patients with atrial fibrillation
in the United States," Circ Cardiovasc Qual Outcomes, vol. 4, no. 3, pp. 313-20,
2011

[15]

D. J. O'Reilly et al., "The burden of atrial fibrillation on the hospital sector in
Canada," Can J Cardiol, vol. 29, no. 2, pp. 229-35, 2013

[16]

N. J. Patel, V. Atti, R. D. Mitrani, J. F. Viles-Gonzalez, and J. J. Goldberger,
"Global rising trends of atrial fibrillation: a major public health concern," Heart,
vol. 104, no. 24, pp. 1989-90, 2018

[17]

A. Verma, L. Macle, J. Cox, A. C. Skanes, and C. C. S. A. F. G. Committee,
"Canadian Cardiovascular Society atrial fibrillation guidelines 2010: catheter
ablation for atrial fibrillation/atrial flutter," Can J Cardiol, vol. 27, no. 1, pp. 60-6,
2011

[18]

P. A. Wolf, R. D. Abbott, and W. B. Kannel, "Atrial fibrillation as an independent
risk factor for stroke: the Framingham Study," Stroke, vol. 22, no. 8, pp. 983-8,
1991

[19]

E. J. Benjamin, P. A. Wolf, R. B. D'Agostino, H. Silbershatz, W. B. Kannel, and
D. Levy, "Impact of atrial fibrillation on the risk of death: the Framingham Heart
Study," Circulation, vol. 98, no. 10, pp. 946-52, 1998

[20]

W. B. Kannel, P. A. Wolf, E. J. Benjamin, and D. Levy, "Prevalence, incidence,
prognosis, and predisposing conditions for atrial fibrillation: population-based
estimates," Am J Cardiol, vol. 82, no. 8A, pp. 2N-9N, 1998

1.7

References

40

[21]

P. S. Miller, F. L. Andersson, and L. Kalra, "Are cost benefits of anticoagulation
for stroke prevention in atrial fibrillation underestimated?," Stroke, vol. 36, no. 2,
pp. 360-6, 2005

[22]

T. J. Wang et al., "A risk score for predicting stroke or death in individuals with
new-onset atrial fibrillation in the community: the Framingham Heart Study,"
Jama, vol. 290, no. 8, pp. 1049-56, 2003

[23]

M. W. Rich and R. B. Fohtung, "Identification of Patients at Risk of Stroke From
Atrial Fibrillation," US Cardiology Review, vol. 10, no. 2, pp. 60-4, 2016

[24]

R. Wakili, N. Voigt, S. Kaab, D. Dobrev, and S. Nattel, "Recent advances in the
molecular pathophysiology of atrial fibrillation," J Clin Invest, vol. 121, no. 8, pp.
2955-68, 2011

[25]

J. Heijman, N. Voigt, S. Nattel, and D. Dobrev, "Cellular and molecular
electrophysiology of atrial fibrillation initiation, maintenance, and progression,"
Circ Res, vol. 114, no. 9, pp. 1483-99, 2014

[26]

S. Nattel, B. Burstein, and D. Dobrev, "Atrial remodeling and atrial fibrillation:
mechanisms and implications," Circ Arrhythm Electrophysiol, vol. 1, no. 1, pp. 6273, 2008

[27]

M. Haissaguerre et al., "Spontaneous initiation of atrial fibrillation by ectopic beats
originating in the pulmonary veins," N Engl J Med, vol. 339, no. 10, pp. 659-66,
1998

[28]

L. Gepstein and S. J. Evans, "Electroanatomical mapping of the heart: basic
concepts and implications for the treatment of cardiac arrhythmias," Pacing Clin
Electrophysiol, vol. 21, no. 6, pp. 1268-78, 1998

[29]

C. Pappone, C. Garzillo, S. Crisà, and V. Santinelli, "Electroanatomical Mapping
Systems. An Epochal Change in Cardiac Electrophysiology," in Medical Imaging
in Clinical Applications: Springer, 2016, pp. 237-55.

[30]

H. Oral et al., "Clinical significance of early recurrences of atrial fibrillation after
pulmonary vein isolation," J Am Coll Cardiol, vol. 40, no. 1, pp. 100-4, 2002

[31]

H. Oral et al., "Segmental ostial ablation to isolate the pulmonary veins during atrial
fibrillation: feasibility and mechanistic insights," Circulation, vol. 106, no. 10, pp.
1256-62, 2002

[32]

A. Arya et al., "Long-term results and the predictors of outcome of catheter ablation
of atrial fibrillation using steerable sheath catheter navigation after single procedure
in 674 patients," Europace, vol. 12, no. 2, pp. 173-80, 2010

41

Introduction and Background

[33]

A. N. Ganesan et al., "Long-term outcomes of catheter ablation of atrial fibrillation:
a systematic review and meta-analysis," J Am Heart Assoc, vol. 2, no. 2, p.
e004549, 2013

[34]

O. M. Wazni et al., "Radiofrequency ablation vs antiarrhythmic drugs as first-line
treatment of symptomatic atrial fibrillation: a randomized trial," Jama, vol. 293, no.
21, pp. 2634-40, 2005

[35]

J. Cosedis Nielsen et al., "Radiofrequency ablation as initial therapy in paroxysmal
atrial fibrillation," N Engl J Med, vol. 367, no. 17, pp. 1587-95, 2012

[36]

C. A. Morillo et al., "Radiofrequency ablation vs antiarrhythmic drugs as first-line
treatment of paroxysmal atrial fibrillation (RAAFT-2): a randomized trial," Jama,
vol. 311, no. 7, pp. 692-700, 2014

[37]

A. Hakalahti, F. Biancari, J. C. Nielsen, and M. J. Raatikainen, "Radiofrequency
ablation vs. antiarrhythmic drug therapy as first line treatment of symptomatic atrial
fibrillation: systematic review and meta-analysis," Europace, vol. 17, no. 3, pp.
370-8, 2015

[38]

D. L. Packer et al., "Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy
on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial
Fibrillation: The CABANA Randomized Clinical Trial," Jama, 2019

[39]

S. K. S. Huang and J. M. Miller, Catheter Ablation of Cardiac Arrhythmias, 4th ed.
Elsevier, 2019.

[40]

C. Herrera Siklody et al., "Incidence of asymptomatic intracranial embolic events
after pulmonary vein isolation: comparison of different atrial fibrillation ablation
technologies in a multicenter study," J Am Coll Cardiol, vol. 58, no. 7, pp. 681-8,
2011

[41]

F. Gaita et al., "Radiofrequency catheter ablation of atrial fibrillation: a cause of
silent thromboembolism? Magnetic resonance imaging assessment of cerebral
thromboembolism in patients undergoing ablation of atrial fibrillation,"
Circulation, vol. 122, no. 17, pp. 1667-73, 2010

[42]

F. Kilicaslan et al., "Transcranial Doppler detection of microembolic signals during
pulmonary vein antrum isolation: implications for titration of radiofrequency
energy," J Cardiovasc Electrophysiol, vol. 17, no. 5, pp. 495-501, 2006

[43]

J. M. Kalman et al., "Biophysical characteristics of radiofrequency lesion formation
in vivo: dynamics of catheter tip-tissue contact evaluated by intracardiac
echocardiography," Am Heart J, vol. 133, no. 1, pp. 8-18, 1997

[44]

D. C. Shah, H. Lambert, H. Nakagawa, A. Langenkamp, N. Aeby, and G. Leo,
"Area under the real-time contact force curve (force-time integral) predicts

1.7

References

42

radiofrequency lesion size in an in vitro contractile model," J Cardiovasc
Electrophysiol, vol. 21, no. 9, pp. 1038-43, 2010
[45]

P. Neuzil et al., "Electrical reconnection after pulmonary vein isolation is
contingent on contact force during initial treatment: results from the EFFICAS I
study," Circ Arrhythm Electrophysiol, vol. 6, no. 2, pp. 327-33, 2013

[46]

V. Reddy et al., "The relationship between contact force and clinical outcome
during radiofrequency catheter ablation of atrial fibrillation in the TOCCATA
study," Heart Rhythm, vol. 9, no. 11, pp. 1789-1795, 2012

[47]

K. H. Kuck et al., "A novel radiofrequency ablation catheter using contact force
sensing: Toccata study," Heart Rhythm, vol. 9, no. 1, pp. 18-23, 2012

[48]

S. Haldar et al., "Contact force sensing technology identifies sites of inadequate
contact and reduces acute pulmonary vein reconnection: a prospective case control
study," Int J Cardiol, vol. 168, no. 2, pp. 1160-6, 2013

[49]

B. J. Tofig et al., "Recurrence after pulmonary vein isolation is associated with low
contact force," Scand Cardiovasc J, vol. 52, no. 1, pp. 28-33, 2018

[50]

W. Ullah, R. J. Schilling, and T. Wong, "Contact Force and Atrial Fibrillation
Ablation," J Atr Fibrillation, vol. 8, no. 5, p. 1282, 2016

[51]

B. Avitall, K. Mughal, J. Hare, R. Helms, and D. Krum, "The effects of electrodetissue contact on radiofrequency lesion generation," Pacing Clin Electrophysiol,
vol. 20, no. 12 Pt 1, pp. 2899-910, 1997

[52]

A. Thiagalingam et al., "Importance of catheter contact force during irrigated
radiofrequency ablation: evaluation in a porcine ex vivo model using a forcesensing catheter," J Cardiovasc Electrophysiol, vol. 21, no. 7, pp. 806-11, 2010

[53]

K. Yokoyama et al., "Novel contact force sensor incorporated in irrigated
radiofrequency ablation catheter predicts lesion size and incidence of steam pop
and thrombus," Circ Arrhythm Electrophysiol, vol. 1, no. 5, pp. 354-362, 2008

[54]

C. Pappone et al., "Atrio-esophageal fistula as a complication of percutaneous
transcatheter ablation of atrial fibrillation," Circulation, vol. 109, no. 22, pp. 27246, 2004

[55]

D. C. Shah and M. Namdar, "Real-time contact force measurement: a key parameter
for controlling lesion creation with radiofrequency energy," Circ Arrhythm
Electrophysiol, vol. 8, no. 3, pp. 713-21, 2015

[56]

A. Ikeda et al., "Relationship between catheter contact force and radiofrequency
lesion size and incidence of steam pop in the beating canine heart: electrogram
amplitude, impedance, and electrode temperature are poor predictors of electrode-

43

Introduction and Background

tissue contact force and lesion size," Circ Arrhythm Electrophysiol, vol. 7, no. 6,
pp. 1174-80, 2014
[57]

J. Kautzner et al., "EFFICAS II: optimization of catheter contact force improves
outcome of pulmonary vein isolation for paroxysmal atrial fibrillation," Europace,
vol. 17, no. 8, pp. 1229-35, 2015

[58]

A. Natale et al., "Paroxysmal AF catheter ablation with a contact force sensing
catheter: results of the prospective, multicenter SMART-AF trial," J Am Coll
Cardiol, vol. 64, no. 7, pp. 647-56, 2014

[59]

V. Y. Reddy et al., "The relationship between contact force and clinical outcome
during radiofrequency catheter ablation of atrial fibrillation in the TOCCATA
study," Heart Rhythm, vol. 9, no. 11, pp. 1789-95, 2012

[60]

V. Y. Reddy et al., "Randomized, Controlled Trial of the Safety and Effectiveness
of a Contact Force-Sensing Irrigated Catheter for Ablation of Paroxysmal Atrial
Fibrillation: Results of the TactiCath Contact Force Ablation Catheter Study for
Atrial Fibrillation (TOCCASTAR) Study," Circulation, vol. 132, no. 10, pp. 90715, 2015

[61]

N. Ariyarathna, S. Kumar, S. P. Thomas, W. G. Stevenson, and G. F. Michaud,
"Role of Contact Force Sensing in Catheter Ablation of Cardiac Arrhythmias:
Evolution or History Repeating Itself?," JACC Clin Electrophysiol, vol. 4, no. 6,
pp. 707-723, 2018

[62]

W. Ullah et al., "Factors affecting catheter contact in the human left atrium and
their impact on ablation efficacy," J Cardiovasc Electrophysiol, vol. 26, no. 2, pp.
129-36, 2015

[63]

H. Makimoto et al., "Incidence and anatomical locations of catheter instability
during circumferential pulmonary vein isolation using contact force," Int Heart J,
vol. 55, no. 3, pp. 249-55, 2014

[64]

K. Rajappan et al., "Acute and chronic pulmonary vein reconnection after atrial
fibrillation ablation: a prospective characterization of anatomical sites," Pacing
Clin Electrophysiol, vol. 31, no. 12, pp. 1598-605, 2008

[65]

A. Furnkranz et al., "Ipsilateral pulmonary vein isolation performed by a single
continuous circular lesion: role of pulmonary vein mapping during ablation,"
Europace, vol. 13, no. 7, pp. 935-41, 2011

[66]

S. Kumar et al., "Effect of respiration on catheter-tissue contact force during
ablation of atrial arrhythmias," Heart Rhythm, vol. 9, no. 7, pp. 1041-1047.e1, 2012

[67]

S. Kumar et al., "Prospective characterization of catheter-tissue contact force at
different anatomic sites during antral pulmonary vein isolation," Circ Arrhythm
Electrophysiol, vol. 5, no. 6, pp. 1124-9, 2012

1.7

References

44

[68]

R. De Ponti, R. Marazzi, L. A. Doni, J. Marazzato, C. Baratto, and J. A. SalernoUriarte, "Optimization of catheter/tissue contact during pulmonary vein isolation:
the impact of atrial rhythm," Europace, vol. 20, no. 2, pp. 288-94, 2018

[69]

A. Sarkozy et al., "Contact force variability during catheter ablation of atrial
fibrillation: the role of atrial rhythm and ventricular contractions: co-force AF
Study," Circ Arrhythm Electrophysiol, vol. 8, no. 6, pp. 1342-50, 2015

[70]

H. Matsuda et al., "Atrial rhythm influences catheter tissue contact during
radiofrequency catheter ablation of atrial fibrillation: comparison of contact force
between sinus rhythm and atrial fibrillation," Heart Vessels, vol. 31, no. 9, pp.
1544-52, 2016

[71]

A. Aizer et al., "Pacing Mediated Heart Rate Acceleration Improves Catheter
Stability and Enhances Markers for Lesion Delivery in Human Atria During Atrial
Fibrillation Ablation," JACC Clin Electrophysiol, vol. 4, no. 4, pp. 483-90, 2018

[72]

J. S. Goode, Jr., R. L. Taylor, C. W. Buffington, M. M. Klain, and D. Schwartzman,
"High-frequency jet ventilation: utility in posterior left atrial catheter ablation,"
Heart Rhythm, vol. 3, no. 1, pp. 13-9, 2006

[73]

N. Elkassabany et al., "Anesthetic management of patients undergoing pulmonary
vein isolation for treatment of atrial fibrillation using high-frequency jet
ventilation," J Cardiothorac Vasc Anesth, vol. 26, no. 3, pp. 433-8, 2012

[74]

L. Di Biase et al., "General anesthesia reduces the prevalence of pulmonary vein
reconnection during repeat ablation when compared with conscious sedation:
results from a randomized study," Heart Rhythm, vol. 8, no. 3, pp. 368-72, 2011

[75]

W. C. Beamer, D. S. Prough, R. L. Royster, W. E. Johnston, and J. C. Johnson,
"High-frequency jet ventilation produces auto-PEEP," Crit Care Med, vol. 12, no.
9, pp. 734-7, 1984

[76]

L. Di Biase et al., "Esophageal capsule endoscopy after radiofrequency catheter
ablation for atrial fibrillation: documented higher risk of luminal esophageal
damage with general anesthesia as compared with conscious sedation," Circ
Arrhythm Electrophysiol, vol. 2, no. 2, pp. 108-12, 2009

[77]

“Biosense Webster, Inc.” [Online]. Available: www.biosensewebster.com.

[78]

D. Bhakta and J. M. Miller, "Principles of electroanatomic mapping," Indian
Pacing Electrophysiol J, vol. 8, no. 1, pp. 32-50, 2008

[79]

“Abbott Laboratories, Ltd.” [Online]. Available: www.abbott.com.

[80]

X. Liu, X.-h. Wang, J.-N. Gu, L. Zhou, and J.-h. Qiu, "Electroanatomical systems
to guided circumferential pulmonary veins ablation for atrial fibrillation: initial

45

Introduction and Background

experience from comparison between the Ensite/NavX and CARTO system," Chin
Med J, vol. 118, no. 14, pp. 1156-60, 2005
[81]

“Boston Scientific, Inc.” [Online]. Available: www.bostonscientific.com.

[82]

P. Maury et al., "Comparison between novel and standard high-density 3D electroanatomical mapping systems for ablation of atrial tachycardia," Heart Vessels, vol.
34, no. 5, pp. 801-808, 2018

[83]

A. Thajudeen et al., "Correlation of scar in cardiac MRI and high-resolution contact
mapping of left ventricle in a chronic infarct model," Pacing Clin Electrophysiol,
vol. 38, no. 6, pp. 663-74, 2015

[84]

Y. Tanaka, M. Genet, L. Chuan Lee, A. J. Martin, R. Sievers, and E. P. Gerstenfeld,
"Utility of high-resolution electroanatomic mapping of the left ventricle using a
multispline basket catheter in a swine model of chronic myocardial infarction,"
Heart Rhythm, vol. 12, no. 1, pp. 144-54, 2015

[85]

L. Rottner et al., "Direct Comparison of Point-by-Point and Rapid Ultra-HighResolution Electroanatomical Mapping in Patients Scheduled for Ablation of Atrial
Fibrillation," J Cardiovasc Electrophysiol, vol. 28, no. 3, pp. 289-97, 2017

[86]

L. M. Ptaszek et al., "Rapid acquisition of high-resolution electroanatomical maps
using a novel multielectrode mapping system," J Interv Card Electrophysiol, vol.
36, no. 3, pp. 233-42, 2013

[87]

B. Pathik and J. M. Kalman, "Perceiving the Imperceptible in Atrial MacroReentry: Ultrahigh Resolution Mapping to Characterize the Critical Isthmus," Circ
Arrhythm Electrophysiol, vol. 10, no. 1, p. e004850, 2017

[88]

H. Nakagawa, A. Ikeda, T. Sharma, R. Lazzara, and W. M. Jackman, "Rapid high
resolution electroanatomical mapping: evaluation of a new system in a canine atrial
linear lesion model," Circ Arrhythm Electrophysiol, vol. 5, no. 2, pp. 417-24, 2012

[89]

D. G. Latcu et al., "Selection of Critical Isthmus in Scar-Related Atrial Tachycardia
Using a New Automated Ultrahigh Resolution Mapping System," Circ Arrhythm
Electrophysiol, vol. 10, no. 1, 2017

[90]

A. Bollmann, S. Hilbert, S. John, J. Kosiuk, and G. Hindricks, "Initial Experience
With Ultra High-Density Mapping of Human Right Atria," J Cardiovasc
Electrophysiol, vol. 27, no. 2, pp. 154-60, 2016

[91]

E. Anter, C. M. Tschabrunn, F. M. Contreras-Valdes, J. Li, and M. E. Josephson,
"Pulmonary vein isolation using the Rhythmia mapping system: Verification of
intracardiac signals using the Orion mini-basket catheter," Heart Rhythm, vol. 12,
no. 9, pp. 1927-34, 2015

1.7

References

46

[92]

E. Anter et al., "Evaluation of a novel high-resolution mapping technology for
ablation of recurrent scar-related atrial tachycardias," Heart Rhythm, vol. 13, no.
10, pp. 2048-55, 2016

[93]

D. L. Rankin and J. C. Potosky, "Force sensing catheter with a magnet and an
inductive sensor," Patent Appl. US20170290617A1, 2017.

[94]

I. Guler, D. L. Rankin, and J. C. Potosky, "Force sensing catheter with a slotted
tube element," Patent Appl. US20170143416A1, 2017.

[95]

D. L. Rankin and J. C. Potosky, "Catheter with inductive force sensing elements,"
United States Patent Appl. US20170035357A1, 2017.

[96]

M. M. Byron, J. I. Laughner, and S. Shome, "Force sensing catheter with
impedance-guided orientation," Patent Appl. US20170215802A1, 2017.

[97]

H. Nakagawa et al., "Locations of high contact force during left atrial mapping in
atrial fibrillation patients: electrogram amplitude and impedance are poor
predictors of electrode-tissue contact force for ablation of atrial fibrillation," Circ
Arrhythm Electrophysiol, vol. 6, no. 4, pp. 746-53, 2013

[98]

E. Leshem et al., "High-Resolution Mapping of Ventricular Scar: Evaluation of a
Novel Integrated Multielectrode Mapping and Ablation Catheter," JACC Clin
Electrophysiol, vol. 3, no. 3, pp. 220-31, 2017

[99]

G. Rozen et al., "Safety and efficacy of delivering high-power short-duration
radiofrequency ablation lesions utilizing a novel temperature sensing technology,"
Europace, vol. 20, no. Fi_3, pp. f444-f450, 2018

[100] E. Leshem et al., "High-Power and Short-Duration Ablation for Pulmonary Vein
Isolation: Biophysical Characterization," JACC Clin Electrophysiol, vol. 4, no. 4,
pp. 467-79, 2018
[101] M. Barkagan, F. M. Contreras-Valdes, E. Leshem, A. E. Buxton, H. Nakagawa,
and E. Anter, "High-power and short-duration ablation for pulmonary vein
isolation: Safety, efficacy, and long-term durability," J Cardiovasc Electrophysiol,
vol. 29, no. 9, pp. 1287-96, 2018
[102] K. Yokoyama et al., "Novel contact force sensor incorporated in irrigated
radiofrequency ablation catheter predicts lesion size and incidence of steam pop
and thrombus," Circ Arrhythm Electrophysiol, vol. 1, no. 5, pp. 354-362, 2008
[103] F. Bourier et al., "Fiberoptic Contact-Force Sensing Electrophysiological
Catheters: How Precise Is the Technology?," J Cardiovasc Electrophysiol, vol. 28,
no. 1, pp. 109-14, 2017

47

Introduction and Background

[104] F. Bourier et al., "Electromagnetic Contact‐Force Sensing Electrophysiological
Catheters: How Accurate Is the Technology?," J Cardiovasc Electrophysiol, vol.
27, no. 3, pp. 347-50, 2016
[105] M. W. Deyell et al., "The impact of steerable sheaths on unblinded contact force
during catheter ablation for atrial fibrillation," J Interv Card Electrophysiol, 2019
[106] C. Piorkowski et al., "Steerable versus nonsteerable sheath technology in atrial
fibrillation ablation a prospective, randomized study," Circ Arrhythm
Electrophysiol, vol. 4, no. 2, pp. 157-165, 2011
[107] W. Ullah et al., "Impact of steerable sheaths on contact forces and reconnection
sites in ablation for persistent atrial fibrillation," J Cardiovasc Electrophysiol, vol.
26, no. 3, pp. 266-73, 2015
[108] T. Kimura et al., "Operator-blinded contact force monitoring during pulmonary
vein isolation using conventional and steerable sheaths," Int J Cardiol, vol. 177,
no. 3, pp. 970-6, 2014
[109] M. Masuda et al., "Steerable versus non-steerable sheaths during pulmonary vein
isolation: impact of left atrial enlargement on the catheter-tissue contact force," J
Interv Card Electrophysiol, vol. 47, no. 1, pp. 99-107, 2016
[110] C. Piorkowski et al., "Steerable sheath catheter navigation for ablation of atrial
fibrillation: a case-control study," Pacing Clin Electrophysiol, vol. 31, no. 7, pp.
863-73, 2008
[111] “Catheter Precision, Inc.” [Online]. Available: www.catheterprecision.com.
[112] E. M. Khan et al., "First experience with a novel robotic remote catheter system:
Amigo mapping trial," J Interv Card Electrophysiol, vol. 37, no. 2, pp. 121-9, 2013
[113] T. Datino et al., "Arrhythmia ablation using the Amigo Robotic Remote Catheter
System versus manual ablation: One year follow-up results," Int J Cardiol, vol.
202, pp. 877-8, 2016
[114] A. Wutzler et al., "Robotic ablation of atrial fibrillation with a new remote catheter
system," J Interv Card Electrophysiol, vol. 40, no. 3, pp. 215-9, 2014
[115] A. Wutzler, T. Wolber, W. Haverkamp, and L. H. Boldt, "Robotic ablation of atrial
fibrillation," J Vis Exp, no. 99, p. e52560, 2015
[116] M. Lopez-Gil et al., "Cavo-tricuspid isthmus radiofrequency ablation using a novel
remote navigation catheter system in patients with typical atrial flutter," Europace,
vol. 16, no. 4, pp. 558-62, 2014
[117] “Hansen Medical, Inc.” [Online]. Available: www.aurishealth.com/hansenmedical.

1.7

References

48

[118] L. Di Biase et al., "Remote magnetic navigation: human experience in pulmonary
vein ablation," J Am Coll Cardiol, vol. 50, no. 9, pp. 868-74, 2007
[119] A. Al-Ahmad, J. D. Grossman, and P. J. Wang, "Early experience with a
computerized robotically controlled catheter system," J Interv Card Electrophysiol,
vol. 12, no. 3, pp. 199-202, 2005
[120] V. Y. Reddy et al., "View-synchronized robotic image-guided therapy for atrial
fibrillation ablation: experimental validation and clinical feasibility," Circulation,
vol. 115, no. 21, pp. 2705-14, 2007
[121] A. Dello Russo et al., "Analysis of catheter contact force during atrial fibrillation
ablation using the robotic navigation system: results from a randomized study," J
Interv Card Electrophysiol, vol. 46, no. 2, pp. 97-103, 2016
[122] B. L. Nguyen, J. L. Merino, and E. Gang, "Remote Navigation For Ablation
Procedures - A New Step Forward In The Treatment Of Cardiac Arrhythmias,"
European Cardiology Review, vol. 13, no. 2, pp. 50-6, 2010
[123] “Stereotaxis, Inc.” [Online]. Available: www.stereotaxis.com.
[124] M. N. Faddis et al., "Novel, magnetically guided catheter for endocardial mapping
and radiofrequency catheter ablation," Circulation, vol. 106, no. 23, pp. 2980-5,
2002
[125] S. Ernst et al., "Initial experience with remote catheter ablation using a novel
magnetic navigation system: magnetic remote catheter ablation," Circulation, vol.
109, no. 12, pp. 1472-5, 2004
[126] C. Pappone et al., "Robotic magnetic navigation for atrial fibrillation ablation," J
Am Coll Cardiol, vol. 47, no. 7, pp. 1390-400, 2006
[127] J. Bradfield, R. Tung, R. Mandapati, N. G. Boyle, and K. Shivkumar, "Catheter
ablation utilizing remote magnetic navigation: a review of applications and
outcomes," Pacing Clin Electrophysiol, vol. 35, no. 8, pp. 1021-34, 2012
[128] K. R. Chun et al., "Remote-controlled magnetic pulmonary vein isolation using a
new irrigated-tip catheter in patients with atrial fibrillation," Circ Arrhythm
Electrophysiol, vol. 3, no. 5, pp. 458-64, 2010
[129] R. Proietti et al., "Remote magnetic with open-irrigated catheter vs. manual
navigation for ablation of atrial fibrillation: a systematic review and meta-analysis,"
Europace, vol. 15, no. 9, pp. 1241-8, 2013
[130] S. Miyazaki et al., "Remote magnetic navigation with irrigated tip catheter for
ablation of paroxysmal atrial fibrillation," Circ Arrhythm Electrophysiol, vol. 3, no.
6, pp. 585-9, 2010

49

Introduction and Background

[131] C. Jilek et al., "Safety of implantable pacemakers and cardioverter defibrillators in
the magnetic field of a novel remote magnetic navigation system," J Cardiovasc
Electrophysiol, vol. 21, no. 10, pp. 1136-41, 2010
[132] “Magnetecs, Corp.” [Online]. Available: www.magnetecs.com.
[133] E. S. Gang et al., "Dynamically shaped magnetic fields: initial animal validation of
a new remote electrophysiology catheter guidance and control system," Circ
Arrhythm Electrophysiol, vol. 4, no. 5, pp. 770-7, 2011
[134] D. Filgueiras-Rama et al., "Remote magnetic navigation for accurate, real-time
catheter positioning and ablation in cardiac electrophysiology procedures," J Vis
Exp, no. 74, 2013
[135] Y. Thakur, J. S. Bax, D. W. Holdsworth, and M. Drangova, "Design and
performance evaluation of a remote catheter navigation system," IEEE Trans
Biomed Eng, vol. 56, no. 7, pp. 1901-8, 2009
[136] Y. Thakur, D. L. Jones, A. Skanes, R. Yee, and M. Drangova, "Right-side RF
ablation using remote catheter navigation: experimental results in vivo," J
Cardiovasc Electrophysiol, vol. 23, no. 1, pp. 81-7, 2012
[137] Y. Thakur, J. H. Cakiroglu, D. W. Holdsworth, and M. Drangova, "A device for
real-time measurement of catheter-motion and input to a catheter navigation
system," in SPIE, 2007, vol. 6509, pp. 65090G-65090G-8.
[138] Y. Thakur, D. W. Holdsworth, and M. Drangova, "Characterization of catheter
dynamics during percutaneous transluminal catheter procedures," IEEE Trans
Biomed Eng, vol. 56, no. 8, pp. 2140-3, 2009
[139] M. A. Tavallaei, Y. Thakur, S. Haider, and M. Drangova, "A magnetic-resonanceimaging-compatible remote catheter navigation system," IEEE Trans Biomed Eng,
vol. 60, no. 4, pp. 899-905, 2013
[140] M. A. Tavallaei, M. K. Lavdas, D. Gelman, and M. Drangova, "Magnetic resonance
imaging compatible remote catheter navigation system with 3 degrees of freedom,"
Int J Comput Assist Radiol Surg, vol. 11, no. 8, pp. 1537-45, 2016
[141] M. A. Tavallaei et al., "Design, development and evaluation of a compact
telerobotic catheter navigation system," Int J Med Robot, vol. 12, no. 3, pp. 44252, 2016
[142] L. Cercenelli, B. Bortolani, and E. Marcelli, "CathROB: A Highly Compact and
Versatile Remote Catheter Navigation System," Appl Bionics Biomech, vol. 2017,
no. 2712453, 2017
[143] S. B. Kesner and R. D. Howe, "Position Control of Motion Compensation Cardiac
Catheters," IEEE Trans Robot, vol. PP, no. 99, pp. 1-11, 2011

1.7

References

50

[144] S. B. Kesner and R. D. Howe, "Design and Control of Motion Compensation
Cardiac Catheters," in IEEE Int Conf Robot Autom, 2010, pp. 1059-65.
[145] S. B. Kesner and R. D. Howe, "Design Principles for Rapid Prototyping Forces
Sensors using 3D Printing," IEEE ASME Trans Mechatron, vol. PP, no. 99, pp. 15, 2011
[146] S. B. Kesner and R. D. Howe, "Force Control of Flexible Catheter Robots for
Beating Heart Surgery," in IEEE Int Conf Robot Autom, 2011, pp. 1589-94.
[147] M. Khoshnam, M. Azizian, and R. V. Patel, "Modeling of a steerable catheter based
on beam theory," in Int Conf Robot Autom, IEEE, 2012, pp. 4681-6.
[148] M. Khoshnam, A. C. Skanes, and R. V. Patel, "Modeling and estimation of tip
contact force for steerable ablation catheters," IEEE Trans Biomed Eng, vol. 62,
no. 5, pp. 1404-15, 2015
[149] M. Khoshnam and R. V. Patel, "Robotics-assisted catheter manipulation for
improving cardiac ablation efficiency," in International Conference on Biomedical
Robotics and Biomechatronics, 2014: IEEE, pp. 308-13.

2

Design and Evaluation of a Catheter ContactForce Controller

This chapter is adapted from “Design and Evaluation of a Catheter Contact-Force
Controller for Cardiac Ablation Therapy.”1
My contribution to this chapter involved (i) designing and developing the catheter contactforce controller, (ii) designing and developing phantoms, (iii) conducting experiments, (iv)
collecting and analyzing data, and (v) writing manuscripts.

2.1

Introduction

Percutaneous radiofrequency (RF) catheter ablation is becoming the standard of care for a
variety of cardiac arrhythmias. Cardiac electrophysiologists (EP) introduce ablation
catheters into the heart and manipulate them until the distal tip contacts the targeted
myocardium. Once reached, RF power is delivered to form ablation lesions that interrupt
the electrical pathways responsible for the arrhythmia. For successful treatment, it is vital

1

Gelman D, Tavallaei MA, Skanes AC, Drangova M. “Design and Evaluation of a Catheter Contact-Force
Controller,” IEEE Transactions on Biomedical Engineering (vol. 63, no. 11, pp. 2301-2307). Permission
for reproduction provided in Appendix A.
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that these lesions are transmural, as superficial lesions leave areas of healthy cardiac tissue
that may result in conduction recurrence and ablation failure.
Catheter tip-to-tissue contact force (CF) is an indicator for assessing lesion development
[1-5], and CF guidelines have been established to label a delivered lesion as effective [68]. Additional studies have shown that monitoring both the duration of the delivery and CF
at a specific RF power can predict lesion volume [3, 6-11]. Conventionally described as
the Force-Time Integral (FTI), the model may be used as a prospective quantitative tool to
determine lesion volume under defined parameters. Unfortunately, this model is dependent
on catheter stability, and while used in the clinic as a guide, it has not been used as a
quantitative metric that can predict lesion volume or transmurality. Finally, lesions
delivered with excessive CF present a risk of deep tissue overheating, which may result in
“steam pop,” perforation and injury outside the heart, including esophageal, pulmonary and
phrenic nerve damage [2]. These potential risks often inhibit the EP and cause them to
deliver the lesion tentatively, with a lower level of CF to lessen the risk of injury. Clinically,
CF information is often used as a guide to ensure catheter tip contact and confine the CF
within acceptable ranges, but is ultimately limited by tissue motion, as seen in the CF
profile in the lower right-hand corner of Figure 2.1.
While ideally, the CF should be regulated within a prescribed range, EP cannot respond
fast enough to compensate for cardiorespiratory motion [12]. Approaches to minimize
cardiac motion during ablation, have been proposed, including high-frequency-jet
ventilation [13]. None have successfully provided a motionless environment in all patients
[14]. Kesner et al. [15] demonstrated CF control of catheters and instruments used for
mitral valve repair; however, the implementation does not address problems associated
with catheter ablation.
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Figure 2.1. Modern electromagnetic catheter tracking systems
(CARTO® 3, Biosense Webster, Irvine, CA) enable visual feedback of
the real-time CF experienced on the tip of the catheter
(THERMOCOOL® SMARTTOUCH™, Biosense Webster, Irvine,
CA). The figure is a snapshot demonstrating catheter location in the
rendered LA (white with green tip) and the CF as a function of time in
the lower right-hand corner. Note the variation in CF with
cardiorespiratory motion. Image courtesy of London Health Science
Center.

Commercial force-sensing ablation catheters enable the EP to simultaneously monitor the
CF in real-time while delivering the lesion, as illustrated in Figure 2.1. Often these
catheters are used together with steerable sheaths, whose added level of versatility and
stability has increased clinical success [13, 16, 17]. The EP typically manipulates the
steerable sheath until the catheter is pointing at the target region, and then advances the
catheter forward through the sheath until the desired level of CF is imparted onto the tissue.
In this chapter, we introduce a tool that enables the delivery of effective RF lesions by
autonomously regulating the CF of a force-sensing ablation catheter, based only on the
real-time CF measurements. The Catheter Contact-Force Controller (CFC) is a hand-held,
modular device that enables robotic control of the catheter within the sheath, which
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otherwise would be done manually by the interventionalist. The CFC is an add-on tool
compatible with commercially available, pre-existing force-sensing ablation catheters and
sheaths.

2.2

System Description

Incorporation of the CFC replaces the manual manipulation of the catheter through the
sheath. Rather than advancing the catheter forward until a sufficient CF level is reached,
the interventionalist would engage the CFC, which monitors the CF in real-time and
updates the position of the catheter to maintain the CF experienced at the tip of the catheter
at the desired level, despite the motion of the target tissue. The CFC system comprises a
hand-held, compact, electromechanical device and an embedded system.

2.2.1

Hand-Held Device

The hand-held CFC device, Figure 2.2, is mechanically clamped to the distal end of the
sheath handle (i.e., at the hemostatic seal and insertion point of the catheter). A catheterlocking adapter rigidly clamps the catheter shaft onto a precision linear actuator (LM 2070,
MICROMO, Clearwater, FL) travelling along a 12 mm diameter 134 mm long precision
magnetic shaft. Movement of the actuator directly translates to movement of the catheter
through the sheath. The specific linear actuator selected in the design was selected based
on velocity, acceleration and torque requirements described in Appendix B.
The adapter and actuator are mounted within an enclosure, which is designed to securely
lock onto the sheath handle while keeping the catheter concentrically mounted within the
hemostatic seal. A set of hinges and latches enables easy clamping and removal of the CFC.
Both the adapter and enclosure were fabricated in polypropylene using additive
manufacturing (Objet3D Pro, Stratasys, Eden Prairie, MN).
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Figure 2.2. Schematic side-view, A, and photograph top-view, B, of the
electromechanical hand-held CFC attached to a steerable sheath and
force-sensing ablation catheter. Movement of the linear actuator along
the fixed magnetic rod moves the catheter through the hemostatic seal of
the sheath handle.

2.2.2

Hybrid Control System

To maintain a prescribed CF between the tip of the catheter and a moving target, we
implemented a hybrid control system. Traditional closed-loop proportional-integralderivative (PID) control algorithms are based on minimizing the error between the desired
and actual inputs and are a viable solution in robotic catheter control systems [18-21]. The
CFC uses a hybrid PID controller, a slight variation of a standard PID controller, whose
control parameters change based on the error argument. The control signal u(t) is calculated
as:
𝑡

𝐾𝑃𝐴 𝑒(𝑡) + 𝐾𝐼𝐴 ∫ 𝑒(𝜏)𝑑𝜏 + 𝐾𝐷𝐴
0
𝑡

𝑢(𝑡) =
{

𝐾𝑃𝐶 𝑒(𝑡) + 𝐾𝐼𝐶 ∫ 𝑒(𝜏)𝑑𝜏 + 𝐾𝐷𝐶
0

𝑑𝑒(𝑡)
𝑑𝑡

𝑒(𝑡) > 𝐹𝑇

𝑑𝑒(𝑡)
𝑑𝑡

0 < 𝑒(𝑡) ≤ 𝐹𝑇
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where the error e(t) is the difference between the desired and current contact forces, FD and
FC(t) respectively. The control parameters KP, KI and KD generate a different control signal
depending on the error measured in real-time. If the error is larger than a predefined CF
threshold, FT, the control system is in an “aggressive” state indicated by KPA, KIA, KDA.
When the error is lower than FT, the control system operates in a “conservative” state
indicated by KPC, KIC, KDC. The CF threshold was empirically assigned to be 5 g – a level
that was observed to retain steady-state accuracy.
Tuning of the aggressive control parameters was achieved using the Tyrues-Luyben tuning
method, as implemented by [22]. The conservative control parameters were manually tuned
for a desired steady-state response; in the current implementation, the conservative control
parameters were at least a factor of 4 smaller than the aggressive ones.

2.2.3

Electronic Hardware Design

The hybrid control system was implemented within an embedded electronic system,
enabling real-time control of the linear actuator. A microcontroller development platform
based on a Atmel SAM3X8E 84 MHz 32-bit ARM architecture (Arduino Due, Arduino,
Turin, Italy) generates a pulse-width modulated (PWM) control signal, based on the
measured and desired CF, which acts as input to the linear actuator controller and driver
circuitry (MCLM 3003, MICROMO, Clearwater, FL). This daughter-board is programmed
with a native velocity proportional-integral (PI) controller that controls the speed of the
motor based on the input PWM signal. Tuning of the PI controller was performed using
the manufacturer’s tuning software, before tuning the hybrid PID system. The update rate
of the hybrid PID system was set to 1 kHz, which was the maximum rate of the linear
actuator controller. A sampling rate exceeding 300 Hz will meet all requirements. This
figure is based on “best practice,” which is to sample the force data at a rate ten times faster
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than the time constant associated with the open-loop response of the system. Figure 2.3 is
a block diagram of the designed embedded system.

Figure 2.3. Block diagram of the CFC control system.

2.2.4

Linear Motion Phantom

To evaluate the CFC’s ability to regulate CF on a moving target in vitro, a custom-built
linear motion phantom was developed (Figure 2.4). The motion phantom was built to
provide sinusoidal and physiologic motion profiles. A gear motor with a Hall effect
encoder (37D Gearmotor, Pololu, Las Vegas, NV) drives a lead screw mechanism
providing linear motion to a carriage. A second PID control system within an embedded
electronic system controls the motion stage: the circuit board assembly includes a
microcontroller development platform (Arduino Due, Arduino, Turin, Italy) and a DC
motor driver daughter-board (VNH5019 Motor Driver Carrier, Pololu, Las Vegas, NV). A
strain gauge capable of detecting the force with 200-milligram resolution (S100, Strain
Measurement Devices, Wallingford, CT), coupled to a linear amplifier (CSG110, FUTEK,
Irvine, CA), is mounted on the carriage and used to measure the CF of the tip of the
catheter. The force signal provided by the strain gauge is a surrogate to the real-time force
signal provided by the catheter tip. A silicone membrane (Dragon Skin 30, Smooth-On,
Macungie, PA) is positioned between the strain gauge and the tip of the catheter to mimic
soft tissue compliance. A setscrew fixes the sheath firmly in place without hindering the

2.2

System Description

58

movement of the catheter housed within the sheath. Linear calibration, according to
Hooke’s law, was first performed to determine the relationship between the displacement
of the tissue and the force measured by the strain gauge.

Figure 2.4. Linear motion phantom with the catheter and sheath loaded,
used to evaluate the CFC. The linear motion imposed on the tip of the
catheter simulates myocardial tissue motion.

The phantom was programmed to execute arbitrary sinusoidal and sine-sweep motion
profiles and to replicate physiological motion. CF profiles were recorded by force-sensing
ablation catheters during typical ablation procedures, similar to the profile illustrated in
Figure 2.1. These profiles, containing both high-frequency low-amplitude cardiac and
low-frequency high-amplitude respiratory motion, were programmed into the motion
phantom as position trajectories, using the linear calibration parameters.
The signal from the strain gauge, measured in real-time, was used as the CF feedback signal
of the CFC control system (Figure 2.3) and represented the CF signal that would be
provided by a commercial force-sensing ablation catheter. Real-time CF data from
proprietary catheters is not available routinely and could not be integrated with the CFC at
the time of these experiments.
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System Evaluation
Linear Motion Phantom Evaluation

The linear motion phantom was first evaluated to ensure that the executed motion profiles
mimic the physiological motion that results in CF profiles similar to those measured
clinically. The catheter was held fixed while the linear motion phantom imposed 16
different patient-specific motion profiles. The sheath was locked in place for half of the
experiments. The real-time CF measurements provided by the strain gauge were recorded
and compared to the corresponding CF profiles. No attempt was made to perfectly match
the executed CF profiles to the corresponding patient profiles, and the measured CF
profiles were only inspected visually, ensuring the range of amplitudes and frequencies
were within the physiologic range.

2.3.2

Catheter Contact-Force Controller Evaluation

Experiments were performed to evaluate the overall accuracy and dynamic performance of
the CFC. For these experiments, the CFC was attached to the rear end of a commonly used
steerable sheath (Agilis™ NxT, St. Jude Medical, St. Paul, MN) and force-sensing ablation
catheter (THERMOCOOL® SMARTTOUCH™, Biosense Webster, Irvine, CA)
combination. Water was introduced via the sheath’s side port to mimic the clinical setting
and reduce the friction between the sheath and catheter. The distal portions of the sheath
and catheter were inserted into the linear motion phantom, as illustrated in Figure 2.5.
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Figure 2.5. The experimental setup used to evaluate the performance of
the CFC. A is a line drawing (not to scale) showing the CFC, B sheath
and catheter mounted with the linear motion phantom; photographs of
the CFC C, and motion phantom D are also shown.

2.3.2.1

Step Response

The response of the CFC control system to a step input (of 25 g) was first evaluated. The
step response was then measured during 25 repeats and the rise time, overshoot, and peak
level were characterized. During these experiments, the linear motion phantom was kept
fixed.

2.3.2.2

Safety

It is vital to ensure that the CFC can respond to excessive, fast and sudden motions that
may result in tissue perforation. The linear motion phantom was programmed to impose a
bi-directional continuous sine sweep motion profile, sweeping from 0.1 Hz to 2.5 Hz with
an amplitude of 70 g peak-to-peak. This unlikely clinical scenario was selected following
Fourier analysis of over 40 patient-specific CF profiles and determining that the maximum
frequency component observed was 2.5 Hz. While the phantom executed the prescribed
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motion, the CFC was engaged and attempted to regulate the CF to the desired reference of
25 g. The maximum error between the desired and actual CF was measured. This
experiment was repeated 10 times.

2.3.2.3

Patient-Specific Dynamic Response

To evaluate the overall performance of the CFC versus manual intervention, the linear
motion phantom was programmed to execute 16 different patient motion profiles. Prior to
any evaluation of the CFC, a control experiment was performed whereby the phantom
replicated each profile with the CFC’s disabled. This is representative of manual
intervention, where the EP contacts the catheter to moving cardiac tissue and holds the
catheter still to deliver a lesion. The experiment was then repeated with the CFC
programmed to deliver 15 g, 25 g, and 40 g for the duration of the motion profile. Statistical
analysis of the regulated CF profiles was performed to calculate mean, confidence interval,
and root-mean-square error (RMSE). Histograms of CF were also plotted for the “manual”
and CFC interventions. Note that for this study, we use the term “manual” to refer to the
CF profile representative of CF profiles recorded during clinical ablation procedures.

2.3.2.4

Force-Time Integral

This experiment was designed to demonstrate that the CFC could be used not only to
regulate the delivered force but also to deliver lesions with prescribed FTI. The CFC was
programmed to deliver a prescribed FTI at the desired CF while the linear motion phantom
imposed a patient motion profile. For each combination of set CF and FTI levels, an
expected duration can be calculated. The CFC was programmed to monitor the FTI, and
automatically retract the tip of the catheter back into the sheath once the desired FTI was
reached. The generated CF profile and duration of catheter engagement was recorded and
compared with expected values. This experiment was then repeated for various
configurations of FTI and CF, which may be user-defined in a clinical setting. The tested
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FTI values were 500, 1000, and 1500 gs, where each was repeated with 25 g and 40 g of
CF. Each configuration was repeated 3 times.

2.4
2.4.1

Results
Linear Motion Phantom

Figure 2.6. Two representative patient CF profiles (A and C) and the
corresponding CF profiles (B and D, respectively) imposed on a fixed
catheter tip by the linear motion phantom, executing the same patient
profile. The motion profiles depicted in B and D are profile #13 and #3
in Figure 2.8D, respectively.

The linear motion phantom was able to replicate a range of patient-specific CF profiles.
The profiles chosen to evaluate the CFC are characteristic of typical cardiorespiratory
patterns depicted in Figure 2.6A as well as irregular profiles associated with patient motion
or catheter instability depicted in Figure 2.6C. The generated CF curves, shown in Figure
2.6B and Figure 2.6D, visually demonstrate a high level of similarity to the corresponding
clinically acquired profiles (Figure 2.6A and Figure 2.6C). These results demonstrate that
the linear motion phantom can replicate cardiorespiratory forces that are typically
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encountered during catheter RF delivery and is appropriate to be used as a phantom for the
CFC’s evaluation. Locking the sheath in place did not affect the results.

2.4.2
2.4.2.1

CFC Performance
Step Response

The response of the CFC’s control system to a 25 g step input is shown in Figure 2.7. The
following step response characteristics were calculated from the measurements: 38 ± 3 ms
rise time, 3 ± 2 g overshoot, and a peak of 29 ± 2 g; means and standard deviations of 25
repeats of the step response are reported. The negligible overshoot and oscillation indicate
that the tuning method used to determine the control parameters has resulted in a desired
transient and steady-state response.

Figure 2.7. Step response of the CFC for a set force level of 25 g. At
every time point, the mean and standard deviation are plotted.

2.4.2.2

Safety

During the control of a 70 g peak-to-peak sine sweep from 0.1 Hz to 2.5 Hz, the maximum
difference between the prescribed and measured CF was 15 ± 2 g, with all measured CF
values being below 42 g. These results demonstrate that the CFC is capable of reacting to
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sudden changes in tissue displacement that would otherwise result in large spikes of CF
and potentially cause tissue damage.

2.4.2.3

Patient-Specific Dynamic Response

Figure 2.8. Histograms A-C show the distribution of manual and CFCcontrolled CF for three unique motion profiles (16,15, and 9 from panel
D, respectively). The manual intervention histograms indicate that: A
majority of time was spent while CF was low (less than 20 g), B
significant myocardial motion resulting in greatly fluctuation CF, and C
a precise lesion was delivered but the force was not centred at the 25 g
target. In each case, CFC-control brings the mean CF to the target.
Histograms of manual D and CFC-controlled E interventions,
represented as grey scale values, show a significant difference in CF
distribution for all 16 motion profiles.

The CFC was able to significantly improve the CF profile in comparison to manual
intervention (p < 0.001). Figure 2.8A through Figure 2.8C depicts the distribution of
measured CF for three motion profiles, representative of CFs measured during the delivery
of different lesions; histograms are plotted for both manual and CFC-controlled
interventions, with a prescribed CF level of 25 g. The images in Figure 2.8D (manual) and
Figure 2.8E (CFC-controlled) are grey-scale representations of the CF histograms for all
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16 motion profiles; they clearly demonstrate that when the CFC is engaged the prescribed
mean force is achieved for all motion profiles.
Similar performance was achieved regardless of the magnitude of the prescribed CF.
Illustrated in Figure 2.9, are the results for one representative experiment where the CFC
was programmed to deliver a CF of three clinically relevant levels – 15 g, 25 g, and 40 g.
Consistently similar force distributions were achieved regardless of the prescribed CF
value. Detailed performance metrics – averaged over all tested motion profiles – are shown
in Table 2.1 for the three prescribed CF levels.

Figure 2.9. A original CF profile (green), while the CFC was disabled.
B illustrates the generated CF profile while the CFC was engaged to
deliver 15 g (cyan), 25 g (orange) and 40 g (navy). Histogram C and
grey-scale representation D illustrate the CF distribution between
manual and CFC intervention at various desired CF levels. The motion
profile depicted here is profile #1 from Figure 2.8D.
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Prescribed CF (g)

15

25

40

5% Percentile

10.1 ± 1.2

19.7 ± 1.2

34.3 ± 1.2

95% Percentile

20.6 ± 1.3

31.1 ± 1.5

46.9 ± 1.7

Mean

15.3 ± 0.1

25.4 ± 0.1

40.4 ± 0.1

RMSE

3.2 ± 0.6

3.4 ± 0.7

3.9 ± 0.8

Table 2.1. All measurements are presented in grams (g) of force. Mean
and standard deviation of all 16 profiles are reported.

2.4.2.4

Force-Time Integral

For all experiments performed to demonstrate that the CFC could achieve a target FTI, the
CFC successfully engaged the catheter with the desired CF until a target FTI was reached.
The results obtained with each configuration of FTI and CF are presented in Table 2.2.

Desired
FTI
(gs)

Expected

Measured

CF
(g)

Duration
(s)

FTI
(gs)

CF
(g)

Duration
(s)

25

20

500

25.7 ± 3.0

19.49 ± 0.01

40

12.5

500

40.7 ± 3.5

12.29 ± 0.01

25

40

1000

25.4 ± 3.1

39.36 ± 0.04

40

25

999

40.4 ± 3.4

24.71 ± 0.01

25

60

1500

25.3 ± 3.0

59.27 ± 0.06

40

37.5

1499

40.4 ± 3.4

36.99 ± 0.22

500

1000

1500

Table 2.2. Results obtained with each configuration of FTI and CF
tested. The measure CF and duration are comparable to the expected
outcome.

A representative experiment is illustrated in Figure 2.10. The lesion delivery time was
within 480 ± 199 ms of the expected duration. This is indicative of a regulated CF profile
throughout the delivery, as excessive CF would result in short lesion delivery times and
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low CF levels would result in the opposite. With each configuration of desired CF and FTI,
a similar profile was generated with an expected and predictable deviation.

Figure 2.10. Interval 0-30 s, the catheter was in contact with the phantom
while the CFC was disabled. Interval 30-49.5 s, the CFC was engaged to
deliver 500 gs at 25 g. Interval 49.5-55 s, the tip of the catheter retracted
into the sheath once the desired FTI (red) had been reached. The motion
profile depicted here is profile #15 from Figure 2.8D.

2.5

Discussion

We have presented a novel and easy-to-use tool that regulates the CF imparted by standard
ablation catheters on moving tissue regardless of the type of motion imposed. The compact
hand-held device is used with commercially available force-sensing ablation catheters and
steerable sheaths, which are widely used in modern EP labs. The presented CFC utilizes
the same tools and information available to the interventionalist but grants the ability to
regulate CF and FTI.
While CF measurement (at the tip of an ablation catheter) has been available to the EP for
some time, it has been used primarily as a visual guide to determine if adequate contact has
been made or if there is a risk of tissue perforation. The CFC has been demonstrated to
control the force at the tip of the catheter to within a few grams of a prescribed force level.
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The CF profiles, recorded during clinical ablation procedures, used to impart clinically
relevant motion for evaluating the CFC and shown in Figure 2.8 demonstrate some of the
problems associated with ablation delivery. For example, profile #16 (Figure 2.8A)
represents a lesion where negligible force existed between the catheter tip and the wall
during most of the time RF power was being delivered; when the CFC was engaged the
mean CF was increased to 25 g, as prescribed. Similarly, the scenario depicted in Figure
2.8B demonstrates large variations in CF (manual) due to motion, which is corrected via
the use of the CFC, reducing the RMSE (about 25 g) from 15.1 to 5.5 g. Even when a tight
distribution of forces is achieved manually, as in Figure 2.8C, the mean CF may not be at
a level sufficiently high for the delivery of a transmural lesion – use of the CFC, in this
case, shifts the distribution of CF from being centred about 15 g to being centred about 25
g. Consistently narrow, and symmetric, distributions of CF were also achieved for different
prescribed CF levels (Figure 2.9, Table 2.1).
Successful control of CF over the duration of lesion “delivery” also enabled control of FTI.
Automatic engagement and retraction of the catheter for specified FTI at the desired CF
has the potential to become a fundamental and powerful tool in the EP lab. While FTI has
been proposed as a useful measure in predicting lesion transmurality and volume, without
a device like the CFC, FTI cannot be easily used as a metric clinically or in preclinical
studies aimed at optimizing lesion delivery parameters.
The study evaluating the performance of the CFC under conditions of rapidly varying
motion have also demonstrated that the use of the CFC clinically has the potential to
minimize tissue damage due to excessive force. The CFC was able to compensate for
changes in CF as fast as 700 g/s and maintain CF within 15 g of the prescribed values.
These results are significant because they indicate that using the CFC, forces able to
perforate tissue [23] would never be achieved.
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The CFC was designed as a hand-held device that would enable the interventionalist to
engage it at any point during a complete ablation procedure but is free to perform all other
tasks as is done under current clinical practice. The CFC can easily be removed from the
catheter and sheath assembly to ensure optimal catheter steerability and be re-clamped
when a target location has been reached, just prior to RF power delivery. The device is
versatile and can be used as a stand-alone CF control aid or can be incorporated with
catheter robotic navigation systems for further improvements in position and force control.
Ongoing in vitro and in vivo studies aim to demonstrate the full effectiveness of the CFC
in controlling lesion volume.

2.6

Limitations

Despite the extremely promising results, it is important to note that the study is limited by
the fact that the motion of an in vitro dynamic phantom was used as a surrogate for contact
force measured at the catheter tip during CFC evaluation; the limitation is manifested in
two ways. First, using a strain gauge positioned behind tissue-simulating silicone to
provide CF measurements introduced damping of the CF that would have been measured
at the tip of the catheter (i.e. at the interface of the catheter and silicone). Implementation
of the CFC with a force-sensing catheter would require re-tuning of the control parameters
to account for the different dynamics. Second, for the phantom based experiments, the
acquired CF data were implemented as linear motion profiles with the catheter placed
perpendicular to the surface of the tissue. This experimental design assumed that the
catheter was oriented the same way during the acquisition of the clinical data. If clinically,
the catheter tip was oriented at an oblique angle, larger motion profiles would correspond
to the measured forces. All tested force profiles were collected in different parts of the left
atrium within a single patient. This has implications as the phantom has a perpendicular
only approach and may not simulate the catheter extended at an angle or with a curve. It is
likely, however, that the exact characteristics of cardiac tissue motion will contain the same
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frequency components as the profiles used in this study, which ultimately does not affect
the implemented control system of the CFC.
All CF profiles used to evaluate the CFC were acquired from patients undergoing
pulmonary vein isolation ablation therapy and may not be representative of the CF profiles
measured during ablation therapies of the left ventricle. During left ventricular ablation
procedures CF may change more rapidly due to systolic motion. The safety experiments
performed as part of the present study contained CF waveforms with high changes of CF,
larger than would be expected in ventricular ablations, and these preliminary tests provide
confidence that the CFC will be able to control force even during ventricular ablations.
In all experiments, the distance between the tip of the catheter and the tip of the sheath was
limited to less than 30 mm. Based on interviews with cardiac electrophysiologists, when
using a steerable sheath, it is uncommon to exceed this distance. The performance of the
CFC has not been tested with greater distances. Furthermore, it is important to note that
the CFC will only work correctly when the catheter is adequately supported by the sheath
at the distal tip. As such, significant catheter deflection and extension may compromise
CFC performance.

2.7

Conclusions

This study represents the first demonstration of contact force control using a versatile handheld catheter contact force controller, which can be coupled to any force-sensing ablation
catheter and steerable sheath combination. The demonstrated control of contact force under
varying motion conditions is promising and suggests that – when implemented in
combination with a force-sensing catheter – the CFC can deliver prescribed ablation
lesions.
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Eliminating the Effects of Motion during RF
Ablation Delivery

This chapter is adapted from “Eliminating the Effects of Motion during Radiofrequency
Lesion Delivery using a Novel Contact-Force Controller.”2
My contribution to this chapter involved (i) integrating technologies, (ii) developing novel
control systems, (iii) designing and developing phantoms, (iv) designing and conducting
experiments, (v) collecting and analyzing data, and (vi) writing manuscripts.

3.1

Introduction

Catheter-tissue contact force is a major determinant of catheter ablation lesion size
uncertainty during radiofrequency (RF) power application [1-5]. Insufficient contact force
results in inadequate lesion production and increased AF recurrence rates [6-8], while
excessive contact force is associated with tissue over-heating, increased incidence of steam
pops, perforation, thrombus formation, and collateral tissue damage to the esophagus and
phrenic nerve [2, 9-13]. In addition to the average force, contact-force variability has been
shown to be an essential parameter in determining RF lesion formation [14]. Improving

2

Gelman D, Skanes AC, Jones DL, Timofeyev M, Baron T, Drangova M. “Eliminating the Effects of
Motion during Radiofrequency Lesion Delivery using a Novel Contact-Force Controller,” Journal of
Cardiovascular Electrophysiology (Accepted).
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contact-force stability enables RF power to be effectively deposited within the tissue and
not the surrounding blood pool, and this, in turn, could be critical to achieving long-term
success [15].
A recent meta-analysis, summarizing all randomized controlled trials investigating contact
force in AF ablation, reports that contact force variability, rather than average force alone,
has emerged as a critical element that governs lesion size and ablation outcomes [16]. The
EFFICAS II trial demonstrated durable PVI using a contact-force target of 20 g, with a
narrow range between 10 g and 30 g [4]. Similarly, the SMART-AF trial showed an
increase in clinical success when more time was spent within a pre-defined force range (i.e.
reduced force variability) [15]; operators who stayed within a selected range for more than
80% of the time during RF applications were more than 4 times more likely to have clinical
success in comparison to those who did not. In further studies, Ullah et al. [17] showed
that, for the same accumulated FTI, RF ablation lesions delivered with contact-force
variation less than 5 g significantly increased impedance drops and achieved higher
maximums compared to lesions with greater variation [17]. The authors of this study
suggest that improving force stability rather than merely delivering more FTI can produce
more effective lesions. In a similar study, Makimoto et al. [18] found that a relative
standard deviation less than 30% of the mean force (e.g. 10 ± 3 g or 20 ± 6 g) correlated
with a reduction in reconnection gaps during PVI [18]. Both of these studies identified
regional locations typically associated with AF reconnection, such as the LA roof, with
parameters demonstrating high contact-force variability.
Despite this evidence, in clinical practice, it is virtually impossible to maintain sufficient
average contact force and reduce contact-force variability reliably [18-22]. The
adjustments made by an operator are limited by human factors (perception and reaction
time) and system delays (including time required to average and display a mean force
level), making it impossible to compensate for force variability in real-time and
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highlighting the clear need for new technology to control catheter-tissue contact force and
optimize catheter ablation techniques.
In our previous work [23], we developed and evaluated a catheter contact-force controller
(CFC) that monitors catheter-tissue contact force in real-time and simultaneously adjusts
the position of the ablation catheter within a sheath to compensate for variations in contact
force that occur due to cardiorespiratory motion. Preliminary lab-bench tests demonstrated
that using the CFC resulted in significant improvement in the stability and control of
catheter-tissue contact force on moving tissue-mimicking material.
The aim of the present study was to demonstrate the ability of the CFC to maintain a set
level of force in vivo and determine the device’s impact on lesion production when
compared to manual intervention. In the first part of the study, the device was tested in a
porcine model in vivo, where an experienced electrophysiologist attempted to maintain a
set force level with and without the assistance of the CFC. In the second part of the study,
an in vitro contractile bench model tested the hypothesis that the CFC helps deliver
prescribed and reproducible ablation lesions despite the presence of clinically relevant
tissue motion under fixed conditions of RF power and duration. In these experiments, the
sizes of lesions delivered to moving tissue samples with and without the CFC were
compared to lesions delivered to stationary tissue.

3.2
3.2.1

Methods
Catheter Contact-Force Controller

The CFC is a simple add-on to a conventional force-sensing catheter used in conjunction
with a steerable sheath, as described in detail in Chapter 2 [23]. Briefly, the CFC actuation
unit is clamped onto the back-end of a steerable sheath near the hemostatic seal (Figure
3.1); a linear motor clamped onto the catheter shaft via a locking adaptor adjusts catheter
motion with respect to the sheath. The CFC’s embedded electronics monitor the CF in real-
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time and use 1 of 2 control algorithms to adjust the catheter position within the sheath in
order to maintain constant force at the catheter tip.

Figure 3.1. Schematic diagram A and photograph B of the CFC
actuation unit attached to an ablation catheter and steerable sheath. A
locking adaptor clamps the CFC to a linear actuator (shown in B), which
enables the catheter to be displaced axially within the sheath.

First, a model-based adaptive control system [24] was implemented to assist in cases where
gradual changes in CF are required (e.g. respiratory motion). However, such adaptive
algorithms perform poorly in the presence of large, rapid fluctuations of CF, such as those
caused by systolic-diastolic motion. To address this, an additional control system, which
uses repetitive control [25], was implemented. Specifically, the repetitive control system
uses the heart rate, derived from the ECG, as a priori information to improve disturbancerejection performance during the presence of fast-moving periodic cardiac motion. In the
current implementation, the user selected the control mode (adaptive versus repetitive)
based on the observed CF profile. Further detail about the two control systems is presented
in Appendix C.
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Force Control Performance In Vivo

Animal studies were performed in accordance with institutional and national guidelines
and approved by the University of Western Ontario Animal Use and Care Committee
(Protocol #2013-064, Appendix D). Two male farm pigs weighing approximately 35 kg
were used for the study.

Figure 3.2. Photograph of the CFC, left, and the in vivo experimental
setup, right.

Using standard procedures, each pig was anesthetized and prepared for catheterization [26].
Each pig was intubated, and the ventilation rate was set for 20 BPM. A research-based
electro-anatomical catheter mapping system (CARTO® 3, Biosense Webster, Irvine, CA),
mobile C-arm fluoroscopic x-ray unit (OEC 9900 Elite, General Electric, Boston, MA),
and intracardiac echocardiography system (Acuson Sequoia, Seimens, Munich, Germany)
were used to assist catheter navigation (Figure 3.2). A steerable sheath (Agilis™ NxT,
Abbott

Laboratories,

St.

Paul,

MN)

and

a

force-sensing

ablation

catheter

(THERMOCOOL® SMARTTOUCH™, Biosense Webster, Irvine, CA) with the CFC
attached were inserted into the heart via right femoral access. A pace-making lead attached
to an external generator was introduced via the right jugular vein and placed in the superior
RA to provide cardiac pacing at 115 BPM throughout the experiment. A shaped trans-
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septal needle (Brockenbrough, Medtronic, Minneapolis, MN) was introduced via the left
femoral vein and used to gain access to the left side of the heart, under the guidance of an
intracardiac echocardiography catheter (Acuson AcuNav, Seimens, Munich, Germany).
A skilled electrophysiologist (A.C.S.) manipulated the catheter and steerable sheath to
target locations in the LA, RA and LV. At each location, the physician attempted to
maintain 20 g for 30 seconds with manual catheter intervention. The CFC was then enabled
and set to maintain the force at 20 g. For all interventions, the catheter tip was maintained
perpendicular to the surface of the tissue to mimic ideal ablation conditions and maximize
motion-related force variability; a catheter-tissue incidence angle of between 0° and 45°
from normal was considered perpendicular, as defined by Ullah et al. [17]. The electroanatomical mapping system continuously displays the force angle, and experiments were
performed only when perpendicular catheter angle was achieved. It is important to note
that the anatomy of the pig LA is quite different from the human. Most importantly, the
PV region is often a confluence with minimal musculature. Also, the LA appendage is very
large and makes up a large portion of the surface area. Sites in the LA were targeted as
follows; after transseptal access was obtained the catheter was advanced to the LA
appendage, withdrawn to the LA roof and turned posteriorly to the posterior LA wall to
allow sampling of several sites within the LA.
Contact-force profiles of manual and CFC-assisted interventions were recorded and
compared. The average contact force and variation were calculated for manual and contactforce-controlled experiments. Variability in contact force and was calculated as contactforce variation (CFV) [17] – i.e. the difference between the mean trough and peak forces –
as well as the relative standard deviation (RSD) or the coefficient of variation [18].
Calculations were performed using a custom script in MATLAB (MathWorks).
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Several CFC-assisted ablations were also delivered within the RA and LA to ensure the
delivery of power did not affect the performance of the CFC. Visual inspection of the
lesions after the pigs were euthanized was performed only to confirm that power was
indeed delivered.

3.2.3
3.2.3.1

Lesion Formation Under Contact-Force Control
In Vitro Setup

Figure 3.3. Setup for the in vitro ablation experiments. A linear motion
phantom capable of producing clinically relevant myocardial motion
moves bovine tissue within a saline bath. The CFC is attached to a forcesensing ablation catheter and steerable sheath, enabling the delivery of
RF lesions to moving tissue under force control.

The impact of the CFC on lesion production was evaluated using an in vitro model
simulating the beating heart, adapted from the experimental setup and protocol of Shah et
al. [14]. Illustrated in Figure 3.3, the distal portion of a steerable sheath, housing a force-
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sensing ablation catheter, was deflected 90 and mounted over a Delrin platform
submerged within an acrylic tank filled with 0.7% saline at room temperature. The platform
was fixed to a custom-built linear motion stage, which could be raised and lowered by a
gear motor. An RF generator (EP Shuttle, Stockert GmbH, Munich, Germany) in powercontrol mode delivered RF energy between the catheter-tip electrode and a ground plate
fixed underneath the platform. Slabs of bovine muscle, 20-30 mm thick, were placed on
the platform. A peristaltic pump (CoolFlow ®, Biosense Webster, Irvine, CA) connected to
the irrigation port of the catheter, delivered 0.7% saline during RF delivery.
The linear motion phantom was driven in 1 of 2 modes, either reproducing CF
measurements recorded by force-sensing catheters during RF delivery in patients [23] or
simulating empirically derived cardiorespiratory motion profiles (Figure 3.4). For the
simulated motion profiles, the respiratory component resembled typical tidal lung volume
profiles, while the cardiac component replicated either intermittent or variable contact
profiles. Simulated cardiac and respiratory motion waveforms with user-defined
amplitudes and frequencies were used to reproduce scenarios of intermittent catheter-tissue
contact, induced patient apnea, and various combinations of dominant respiratory or
cardiac motion. Simulated motion was used to isolate tissue motion, without the
introduction of artifacts potentially introduced by a physician operation or the force sensor
itself (e.g., noise).
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Figure 3.4. Sample CF profiles measured as the linear motion phantom
moves tissue against a fixed catheter. The CF profiles in A through C
simulate force generated during patient ablations. The profiles in D
through F represent examples of simulated profiles: D combination of
cardiac and respiratory motion (cardiac: 75 BPM, 15 g peak-to-peak;
respiration: 12 BPM, 30 g peak-to-peak; offset: 10 g), E intermittent
cardiac motion (cardiac: 75 BPM, 30 g peak-to-peak; respiration: none;
offset: none), and F variable cardiac motion (cardiac: 75 BPM, 30 g
peak-to-peak; respiratory: none; offset: 20 g).

3.2.3.2

Protocol

RF energy was delivered to the tissue at 20 W for 30 seconds; the irrigation flow rate was
at 17 ml/min. First, CFC-assisted ablation lesions were delivered to stationary tissue at 4
force levels (5 g, 15 g, 25 g, and 35 g). These lesions were used as “control lesions” – i.e.
created in the absence of motion. The same set of ablation protocols was then repeated, but
the motion stage was set to execute randomly selected motion profiles with the CFC
enabled to maintain the force constant at 1 of the 4 force levels. Lastly, to mimic lesion
production during manual intervention, lesions were delivered to moving tissue while the
CFC was disabled. For all experimental conditions, CF profiles were recorded, and the
mean, CFV and RSD were calculated.
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Lesion Measurement

Once lesions were delivered, the tissue slabs were sliced along the centre of each lesion
using a scalpel to expose the cross-section. Photographs of sectioned lesions were taken
with a camera mounted in a 3D-printed custom bracket to ensure that the cross-section of
the lesion was centred and parallel to the aperture of the camera; a constant distance
between the camera and lesion surface enabled calibration of the images. The photographs
were randomized prior to analysis by a blinded observer. The dimensions of the necrotic
zone within each lesion were measured using digital callipers in the image-analysis
software ImageJ [27]. The maximum diameter, maximum depth, and depth at the
maximum diameter for each lesion were measured (Figure 3.5). Lesion volumes were
calculated using the formula for a truncated oblate spheroid:

𝑉𝐿𝑒𝑠𝑖𝑜𝑛 = 𝑉𝑆𝑝ℎ𝑒𝑟𝑜𝑖𝑑 − 𝑉𝑆𝑝ℎ𝑒𝑟𝑜𝑖𝑑𝑎𝑙 𝐶𝑎𝑝 =

4𝜋𝑎2 𝑐 𝜋𝑎2 ℎ2 (3𝑐 − ℎ)
−
3
3𝑐 2

where a = Maximum Diameter / 2, c = Maximum Depth - Depth at Maximum Diameter,
and h = c - Depth at Maximum Diameter. Similar ellipsoidal modelling of lesion volume
has been used previously [14].
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Figure 3.5. Photograph of a cross-section through an ablation lesion
(left) illustrating the locations where measurements were made in order
to calculate lesion volume: maximum diameter (Ø); maximum depth
(D); and depth at maximum diameter (DØ). The truncated oblate spheroid
approximation (right) was used to measure volume, characterized by
dimensions a, c, and h. The indentation left by the catheter tip pushing
into the tissue was included in lesion volume calculation.

3.2.3.4

Statistical Analysis

Statistical analysis was performed using Prism 7 (GraphPad Software, USA). Two-way
analysis of variance (ANOVA) was performed for both lesion volume and lesion depth to
determine if the set-force level effect on lesion size was statistically significant. Means at
each set force level were compared and the Sidak multiple comparison test was used to test
the hypothesis that the volume and depth of CFC-controlled lesions delivered to moving
tissue do not differ from those of lesions delivered to stationary tissue. A p-value of < 0.05
was considered statistically significant.

3.3
3.3.1

Results
In Vivo Experiments

Fourteen CF-control experiments were performed, 8 in the LA, 5 in the RA, and 1 in the
LV. Of these, 12 experiments were performed with the CFC set to repetitive control mode
using the heart rate determined from ECG and 2 with the CFC set for adaptive control
mode (the results below are averages of all 14 experiments). Representative examples of
the CF profiles achieved when using repetitive control and adaptive control are provided
in Figure 3.6A through Figure 3.6C and Figure 3.6D, respectively. Through manual
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catheter intervention, the interventionalist was able to maintain an average force level of
24.6 ± 6.4 g, which was larger than the target of 20 g; the smallest average force was 14.9
g, and the largest average was 30.5 g. In contrast, for all CFC-assisted interventions, with
a set force of 20 g, the average CF was 19.9 ± 0.3 g [range 18.9 g to 20.1 g]. When
compared to manual intervention, CFC-assistance resulted in a reduction in CFV from 31.6
± 15.9 g to 4.6 ± 1.1 g (p < 0.0001) and RSD from 53 ± 24 % to 20 ± 7 % (p = 0.005).

Figure 3.6. Results from four experiments performed in various
locations in the LA and RA. Each CF profile begins with manual
intervention prior to CFC engagement (red line). The regions targeted
were: LA appendage without A and with apnea B; high RA with apnea
C while changing the set level of force from 20 g (blue area) to 10 g
(green area); D while delivering a lesion (red area) to the RA septum.
The mean CF ± CFV (RSD) during manual and CFC-assisted
intervention is reported. Note: the CFC was able to compensate for
myocardial motion greater than that observed in humans (A and B),
where the CFC was capable of reducing spikes of over 50 g at a heart
rate over 110 BPM down to negligible disturbances. Note the difference
in time and force scales.

Analyzing CFC-assisted performance on a regional level, no significant difference in CFV
between the LA (4.9 ± 1.2 g, n = 8) and RA (4.0 ± 0.6 g, n = 5) was observed (p = 0.161).
While testing the CFC in the LV, catheter engagement induced premature ventricular
contractions (PVC). The presence of PVC caused the repetitive control system to
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temporally lose synchrony with the cardiac motion of the pig heart, resulting in poor
performance. In the single case where PVCs were not induced (Figure 3.7), the CFV was
reduced from 32.9 g to 8.6 g when the CFC was engaged. Importantly, the maximum force
measured did not exceed 50 g in any of the cases when the CFC was engaged (all three
chambers) and was lower than the maximum measured during manual intervention.

Figure 3.7. An example experiment of the CFC employed in the LV.
Interval A reveals significant cardiac motion. Engaging the CFC in
repetitive control mode (red line) induced PVCs resulting in poor force
control performance. The CFC was able to resynchronize with the
heartbeat, likely due to the disappearance of PVCs (blue line), resulting
in improved control, Interval C.

3.3.2

Contact-Force Control In Vitro

The mean, CFV and RSD of the CF profiles recorded during CFC-assisted ablation-lesion
delivery for the 3 sets of experiments (CFC-assisted lesion delivery to stationary tissue,
CFC-assisted lesion delivery to moving tissue, and manual lesion delivery to moving
tissue) are shown in Table 3.1. Similar to the in vivo results, the average CF remained
within 1 g of the set level, and the CFV reduced to less than 5 g on average for all set levels
of the CFC. Specifically, CFC-assisted intervention reduced CFV from 19.4 ± 10.2 g to 4.0
± 1.0 g (p < 0.0001) and RSD from 64 ± 39 % to 25 ± 14 % (p < 0.0001). When setting the
CFC with a modest set force (15 g and greater), the resulting RSD improved to 17 ± 7 %.

3.3

Results

86

Versus manual intervention, employing the CFC narrowed the distribution of contact
forces and centred in on the set force, improving precision and accuracy. Furthermore, the
range (the difference between maximum and minimum) of contact forces was reduced by
at least a factor of 2.

Stationary Tissue
5g
15 g
25 g
35 g
Moving Tissue
CFC-Assisted
5g
15 g
25 g
35 g
Manual

n

Mean
(g)

Nadir
(g)

Peak
(g)

Range
(g)

CFV
(g)

RSD
(%)

6
6
6
6

4.9 ± 0.03
14.9 ± 0.02
24.9 ± 0.03
34.9 ± 0.03

1.7 ± 0.3
11.1 ± 0.5
20.5 ± 0.7
30.4 ± 1.0

8.2 ± 0.2
18.9 ± 0.5
29.4 ± 0.6
39.8 ± 0.7

6.5 ± 0.4
7.8 ± 1.0
8.9 ± 1.2
9.4 ± 1.4

1.7 ± 0.1
1.7 ± 0.1
1.8 ± 0.1
1.8 ± 0.1

21 ± 1
8±0
5±0
4±1

6
9
6
7
15

5.1 ± 0.1
14.7 ± 0.3
25.0 ± 0.1
34.4 ± 0.6
15.9 ± 7.3

-2.8 ± 0.7
6.4 ± 1.8
12.2 ± 2.2
26.6 ± 1.1
0.02 ± 6.0

13.0 ± 2.0
26.1 ± 5.0
39.1 ± 5.1
44.1 ± 1.0
42.9 ± 12.0

15.8 ± 2.9
19.7 ± 6.7
23.5 ± 2.7
17.5 ± 1.5
42.9 ± 13.4

3.0 ± 0.4
4.1 ± 1.1
4.7 ± 1.2
4.1 ± 0.8
19.4 ± 10.2

47 ± 8
22 ± 5
19 ± 3
9±0
64 ± 39

Table 3.1. Characteristics of CF profiles recorded during CFC-assisted
and manual ablation delivery. Comparison of generated CF profiles with
and without (i.e., manual intervention) the CFC on stationary and
moving tissue. Values are expressed as mean ± standard deviation. Note
that for manual lesion deliver to moving tissue, there was no desired
force actively compensated for.

It is important to note that these results include several ablation experiments performed
while the motion phantom was driven to reproduce variability that resembles patient,
catheter, or unpredictable cardiorespiratory motion. Even in these irregular motion cases,
CFV was reduced to less than 5 g (and RSD to below 30%) when the CFC was used.
Comparative example force profiles achieved with the CFC when the motion was irregular
are shown in Figure 3.8.
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Figure 3.8. Results from two experiments performed in vitro where the
phantom was driven to reproduce motion profiles based on force
measurements obtained from force-sensing catheters during RF delivery
in patients. The beginning of each experiment shows tissue motion
characteristic of unpredictable respiration. With the absence of
significant periodic tissue motion, the adaptive control mode of the CFC
was engaged (red line) with a set force level of 25 g (left) and 15 g
(right). Average contact force ± CFV (RSD) are reported.

3.3.3

Lesion Production With and Without Force Control

Representative example photographs of cross-sections of delivered lesions are provided in
Figure 3.9. The measured depths and calculated volumes of the CFC-assisted ablation
lesions on stationary and moving tissue, as well as lesions delivered to mimic manual
intervention (without the CFC), are presented in Figure 3.10. As determined by two-way
ANOVA, statistically significant differences were observed between lesion depth and
volume for lesions delivered to stationary or moving tissues at different set force levels (p
< 0.0001). Most importantly, motion during lesion delivery (while employing the CFC)
had no effect on lesion depth or volume (p = 0.82 and 0.78, respectively) compared to
stationary lesions. On the other hand, manual intervention delivered to moving tissue
resulted in highly inconsistent lesion depth and volume. Multiple comparison analysis
revealed a small difference in lesion depth (not volume) between stationary and moving
tissue when the set level was 5 g.
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Figure 3.9. Photographs of the cross-sections of delivered ablation
lesions to moving tissue. Representative examples of ablation sizes while
the CFC is disabled, representing manual intervention, and while the
CFC is set to desired forces of 5 g, 15 g, 25 g, and 35 g (organized in
columns). Lesions delivered during manual intervention vary in size,
while prescribed CFC-assisted ablation lesions are precise and
reproducible, despite myocardial motion.

Figure 3.10. Measured lesion depth and volume are presented for CFCassisted lesion creation on stationary tissue (A and D) and on moving
tissue (B and E). For comparison depth and volume are also presented in
panels C and F for lesions created under manual intervention (i.e. no
control); these lesions were generated while the phantom was moving
with the same motion profile as the controlled lesions generated in B and
E. For the same set force, no statistical differences between lesions
volumes delivered to moving tissue and lesions delivered to stationary
tissue were observed. Note that retrospectively analyzed average force
values for the manually delivered ablations (C and F) demonstrated a
similar relationship between depth/volume and achieved contact force,
as expected; however, unlike the CFC-assisted case, the force level could
not be set prospectively by the operator.
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Discussion

In this study we demonstrated that: a) on average, the CFC can consistently control force
to within 1 g of the set level; b) the variation in contact force dropped below 5 g when
using the CFC – a 5-fold improvement over manual intervention; c) when using the CFC,
the catheter tip never lost contact with the tissue and never approached dangerous force
levels; d) delivered ablation lesions were reproducible regardless of myocardial motion,
and finally, e) delivered lesions to moving tissue were of the same depth and volume as
lesions delivered in the absence of tissue motion. Recalling the clinical studies performed
by Ullah et al. [17] and Makimoto et al. [18], which respectively report that a CFV of less
than 5 g ensures a maximum impedance drop and RSD less than 30% is correlated with
more durable lesions, our results suggest that using the CFC can assist clinicians in
achieving these previously unattainable goals.
During the in vitro ablation experiments, on average a 2-fold reduction was observed
between the standard deviations of lesion volume (and depth) of CFC-assisted and
manually delivered lesions. This indicates improved precision and accuracy in lesion
production over manual intervention while the tissue was moving. More importantly,
regardless of tissue motion, lesions delivered were reproducible and statistically identical
in size compared to lesions delivered to stationary tissue, indicating that lesions were
delivered to moving tissue as if no motion was present. The slightly significant difference
in lesion depth noted at the 5-g level is attributed to the likelihood that at low force levels,
lesion production is more vulnerable to variation in force – improving the control
performance of the CFC may prevent this.
During in vivo evaluation in the porcine model, the CFC demonstrated the ability to
compensate for significant cardiac tissue motion, greater than those observed in humans.
The CFC was capable of reducing spikes of 50 g caused by the systolic-diastolic motion of
the heart at over 110 BPM to negligible disturbances (Figure 3.6A and Figure 3.6B). This
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performance was achieved in all target locations in the LA and RA. However, in the LV,
we observed poorer performance, likely due to the occurrences of PVCs and the fact that
the repetitive controller was optimized for atrial use. Further development of the CFC
control system, which may involve fine-tuning of the repetitive controller or utilizing the
adaptive controller, is required before a more extensive evaluation in the LV.
A primary concern of using the CFC is the possibility of perforating the tissue while the
CFC is engaged. For this reason, the CFC is programmed to continuously monitor contact
force and automatically retract the catheter back into the sheath and disable the force
control algorithm if the force level exceeds a user-defined limit of 80 g. It is important to
note that for all CFC-interventions performed during the in vivo and in vitro experiments,
the force never exceeded 50 g. Demonstrated in Chapter 2, the CFC has shown to
effectively react to large and sudden changes in tissue displacement that would otherwise
result in large spikes of contact force and potentially cause tissue damage.
The development of two different control systems (adaptive and repetitive) was required
to handle types of motion typically observed during patient therapy. Different controllers
were required to compensate for the delay, sampling rate and noise characteristics of the
force sensor incorporated on the catheter tip. The repetitive control system can be used to
eliminate fast systolo-diastolic force variations when they are the most dominant
component, but strictly requires that tissue motion is periodic (i.e. normal sinus rhythm).
The current version of the repetitive control system is unable to effectively handle the nonperiodic disturbances observed in patients in AF or instances of mechanically-induced
PVCs but was able to compensate for motion associated with heart-rate drifts up to ± 7%.
On the other hand, the adaptive control system ignores fast disturbances caused by cardiac
motion and can only reject gradual changes in force variations and is suitable for most
interventions where the largest motions are caused by respiration or involuntary movement.
The adaptive controller may, therefore, be ideally suited for use during arrhythmias, where

91

Eliminating the Effects of Motion during RF Ablation Delivery

cardiac-induced motion is expected to be smaller. Lastly, in the cases where both cardiac
and respiratory motion is large, both control algorithms will have reduced benefit;
however, such cases are rare.
The benefit of the CFC is dependent on the angle between the catheter tip and the surface
of the tissue, with the highest improvement achieved during perpendicular contact, when
the effect of motion is greatest. On the other hand, when the catheter is nearly parallel to
the tissue, such as during CTI ablation, the CFC is expected to have little benefit. In this
study, the CFC was evaluated at angles up to 45°; however, a significant reduction of force
variability has been observed at angles as large 60° from the normal (data not shown).
Additional studies are required to determine a threshold angle beyond which using the CFC
will not provide benefit.
Systolo-diastolic cardiac motion and respiration are the primary contributors to variability
in contact force [19, 21, 28]. Clinical techniques used to mitigate their effect include rapid
atrial pacing, high-frequency jet ventilation (HFJV), and induced apnea [28-33]. Rapid
pacing has been shown to reduce the standard deviation in force by less than 1 g compared
to its non-paced counterpart, and its effectiveness is dependent on regional anatomical
location within the LA [29]. In a study examining almost 30,000 RF applications, HFJV
only reduced force variability index by 0.06 on average in comparison to normal ventilation
[33]. In contrast, to achieve optimal force variability based on the variability criteria of
CFV (less than 5 g [17]) and RSD (less than 30% [18]), the CFC reduced standard deviation
in the force profiles by 6.3 g on average and the force variability index by 0.21. Importantly,
the CFC is a device that can be used independently to compensate for the effect of motion
or to supplement one of these techniques. In particular, the combination of induced apnea
and the CFC working in repetitive-control mode would be an extremely effective way to
control force (Figure 3.6B).

3.5

Study Limitations

92

Emerging catheter ablation techniques in treating AF include delivering RF energy with
high-power (typically 70-90 W) for 4-8 seconds. In pre-clinical porcine studies, highpower short-duration (HP-SD) ablation have been shown to successfully isolate the
pulmonary veins [34, 35]. However, in these studies, HP-SD in swine have demonstrated
that CF values between 10 g and 20 g resulted in successful ablation [34] while fluctuating
forces exceeding 40 g caused steam pops [35]. For clinical applications of HP-SD, the EP
would need to maintain CF within the guidelines set out by these studies, which may be
difficult to achieve reliably. These preclinical studies indicate the importance of controlling
CF and minimizing variability, regardless of the method of RF delivery. Further studies
evaluating the role of CF variability in HP-SD lesion production is needed.

3.5

Study Limitations

While the study demonstrates that the CFC can reduce the effects of motion on contact
force during ablations in vivo and in vitro in a limited set of experiments, more
comprehensive studies of the device are required (e.g. in the LV) before the real impact of
using the CFC can be determined.
Typical CF profiles observed in the clinical setting are dominated by respiration; CF
disturbances caused by cardiac motion are often negligible in most targets. Surprisingly,
the opposite relationship was observed in the porcine model, where for most target
locations, disturbances were dominated by systolo-diastolic cardiac motion, while
disturbances caused by respiration were smaller in comparison. As a result, the primary
control mode that was tested in vivo was the repetitive control system. While the adaptive
control system could not be extensively evaluated in vivo, this control mode was
thoroughly tested in the in vitro experiments.
Lesion production in the in vitro study does not directly reflect lesion production in
humans. Our experimental set up did not mimic blood and tissue temperature and did not
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model convective and perfusive cooling. However, all experimental conditions remained
consistent from lesion-to-lesion, and the results generated from these experiments were
solely dependent on tissue motion and CF. The measured reference impedance (75-85 Ω,
achieved by titrating the salinity to 0.7%) was low compared to clinical levels but was
chosen to enable the generation of measurable lesions at clinically relevant CF levels and
duration. Finally, lesion volume was measured only by a single observer and was based on
measurements of the necrotic area. Systematic bias was avoided by cropping, anonymizing,
and randomizing the photographed tissue samples, thereby blinding the observer to the
ablation protocol used for each lesion.

3.6

Conclusions

Monitoring catheter-tissue force has become an important tool for RF catheter ablation in
patients and has become a standard-of-care. Until this work, CF information has been
strictly used for visual guidance and navigation. The CFC uses this available information
and optimizes lesion production on moving tissue by controlling catheter-tissue CF. In this
study, we demonstrated the ability for the CFC to significantly improve catheter-tissue CF
profiles and their impact on lesion production in moving tissue. The results obtained in this
study suggest that the CFC can be a valuable add-on tool available to electrophysiologists
to optimize lesion delivery techniques and ultimately improve patient outcomes.
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Remote Catheter Navigation and ContactForce Control

This chapter is adapted from “Remote Catheter Navigation and Contact-Force Control:
Design and Evaluation of a Novel Steerable Sheath and Catheter Robotic Navigation
System.”3
My contribution to this chapter involved (i) designing and developing all components of
the robotic navigation system, (ii) designing and developing phantoms, (iii) preparation
and conducting experiments, (iv) collecting and analyzing data, and (v) writing
manuscripts.

4.1

Introduction

Radiofrequency (RF) catheter ablation is a widely used therapy to permanently treat atrial
fibrillation (AF) – the most common form of cardiac arrhythmia. Delivering contiguous
transmural ablation lesions is crucial for improving clinical outcomes by increasing firstprocedure efficacy rates [1]. Unfortunately, 40% to 70% of patients experience a
recurrence of AF symptoms due to electrical reconnections of isolated pulmonary veins [2-

3

Gelman D, Skanes AC, Drangova M. “Remote Catheter Navigation and Contact-Force Control: Design
and Evaluation of a Novel Steerable Sheath and Catheter Robotic Navigation System,” IEEE Transactions
on Biomedical Engineering (In Preparation).
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4]. AF ablation strategies are complex, technically challenging, require a high degree of
dexterity and physical effort.
To this end, over the past two decades, three remote catheter navigation systems (both
robotic [RNS] and magnetic navigation systems [MNS]) have been developed, approved
by the FDA, and introduced clinically. The Amigo™ RNS developed by Catheter Precision
facilitates control of a single conventional ablation catheter by loading it into an
electromechanical manipulator providing full-range of its functions (insertion, withdrawal,
deflection, and rotation) operated by a hand-held remote. However, the system lacks a
steerable sheath, thereby significantly reducing the degrees-of-freedom (DOF) associated
with catheter manipulation. Steerable sheaths are widely used as they improve
maneuverability, stability, and catheter-tissue contact, collectively resulting in better
clinical outcome [5-8]. The Sensei® X RNS developed by Hansen Medical (acquired by
Auris Health), solves this problem by robotically steering two concentric sheaths, through
which any catheter can be introduced. The entire assembly is manipulated within the heart
using pull-wires actuated by a robotic arm controlled by a 3D joystick [9]. Early reports of
high incidence of clinical complication, steep learning curve, and the inability to navigate
within the left ventricle and the coronary sinus due to the large 14 Fr outer sheath are
reported shortcomings of this system [9-12]. Lastly, the NIOBE® MNS developed by
Stereotaxis uses a specialized magnetic catheter, which can be navigated to target locations
by changing the orientation of two permanent magnets positioned on each side of the
patient’s body. The weak magnetic field (0.08 T) and flexible catheter ensures a safe
procedure. However, it results in relatively low catheter-tissue contact force, which is
associated with ineffective lesion production and increased rates of AF recurrence [13-16].
The magnetic catheter is not responsive in real-time as motions require mechanical
movement of external magnets followed by electromechanical actuation. However, the
primary shortcoming among MNS is the inability of the magnetic catheter to detect real-
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time catheter-tissue contact force used clinically to guide and assess lesion deliver in realtime. Robotic and magnetic navigation systems have shown to reduce radiation exposure,
physician exhaustion, and RF duration [17]. However, none of these systems has
demonstrated better clinical outcome versus the manual catheter intervention, and the
potential advantages of these systems are offset by additional costs for the systems itself,
consumables and maintenance contracts. Emerging technologies must not only provide the
ability to precisely place lesions but also optimize lesion production.
Among all factors that influence lesion production, the catheter-tissue contact force (CF)
is one of the most critical [18-21]. As such, the incorporation of novel force-sensing
ablation catheters into standard practice has become the cornerstone for RF ablation
therapy, as it has demonstrated improved clinical outcome [22-24]. Higher levels of force,
although delivering larger lesions, can result in tissue perforation, intramural boiling, and
collateral tissue damage [20, 25-28]. Lesions delivered with insufficient force produce
ineffective superficial lesions [16] and have a higher risk of intermittent contact [29].
Recent literature also highlights the importance of CF variability on lesion production, not
merely just CF quantity [21, 30, 31]. Unfortunately, current tools and techniques to
improve the stability of CF are limited and reliably achieving an optimal CF profile is
virtually impossible.
Our group has developed a novel RNS, enabling remote navigation of a conventional
steerable sheath and force-sensing ablation catheter. The Steerable Sheath and Catheter
Robotic Navigation System (SSC-RNS) allows for full-range manipulation of a
conventional steerable sheath (insertion, withdrawal, rotation, and deflection) in 3-DOF,
as well as insertion and withdrawal of a force-sensing ablation catheter within the sheath
in 1-DOF. The 4-DOF SSC-RNS also incorporates a catheter contact-force controller – a
compact device, which has been independently evaluated previously [32, 33]. The force
controller improves the catheter-tissue CF profile and can deliver optimal and reproducible
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ablation lesions, even in the presence of cardiac tissue motion. The device maintains an
average CF to within 1 gram (g) of the set level and reduces CF variability to less than 5
grams – a variability considered optimal for lesion production [31].
The purpose of this study is to evaluate the SSC-RNS ability to enable remote navigation
of a force-sensing ablation catheter. First, to evaluate the performance of the SSC-RNS, an
electromagnetic tracking system was used to track the input device and the catheter tip
during dynamic motion. Second, an in vitro contractile bench model representing a cardiac
chamber was used to test the hypothesis that the SSC-RNS can navigate a catheter to
specific target locations under the control of a skilled electrophysiologist (EP) and maintain
a set amount of force on moving tissue-mimicking material, despite the presence of
cardiorespiratory motion.

4.2

Steerable Sheath and Catheter Robotic Navigation
System

The SSC-RNS comprises three distinct components: an intuitive master input device,
where the EP interfaces to control the robotic system, a robotic system, which is
responsible for positioning the catheter and sheath according to the changes in motion of
the input device, and finally, the catheter contact-force controller – a device incorporated
within the robotic system – which employs closed-loop CF control between the catheter
tip and moving tissue.

4.2.1

Master Input Device

The input device to the SSC-RNS, which has been validated in previous work [34],
provides an interface to the user to control the robotic system. The input device embodies
a repurposed steerable sheath handle (Agilis™ NxT, Abbott Laboratories, St. Paul, MN)
fitted with 3D-printed inserts that extend to support walls mounted with two optical
encoders (Figure 4.1). One optical encoder (HEDS 5600, Infineon Technologies,
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Neubiberg, Germany) detects the rotation of the sheath handle, and another encoder is used
to detect the deflection mechanism of the sheath. The entire assembly is then mounted on
a linear rail fitted with a rack, where a third encoder coupled to a pinion detects insertion
and withdrawal of the sheath handle.

Figure 4.1. Photograph of the input device to the robotic system A.
Three optical encoders (blue arrows) detect all motion from a steerable
sheath handle (insertion, withdrawal, rotation, and deflection indicated
by yellow arrows). A digital user interface programmed with a menu
system provides the user full control of all features of the robotic system
B.

A microcontroller-powered (Teensy, PJRC, Sherwood, OR) electronics system, mounted
onto the assembly, is responsible for quadrature encoding and transmitting the position
information to the robotic system using a wireless transceiver (XBee, Digi International,
Minnetonka, MN). The electronics also provide a digital user interface (LCD with tactile
buttons), which allows the EP to set parameters of the SSC-RNS including: inserting and
withdrawing the catheter through the sheath; setting robotic motion scaling; disabling the
input device, and home the robotic system (Figure 4.1B). Importantly, the interface allows
the user to configure the parameters for the force controller including setting the desired
level of force and force-time integral (a metric used in the clinic to access lesion
production) and other parameters such as cardiac or respiratory gating.
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Robotic System

Figure 4.2. The robotic system takes the form of a cylindrical gantry,
which opens along its long axis, A. Within the gantry; battery-powered
electronics receive position data from the input device to insert and
withdraw the catheter and sheath as well as deflect the sheath tip using a
deflection mechanism (indicated with yellow arrows). The electronics
also receives force information and processes a control algorithm to
drive the force controller. While in a closed position, the gantry sits on
two pairs of rollers driven by a DC motor affixed to the back of the unit,
B. A separate electronics control system received rotational position data
from the input device to rotate the catheter and sheath.

The robotic system (Figure 4.2) incorporates a cylindrical gantry with hinges allowing it
to open up along its long axis. Within the gantry, two carriages sitting on linear guide rail
are driven by a lead screw mechanism coupled to a DC motor (9.7:1 25D Gearmotor,
Pololu, Las Vegas, NV). One of the carriages houses a sprocket and chain mechanism
powered by another DC motor (47:1 25D Gearmotor, Pololu, Las Vegas, NV) designed to
actuate the deflection mechanism of the sheath handle. An electronic control system and
battery are mounted within the gantry. An ARM-based microcontroller (Arduino Due,
Arduino, Turin, Italy) uses a wireless transceiver to receive position data from the input
device and process two proportional-integral (PI) controllers: 1) to control the lead screw
mechanism resulting insertion and withdrawal the catheter and steerable sheath; and 2) to
control the deflection mechanism to deflect the tip of the steerable sheath. Generated pulsewidth modulated (PWM) control signals are received and amplified by motor drivers
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(VNH5019 Motor Driver Carrier, Pololu, Las Vegas, NV) before driving each
corresponding motor.
While in a closed position, the gantry sits securely on two pairs of rollers, which are driven
by a final DC motor (131:1 37D Gearmotor, Pololu, Las Vegas, NV) affixed on the back
of the unit (Figure 4.2B). An electronic control system receives wireless position data from
the input device and processes a PI control algorithm to generate a PWM signal. The
control signal is then received and amplified by a motor driver, resulting in rotational
tracking of the sheath and catheter. The robotic system measures approximately 86 cm
long, 16 cm wide, and 20 cm tall.

4.2.3

Catheter Contact-Force Control

The force controller is an independent compact device, which monitors real-time CF
measurements and autonomously adjusts the position of a force-sensing ablation catheter
(THERMOCOOL® SMARTTOUCH™, Biosense Webster, Irvine, CA) within a steerable
sheath thereby maintaining the force level set by the EP. The device, described in detail in
Chapter 2 and Chapter 3, is clamped onto the back-end of a steerable sheath (Agilis™ NxT,
Abbott Laboratories, Chicago, IL) near the hemostatic seal; a linear DC servomotor (LM
2070, MICROMO, Clearwater, FL) clamped onto the catheter shaft via a locking adaptor
adjusts catheter motion with respect to the sheath (Figure 4.3). The force-sensing catheter,
steerable sheath and contact-force control device are placed and secured onto the two
carriages within the gantry of the SSC-RNS. The electronics control system (within the
gantry) receives real-time CF measurements transmitted by a separate microelectronics
system; this stand-alone system receives, parses, and transmits incoming force information
through a local area network connection with a research-based catheter mapping system
(CARTO® 3, Biosense Webster, Irvine, CA). The SSC-RNS electronics process a control
algorithm and generate a PWM signal, which sent to a separate motor controller and driver
(MCLM 3003, MICROMO, Clearwater, FL). The signal directly adjusts the catheter
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position within the sheath to maintain constant force at the catheter tip under closed-loop
control. The force controller of the SSC-RNS uses similar control algorithms described in
Appendix C.

Figure 4.3. Line drawing A and photograph B of the force controller
attached to a force-sensing ablation catheter and steerable sheath. A
locking adaptor clamps the catheter to a linear actuator (shown in B),
which enables the catheter to be inserted and withdrawn within the
sheath.

4.3
4.3.1

Evaluation
SSC-RNS Catheter Positioning

Prior to performing in vitro evaluation of the system, the tracking performance of the SSCRNS was quantified using an electromagnetic tracking system (Aurora®, Northern Digital,
Waterloo, ON, Canada). An electromagnetic field generator captured the location of a 5DOF sensor, which was fed through the steerable sheath to the distal tip (in place of the
catheter). A second 5-DOF sensor was fixed to the repurposed sheath handle of the input
device. A series of six 10-second dynamic motion profiles were performed on the input
device (three insertion and withdrawal, three rotation) and mimicked by the robotic system;
position coordinates of both sensors were recorded in real-time. Root-mean-squared error
(RMSE) with respect to the reference position and angle of the input device was calculated.
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Additionally, steady-state error and lag between the input device and the robotic system
were determined.

4.3.2

In Vitro Experimental Setup

A lab-bench motion phantom representing a beating heart was designed and developed
(Figure 4.4). The phantom comprises a 60-cm long Tygon tube, which enters a 3D-printed
hollow truncated 10-cm diameter sphere with 18 6-mm diameter divots scattered on the
outside of the shell. The opening of the stationary sphere leads to a frame affixed to the
linear motion stage, which was driven to reproduce cardiorespiratory motion. To mimic
tissue compliance, a rubber sheet was stretched within the frame. Described in detail in our
previous work, the linear stage can reproduce both cardiac and respiratory motion, whereby
the frequency and relative amplitude of each component is user-defined [33].
The phantom was scanned using a mobile CT scanner (O-Arm™ 1000 Imaging System,
Medtronic, Littleton, MA) and the volume image was imported into the catheter mapping
system (CARTO® 3, Biosense Webster, Irvine, CA). A force-sensing ablation catheter
(THERMOCOOL® SMARTTOUCH™, Biosense Webster, Irvine, CA) was manually
placed within the centre of five divots on the outside of the phantom, enabling a five-point
landmark registration to be performed to register the phantom to the reference coordinates
of the catheter mapping system. The coordinates of the remaining divots were then
acquired in the same way – these points represent the “target locations.”
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Figure 4.4. Photograph (top-down perspective) of the in vitro motion
phantom representing a beating heart chamber A. The phantom was CTscanned and imported into the catheter mapping system B, where the
phantom was registered, and target location (white spheres) were
acquired. B shows the catheter (green arrows) inside the phantom in
contact with a rubber sheet mounted on a moving wall resulting in a CF
profile (green square) due to the cardiorespiratory motion reproduced by
the linear motion stage.

4.3.3

In Vitro Protocol

Comparison between manual and remote navigation was performed. A skilled EP (A.C.S.)
was instructed to navigate a catheter tip (in conjunction with a steerable sheath) to eight
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stationary target locations using traditional catheter manual intervention. The EP
manipulated the catheter to each target location between two and six times, resulting in 27
total navigational tasks. Once the EP reached each target location, the final position of the
catheter tip was acquired, and the duration of the task was recorded. Between each task,
the catheter was retracted back to the starting position within the Tygon tubing.
The EP was then instructed to navigate to two targets on the moving wall – one with a 90°
catheter-rubber incidence angle and the other with a 45° angle. The linear stage was
programmed to execute cardiorespiratory motion with randomly selected but clinically
relevant amplitudes and frequencies for both cardiac and respiratory components. The EP
was instructed to maintain 15 g of CF between the catheter tip and moving wall for 30
seconds; the resulting CF profile was recorded. This was repeated three times, each with
the linear motion stage set to different cardiorespiratory motion parameters.
The above protocol was repeated by the same EP using the SSC-RNS. The EP was given
a brief introduction to the user interface of the input device and 5-10 minutes of training.
The operator was encouraged to use all functions of the SSC-RNS such as catheter insertion
and withdrawal within the sheath as well as robotic motion scaling. The EP robotically
manipulated the remote catheter to the same eight stationary targets between one and three
times, resulting in 22 total navigational tasks (Figure 4.5). During robotically assisted CF
control experiments on moving targets, the EP was instructed to use to the input device to
employ the force controller set for 15 g of force.
The coordinates of the final catheter tip position and their corresponding target location
were exported from the catheter mapping system, and the relative distance between those
coordinates was calculated. It is important to note that 0.635 mm separate the inner wall of
the phantom from the acquired target locations (center of the divot); this value was
subtracted from each distance measurement. Distances achieved, duration of each task, and
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recorded CF profiles using manual and robotically assisted intervention were compared
with one another using a paired t-test to determine significance. The overall interaction
time by the EP with the SSC-RNS was also recorded.

Figure 4.5. Photograph of the electrophysiologist using the SSC-RNS to
navigate a remote catheter tip within the in vitro phantom A. The catheter
tip (green arrow), stationary target locations (white spheres), and final
catheter tip position (red spheres) are captured and recorded by the
catheter mapping system B.

In this study, contact-force variability (CFV) was defined as the difference between the
mean trough and peak forces. CFV of less than 5 g significantly increased impedance drops
and achieved higher maximums compared to lesions with greater variation [31]. Other
metrics have previously been shown to be important for lesion delivery [31, 35, 36].
Specifically, the relative standard deviation (RSD) [36] or the coefficient of variation,
defined as the ratio between the standard deviation of CF to its mean. RSD less than 30%
(e.g. 10 ± 3 g or 20 ± 6 g) correlated with a reduction in reconnection gaps during PVI [36].
CFV and RSD were calculated using a custom script in MATLAB (MathWorks, Natick,
MA).
Statistical analysis was performed using Prism 8 (GraphPad Software, San Diego, CA).
Two-way analysis of variance (ANOVA) was performed to determine if the intervention
method (manual or SSC-RNS) and catheter angle (90° or 45°) had a significant effect on
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the force profile. The average CF, CFV and RSD were compared and the Sidak multiple
comparison test was used to test the hypothesis that robotically assisted intervention
resulted in improved force profile that is independent of catheter angle. A p-value of less
than 0.05 was considered statistically significant.

4.4
4.4.1

Results
SSC-RNS Tracking Performance

The SSC-RNS is capable of accurately navigating a catheter remotely, with the following
specification. While dynamically inserting and withdrawing the catheter and sheath, the
steady-state error of 0.5 ± 0.4 mm, RMSE of 1.53 ± 0.25 mm and a lag of 24 ± 6 ms was
observed. While rotating the catheter and sheath, the steady-state error was 2.2 ± 1.9°,
RMSE of 7.54 ± 0.27° and lag of 63 ± 12 ms (Figure 4.6).

Figure 4.6. Example experiments demonstrating the tracking
performance of the SSC-RNS. A illustrates the insertion and withdrawal
of the input device (blue) and corresponding motion of the sheath tip
(red), resulting in a minimal error. B illustrates rotational tracking and
error.

4.4

4.4.2

Results

110

Catheter Navigation and Contact-Force Control In Vitro

All navigation tasks were performed successfully. During manual catheter navigation, the
EP was an average distance of 2.5 ± 0.9 mm from the target location and took 28.7 ± 9.9
seconds to complete each task. In contrast, while using the SSC-RNS, the EP was an
average distance of 1.7 ± 0.8 mm from the target location and required 53.1 ± 19.3 seconds
to complete each task (Figure 4.7). There was a significant difference in the distances to
the corresponding targets achieved (p = 0.003) as well as the time duration to accomplish
navigational tasks (p < 0.0001) between manual and robotic intervention. These results
suggest that there is a higher level of accuracy when using the SSC-RNS over the manual
approach. Including instruction to the SSC-RNS and performing all navigation tasks, the
EP’s interaction time with the SSC-RNS was approximately 63 minutes.

Figure 4.7. Distances between target locations and the catheter tip
position A and their task durations B using manual (n = 27) and robotic
intervention (n = 22). Within an hour of using the SSC-RNS, the EP was
completing tasks in a time comparable to the manual approach.

Through manual catheter invention, the EP was able to maintain an average force level of
16.8 ± 3.9 g. In contrast, for all robotically assisted interventions, with a set force of 15 g,
the average CF was 14.9 ± 0.2 g (p = 0.1919) (Figure 4.8). Robotically assisted force
control resulted in a reduction in CFV from 19.6 ± 11.2 g to 4.7 ± 1.9 g (p = 0.0024), and
RSD from 48 ± 20 % to 26 ± 3 % (p = 0.007). The above results represent the average of
four experiments performed with the contact-force controller set to cardiac gating and four
experiments set to respiratory gating.
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Figure 4.8. Results from three pairs of experiments, each performed with
a different motion profile programmed into the linear motion stage. A,
C, and E illustrates the resulting CF profile using the manual approach.
Respectively, B, D, and F are the resulting CF profile using the force
controller of the SSC-RNS. The linear motion stage was programmed
with dominant cardiac motion, A and B, dominant respiratory motion, C
and D, and typical cardiorespiratory motion combining both
components, E and F. For all experiments, the force controller of the
SSC-RNS was set for 15 grams of force (red line). Average CF ± CFV
(RSD) is provided for each experiment.

With a 90° catheter-rubber incidence angle, throughout manual catheter intervention the
EP achieved an average CF of 19.5 ± 3.7 g; larger than the target force level of 15 g. When
the incidence angle was reduced to 45° the average force improved to 14.2 ± 1.6 g (p =
0.013), demonstrating better force control to the desired 15 g level. Importantly, by
reducing incidence angle the EP was able to significantly reduce CFV from 28.5 ± 8.3 g to
10.7 ± 3.5 g (p = 0.0011), and RSD from 63.0 ± 10.7 % to 33.8 ± 15.8 % (p = 0.006). In
contrast, during robotically assisted catheter intervention, no significant difference in
average CF between incidence angles of 90° (14.9 ± 0.2 g) and 45° (15.0 ± 0.2 g) was

4.5

Discussion

112

measured (p > 0.999). Similarly, there was no significant difference in CFV [90°: 4.7 ± 1.9
g, 45°: 4.8 ± 2.3 g, p > 0.999] and RSD [90°: 26.3 ± 2.6 %, 45°: 25.8 ± 3.5 %, p > 0.999]
(Figure 4.9). Unlike manual catheter intervention, robotically assisted force control was
not dependent on catheter incidence angle; consistent average CF at the set level, and
reduced CFV and RSD, regardless of the angle tested.

Figure 4.9. Comparison of force profiles while the catheter-rubber
incidence angle is reduced from 90° (perpendicular) to 45°. Manual and
robotically assisted catheter intervention are reported. Manual catheter
intervention resulted in a slight improvement in the force profile. Using
the SSC-RNS ensured the average force maintained to 15 g set level (left,
red line), reduced CFV to less than 5 g (middle, red area) and RSD to
less than 30 % (right, red area), regardless of catheter angle.

Results comparing the force control performance of the SSC-RNS in vitro with its
simulation is provided in Appendix E.

4.5

Discussion

The design, development and evaluation of a novel robotic platform permitting remote
navigation of a conventional steerable sheath and catheter and enabling catheter-tissue CF
control was presented in this study. First, the tracking performance of the steerable sheath
and catheter robotic navigation system was validated using an electromagnetic tracking
system. Second, the SSC-RNS was also tested by a skilled operator using an in vitro model
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representing a beating cardiac chamber. We demonstrated that the robotic system could
track the input device as well as enabling remote navigation of a steerable sheath and
catheter, while also providing the capability of maintaining a set force level between the
catheter tip and moving tissue-mimicking material.
Measured steady-state errors using SSC-RNS to track the input device were minimal, and
the lag between the input device and robotic system was negligible (average delay found
to be no greater than 63 ± 12 ms). During the in vitro experiment, the EP was able to
successfully reach all target locations using the robotic system with an accuracy
significantly better in comparison to manual catheter intervention. Furthermore, the robotic
system provides the ability to control catheter-tissue CF – a task virtually impossible to
accomplish with manual the approach. The force control performance of the robotic system
was similar to the results obtained in our previous work, where we evaluated the device
independent from the SSC-RNS [32, 33]. Similar to the results discussed in detail in
Chapter 3, force control of the SSC-RNS ensured that the average force is less than 1 g of
the set level. Under force control, RSD reduced to less than 30% on average, implying
more durable lesion delivery would occur in the clinic, according to Makimoto et al. [36].
CFV reduced to less than 5 g, implying that the force controller of the SSC-RNS would
provide improved durability in PVI, according to Ullah et al. [31].
During manual catheter intervention, as demonstrated in this study, the EP can improve the
CF profile by reducing the catheter-tissue incidence angle. The shallower incidence angle
allows the distal catheter tip to deflect along with the displacement of tissue in a springlike fashion. Achieving a shallow angle is often not possible, and controlling the amount
of average CF is limited in this orientation [37]. Importantly, deeper lesions are achieved
when the catheter tip is perpendicular to the tissue (i.e. 90° incidence angle) [38]. However,
as demonstrated in this study, perpendicular orientation results in more CF instability.
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Unlike the manual approach, robotically assisted force control ensured that the CF profile
is optimal and independent of catheter incident angle.
One of the features of the SSC-RNS includes robotic motion scaling. This feature allows
scaling of the motion of the robotic system in relation to the input device. For instance, if
a motion scaling setting of four were to be used, an advancement of the input device of 10
cm would result in 2.5 cm advancement of the remote catheter and sheath; the same
principle is applied for rotation and deflection. During the experiments, the EP robotically
guided the catheter to the general area of the target location, then enabled motion scaling
(set to two) to adjust the catheter tip position to the target location finely; the EP found this
feature to be very useful in getting the catheter tip closer to target. The authors suspect this
contributed to the improved accuracy in comparison to manual catheter intervention.
The EP acknowledged that the robotic system greatly enhanced the stability of the catheter.
Since the SSC-RNS always holds the remote catheter and sheath, it allows the EP to focus
on slight adjustments to hit the target location – this implies that the robotic system would
be ideal for line or “drag” ablation strategies. Furthermore, engaging the force controller
without the need of manually holding the catheter and sheath position throughout an RF
application (30-60 seconds) is a considerable advantage over the manual approach as it
improves catheter stability and reduces operator fatigue.
Through formative studies our group performed prior to this study, the majority of EPs
manipulate the steerable sheath to guide the catheter tip to a target and dial in the force by
advancing or retracting the catheter within the sheath. The operator involved in this study
manipulated the instruments differently, whereby the catheter (rather than the sheath) is
manipulated for most of the procedure. The SSC-RNS was designed for operators who use
the former strategy. Because the EP interacted with the SSC-RNS for approximately an
hour, the amount of time required to complete each navigational task remotely was greater
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than that required for manual intervention. However, it is expected that subsequent
sessions, with minimal additional practice, would result in faster navigation times.
Additional studies with multiple users need to be performed to evaluate the learning curve
of the SSC-RNS. We suspect that other EPs who use the former strategy would require less
training due to the intuitive input device and the principal design of the SSC-RNS. A
primary limitation in this work is that only one EP was involved in this study. Involving
more operators, particularly EPs who manipulate the steerable sheath and catheter using
the former strategy, may affect the reported results.
Several other issues relating to the design of the SSC-RNS were identified. First, the
inability for the operator to rotate and deflect the ablation catheter independently of the
sheath limits the degrees-of-freedom associated with catheter and sheath manipulation.
Second, the loss of haptic feedback from the sheath handle prevents the EP from
determining the sheath deflection angle in relation to its “neutral position” (i.e., when the
sheath tip is not deflected). Finally, a digital menu system for the user interface is
cumbersome; changing parameters and operations of the robotic system should be easily
accessible. Future iterations of similar catheter RNS must consider these design flaws.

4.6

Conclusion

Commercially available robotic and magnetic catheter navigation systems have been
demonstrated to be safe and feasible in treating cardiac arrhythmia using catheter ablation
techniques. Although they show to reduced reduce x-ray radiation exposure and fatigue to
the EP, they have not yet demonstrated better first-procedure success rates over the manual
approach. For clinical uptake of new technologies entering the market, it is critical that
they demonstrate better clinical outcomes over the manual approach. One strategy is to
develop technologies that do not merely mimic the manual intervention, instead provide a
level of automation such as catheter-tissue CF control.
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In the work presented in this study, we took advantage of robotic technology to optimize
the CF profile between the catheter tip and moving tissue. The novel RNS uses available
force information to improve lesion production by incorporating this feature. The results
obtained in this study suggest that the SSC-RNS can be a valuable tool available to the EP
to not only allow or remote catheter navigation but also optimize lesion delivery techniques
and ultimately improve first-procedure efficacy rates.
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Conclusions and Future Work

5.1

Thesis Summary

The chapters in this thesis describe the individual steps required for the design,
development, and evaluation of robotic technology that address problems associated with
current cardiac catheter ablation therapy – specifically, the Catheter Contact-Force
Controller (CFC) and Steerable Sheath and Catheter Robotic Navigation System (SSCRNS). These systems were evaluated in several in vitro and in vivo experiments, which
were designed to compare robotically assisted intervention to the manual approach.
Chapter 2 described the design, development, and in vitro evaluation of the CFC. This
chapter also described the development and evaluation of a linear motion stage
programmed to reproduce motion profiles corresponding to force profiles recorded during
RF ablation in patients. The CFC was tested for its force control performance using the
motion stage, which was fitted with a strain gauge to measure CF between the catheter tip
and tissue-mimicking material in real-time. The control system of the CFC monitors the
CF and processes a hybrid PID control algorithm to displace the catheter within sheath,
thereby ensuring the set force level is always met. The CFC showed to be safe and effective
in controlling CF. When using the CFC, the average force is within 1 g of the set level and
variability is reduced to less than 5 (calculated as RMSE with respect to the set level) for
each clinically appropriate force level tested (15 g, 25 g, and 40 g). In this study, the CFC
also demonstrated to employ CF control at a set desired force level with a prescribed FTI.
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The demonstrated control of contact force under varying motion conditions is promising
and suggests that – when implemented in combination with a force-sensing ablation
catheter – the CFC can deliver prescribed ablation lesions.
The CFC was then integrated with an EAM system fitted with specialized software
allowing real-time CF measurements, detected by a force-sensing ablation catheter, to be
continuously streamed to the CFC electronics in real-time. System integration enabled
additional in vitro and in vivo evaluation, described in Chapter 3. Due to the characteristics
of the force sensor incorporated on the catheter tip (e.g., sampling time, dead-time, noise,
et cetera), the design and implementation of two new control algorithms, replacing the
existing hybrid PID control algorithm, were required. These algorithms were designed to
compensate for different types of cardiorespiratory motion observed in the clinic. The force
control performance of the CFC was first evaluated in an animal model, where a trained
operator employed the CFC (set for 20 g) on moving targets in the RA, LA, and LV. The
recorded CF profiles were compared to a repeat experiment whereby the operator
attempted to maintain the desired force of 20 g using manual catheter intervention. An
additional in vitro study was then performed to investigate CFC-assisted RF delivery to
moving tissue, achieved by modifying the linear motion stage (described in Chapter 2) with
a saline bath. CFC-assisted RF ablation lesions (set at different clinically relevant force
levels) were delivered to moving tissue samples and were compared to lesions in the
absence of motion. To compare to manual catheter intervention, a third set of RF lesions
to moving tissue without the assistance of the CFC were delivered. For both in vivo and in
vitro experiments, the CFC maintained an average force to within 1 g of the set level and
significantly reduced both the contact-force variability (CFV) and relative standard of
deviation (RSD). Specifically, in comparison to manual catheter intervention, CFCassisted ablation reduced the average CFV by a factor of 6.0 to less than 5 g and reduced
the average RSD by a factor of 2.5 to less than 30%. On average, the CFC reduced the
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standard deviation of CFV and RSD by a factor of 13.1 and 2.5, respectively. These results
reinforce the notion that CFC-assisted ablation delivery ensures a constant CF resulting in
more durable lesion delivery [1, 2]. Importantly, CFC-assisted ablation lesions were
reproducible in size despite the presence of randomly selected cardiorespiratory motion.
These lesions were statistically identical in size (depth and volume) to lesions delivered to
tissue absent of motion, indicating precise lesion delivery.
The CFC was then incorporated into a robotic platform enabling remote actuation of a
steerable sheath. The novel SSC-RNS was designed to allow for full-range manipulation
of a commercially available steerable sheath in 3-DOF (insertion, withdrawal, rotation, and
deflection). Using the incorporated CFC, the SSC-RNS also allows for remote
manipulation of the force-sensing ablation catheter through the sheath in 1-DOF (insertion
and withdrawal), further enabling catheter-tissue CF control. An intuitive input device,
designed around a repurposed steerable sheath handle fitted with embedded electronics,
allows for wireless remote control of the robotic system. This design approach allows the
operator to remotely navigate a catheter tip to target locations guided by an EAM system
and employ CF control on moving targets. The SSC-RNS was first evaluated using an
electromagnetic tracking system with sensors placed on the input unit and within the tip of
the remote steerable sheath. This first test demonstrated sub-millimetre insertion and
withdrawal error, a few degrees of rotational error, and negligible lag between the input
device and robotic system of the SSC-RNS. The SSC-RNS was then evaluated in vitro
using the linear motion stage (used in Chapter 2 and Chapter 3) modified to represent a
beating heart phantom. Under EAM guidance, a skilled operator first navigated a remote
catheter tip to several stationary and moving targets within the phantom. When engaging
with moving targets, the operator employed CF control (set at 15 g) using the interface
provided by the input device. Distances between the catheter tip and stationary target as
well as the CF profiles generated between the catheter tip and moving targets were recorded
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and compared to a repeated experiment using manual catheter intervention. Although
navigational tasks took longer to complete, the catheter tip was significantly closer to the
corresponding targets, demonstrating improved accuracy. Similar to the results obtained in
Chapter 2 and Chapter 3, the SSC-RNS with the incorporated CFC, significantly improved
the CF profile over manual catheter intervention.

5.2

Contributions

In current clinical practice, an EP would manipulate a catheter tip to a target and use the
force information strictly as a visual guide. To the best of their abilities, the operator would
make sure the catheter makes contact and does not exceed dangerous force levels. Whether
or not stable CF is achieved, the EP would then deliver an RF lesion. These lesions are less
safe, but more importantly, difficult to assess clinically – potentially increasing the risk of
leaving reconnection gaps deep into the tissue, which may lead to early AF recurrence. As
discussed in this thesis, the current tools and techniques available to the EP to address this
problem is limited.
The introduction of the CFC allows the operator to ensure that RF ablations are delivered
safely and prescribed for each application precisely, independent of its regional location in
the heart and extent of motion. The CFC is the first device to use the available force
information to implement a closed-loop system to enable CF control between the catheter
tip and moving tissue, eliminating the effects of cardiorespiratory motion on lesion
production. The CFC is also the first device to demonstrate the ability to deliver reliably
reproducible and precise ablation lesions in vitro. The CFC is the first tool to use robotic
technology to optimize point-point RF lesion production.
Clinically available robotic and magnetic navigation systems enable remote navigation of
an ablation catheter. This design mainly provides ancillary benefits such as reduced
fluoroscopic x-ray exposure and reduced operator fatigue. However, each of these systems
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has its list of shortcomings that are not present in manual catheter intervention. Importantly,
in the context of first-procedure success, none of these systems have demonstrated clear
superiority over the manual approach. It is suspected that this is the primary reason for the
lake of uptake of these systems into the clinic. Unless the benefits outweigh their
shortcomings, it will be difficult for hospitals to justify purchasing and adopting these
systems into clinical practice. Robotic systems for cardiac ablation therapy must limit their
trade-offs and take advantage of robotic technology to improve ablation efficacy by
implementing forms of automation.
The SSC-RNS is a promising example of such a system. The SSC-RNS uses of
conventional catheters and steerable sheaths permitting access to all anatomical regions of
the heart, preserve the natural hand-eye coordination of the operator by providing an
intuitive input device, and importantly, implements an automatic feature of closed-loop CF
control between the catheter tip and moving cardiac tissue. To this end, the SSC-RNS is
the only device of its kind, in the context of RF catheter ablation, that enables remote
catheter navigation with an autonomous catheter-tissue CF control. The SSC-RNS can be
a valuable tool available to the EP to optimize the placement and production of RF ablation
lesions, which can ultimately lead to improved first-procedure efficacy rates.

5.3

Future Research

Throughout this research project, several discussions with advisors, collaborators, and
physicians sparked ideas of further development and evaluation of the CFC and SSC-RNS.
Proposed research projects involving both robotic systems are described in detail in the
following sections.

5.3.1

Fully Automated Catheter Intervention

Implementing functional automation designed to allow for automatic movement of the
catheter to specific targets within the cardiac chamber under EAM guidance is the future
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direction for the SSC-RNS. The proposed added feature to the SSC-RNS would enable an
operator to select a target within the EAM system and employ the robotic system to
automatically guide the steerable sheath to point to the selected target and engage force
control. The input device to the SSC-RNS would be used for fine adjustment if necessary.
This implementation allows for fully automated catheter delivery of reliably transmural RF
ablation lesions.
Several robotic systems that allow for automatic catheter movements have been proposed
and evaluated in academia. Design and evaluation of the CathROB RNS is described by
Cercenelli et al. [3]. This system allows for remote navigation of an ablation catheter and
implements an automatic repositioning algorithm to guide the catheter to preselected and
memorized targets. It is assumed that this method actuates each DOF to the reference
position previously acquired. This method is highly susceptible to external factors,
including cardiac and patient motion, as well as a change in the position of the robot itself.
Importantly, this method assumes the catheter is a rigid body. Due to the flexibility and
compliance of the catheter, simply repositioning to a reference position will not reliably
result in a tip position identical to when the reference position was acquired. Loschak et al.
developed a more robust approach. The group developed a sophisticated 4-DOF RNS to
manipulate intracardiac echocardiography (ICE) catheters [4, 5]. Briefly, the system uses
an electromagnetic sensor to locate the position of the catheter tip and uses a kinematic
model of a catheter within the control loop to robotically guide an ICE catheter along the
pre-defined path [6, 7]. This solution enables closed-loop control of the catheter tip position
and the ultrasound imaging plane. Other catheter kinematic models to enable automatic
positioning of intracardiac catheters have been proposed [8, 9].
An automated version of the SSC-RNS would implement closed-loop control of the
catheter tip position by developing a control system incorporating a kinematic model of
the catheter and sheath. Since the sheath tip is (generally) not tracked by the EAM system,
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the kinematic model must be derived while the catheter tip is in a fixed position relative to
the sheath tip. For reliable control, this fixed position must be retained throughout
automated navigation.

Figure 5.1. Illustration of an EAM of the animal’s LA. The automated
SSC-RNS actuates the steerable sheath (not shown) to point the tip
towards one of six targets (white dots). The robotic system then advances
the catheter tip (green arrow) forward and employs the force controller.
Once an improved CF profile (green circle) is achieved, the final catheter
tip position can be acquired (red dot).

An in vivo study to evaluate automated SSC-RNS can be performed in a porcine model in
a similar approach described in Chapter 3. First, an adequate electro-anatomical map of a
pig’s LA is acquired (Figure 5.1) and registered correctly; a force-sensing ablation catheter
can then be introduced into the cardiac chamber. The catheter and sheath can then be loaded
into the SSC-RNS. Through the EAM, the EP can select the target location and the SSCRNS will automatically navigate the sheath to point towards each corresponding target.
The force controller with then advance the catheter forward, make initial contact with the
moving tissue, and maintain a set force level of 15 g.
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In comparison to the manual approach, we anticipate an improved accuracy and CF profile
using the automated SSC-RNS. Like the results obtained in Chapter 4, the catheter tip will
be closer to the corresponding target. Additionally, similar to the results obtained in
Chapter 2 and Chapter 3, the automated SSC-RNS will enable improved CF control and
reduction in CF variability. The SSC-RNS will allow the operator to engage targets
accurately and safely in a fully automated process.

5.3.2

Further In Vivo Evaluation of CFC Impact

To further investigate the CFC’s impact in lesion production, a series of additional in vivo
experiments are proposed. The following section first describes a more representative
method of performing in vivo evaluation for RF ablation experiments. This method will be
used to investigate how the CFC can be utilized within existing lesion assessment
techniques and emerging RF catheter technologies.

5.3.2.1

Thigh Muscle Preparation

In Chapter 3, the CFC was evaluated in vivo to examine its force control performance on a
beating heart. During these experiments, RF ablation lesions were delivered to moving
tissue with the CFC. These lesions were not quantified; instead, CFC-assisted lesion
production was investigated in vitro to control for other factors that would have had
unmeasurable influences on lesion production. The development of an RF-enabled
contractile motion phantom allowed for the delivery of ablation lesions into tissue
undergoing reproducible cardiorespiratory motion, while keeping other factors that
influence lesion production consistent. Unfortunately, the experimental set up did not
mimic blood and tissue temperature and did not model convective and perfusive cooling.
Furthermore, the salinity of the water bath within the phantom was titrated to enable the
generation of measurable lesions at the clinically relevant CF levels, RF duration, and RF
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power. Thus, lesion production using this model does not directly reflect lesion production
in humans.
Typically, a thigh muscle preparation using a porcine or canine model is used in such RF
ablation experiments [10-15]. In comparison to cardiac tissue, a thigh model is a reasonable
technique for evaluation of ablation catheter technology [16] (Figure 5.2). In this setup, an
incision is made within the thigh of the animal, and a thick portion of the femoris muscle
is exposed. The skin is raised to form a chamber overlying the thigh muscle. Arterial blood
is collected from the femoral artery, heparinized, heated to 37°C, and circulated through
an external pump (flow rate of 200 ml/min) introduced over the exposed muscle within the
cavity of the femoral chamber. The linear motion stage, which was used extensively and
modified throughout this thesis, can be fitted to the leg of the animal and employ
cardiorespiratory motion profiles, resulting in motion of the thigh muscle. A lesion
protocol, such as the protocol described in Chapter 3, can then be performed to the thigh
muscle; motion can be introduced by merely engaging the linear motion stage. After each
RF application, the catheter is moved to a new position along the muscle, the femoral
chamber is emptied, and new heated heparinized blood is introduced. The thigh muscles
can be harvested and placed in formaldehyde and stained with 2% triphenyl tetrazolium
chloride in phosphate-buffered saline, which is used to differentiate the necrotic tissue from
the untreated tissue accurately. Lesion measurement and statistical analysis can follow.
The thigh muscle preparation technique is a widely used and acceptable method for RF
ablation experiments. Studies that adopt this experimental setup is considered to be more
representative of lesion delivery in human. Several proposed studies, described in the
following sections, should be performed using this technique to further evaluate the CFC
and its effect on RF lesion production.
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Figure 5.2. Illustration of thigh muscle preparation. Arterial blood,
collected from the animal, is heparinized and pumped through a heat
exchanger which is submerged in a water bath heated for 37°C. The
blood is pumped over the femoris muscle within the chamber. A linear
motion stage, attached to the leg of the animal, moves the femoris muscle
resulting in cardiorespiratory motion. Illustrated was adapted from
Leshem et al. [16].

5.3.2.2

Force-Time Integral Prescribed Ablation

Force-Time Integral (FTI), defined as the area under the CF curve with respect to time
(represented in gs), is a real-time lesion assessment tool and is commonly used during RF
ablation therapy (Figure 5.3). In the original study that introduced this metric, performed
by Shah et al. [17], the group demonstrates that during a 60-second RF application (at fixed
RF power and irrigation), the highest FTI occurred when CF remained constant, which
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resulted in the largest and deepest lesions. However, this study did not attempt to examine
whether FTI-prescribed lesion production is dependent on CF variability. In clinical
practice, the intended use of FTI primarily involves stopping the RF application when the
appropriate amount of FTI is accumulated. The value is then automatically annotated
within the EAM system at each corresponding ablation point, which can be referenced and
evaluated throughout the procedure. Generally, the EP does not take into account CF
variability during FTI-prescribed RF application. In other words, it is unknown whether or
not lesion size may vary with different CF profiles (average and variability), despite
maintaining a constant FTI.

Figure 5.3. A representative example of a CF profile with 725 gs of FTI,
indicated by the area under the CF curve with respect to time.

One study that demonstrates the importance of CF variability in the context of FTI is the
work done by Ullah et al. [18]. The group demonstrated that with the same FTI, the
presence of CF variability (greater than 5 g) is associated with lower impedance drop,
which is a surrogate for poor lesion production. This study suggests that there is a profound
negative impact of CF variability even when FTI remains the same. The authors suggest
that EPs should actively improve CF variability rather than delivering more FTI. Other
than this work, there is no published data describing the role of CF variability in lesion
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production in the context of FTI. To this end, we propose an additional in vivo study to
evaluate the effect of CF variability on FTI-prescribed lesion production.

Figure 5.4. Representative CF profiles on moving tissue with
approximately 600 gs FTI. A illustrates a CF profile caused by typical
cardiorespiratory motion, B is a CF profile extracted from RF ablation
during patient treatment, and C illustrates intermittent contact.

Figure 5.5. Simulated CF profiles during CFC-assisted intervention
when the CFC is set to deliver 600 gs FTI at 10 g, 25 g, and 40 g set force
levels, A to C respectively. Note: achieving 600 gs FTI with low set force
level (10 g A) requires a longer lesion duration (over 60 s), and viceversa (C: 40 g over 15 s).

Using the aforementioned thigh muscle preparation, sets of ablation lesions (similarly to
the protocol described in Chapter 3) can be delivered with and without the CFC. All RF
applications will accumulate a total of 600 gs FTI, which can be programmed into the CFC
to automatically retract the catheter once a set FTI is reached, Figure 2.10. Representative
examples of 600-gs CF profiles using the manual approach and assisted by the CFC is
illustrated in Figure 5.4 and Figure 5.5, respectively.
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Although all lesions will be delivered with 600 gs, we suspect a variation in lesion sizes
using the manual approach, as suggested by Ullah et al. [18]. Specifically, we anticipate a
severe drop in lesion size in the presence of intermittent contact (Figure 5.4C). We also
suspect that 600-gs CFC-assisted intervention will results in the reproducible lesion size,
regardless of the presence of cardiorespiratory motion. Lastly, we hypothesize that 600-gs
CFC-assisted lesions delivered with a higher set force will yield deeper lesions versus CFCassisted lesions set at a lower force.
The results of this experiment would further demonstrate the importance of maintaining
reduced variability in CF during RF application. Although there is an abundance of clinical
data that suggest that CF variability is a crucial element to lesion production, there are no
studies to date that show the importance of CF variability in lesion production in the context
of FTI. Although FTI is a useful marker for lesion assessment, it may not tell the full story.

5.3.2.3

Catheter Stability Under Contact-Force Control

Maintaining spatiotemporal stability is critical for efficient transfer of RF energy into the
tissue, resulting in a deeper, more durable RF ablation lesion. In the clinic, the stability of
the catheter in relation to its target is affected by applied forces to the tip of the catheter,
primarily caused by cardiorespiratory tissue motion. This results in the catheter sliding
along the endocardium dispersing RF energy over a wider area, as illustrated in Figure 5.6.
Increased catheter drift is associated with reduced ablation efficacy [18]. Specifically,
catheter drift of less than 3.5 mm is associated with a higher impedance drop, even if FTI
remains constant. A 300-gs lesion with less than 3.5 mm drift has the same impedance drop
in comparison to a 500-gs lesion with greater than 3.5 mm drift. Furthermore, FTI levels
greater than 400 gs did not significantly increase the impedance drop if catheter drift
exceeded 3.5 mm. However, a stable catheter tip showed a strong correlation between
impedance drop and FTI levels up to 900 gs. Therefore, the authors suggest that achieving
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more efficacy lesion production is ensuring greater spatiotemporal stability, rather than just
ablate to a higher FTI.

Figure 5.6. Cardiorespiratory tissue motion (indicated in yellow) causes
the catheter tip to slide along the surface of the endocardium (indicated
in purple). This results in a linear but shallow ablation lesion. This effect
may depend on the catheter-tissue incident angle, θ.

The CFC enables CF control by adjusting the catheter within the sheath by reacting to the
same applied external forces that cause catheter drift (cardiorespiratory motion). This
suggests that the CFC may have an impact on catheter tip stability. In our original CFC
studies (Chapter 2 and Chapter 3), CF control was of primary focus and catheter drift was
not evaluated. To this end, we propose an additional in vivo study to evaluate if using the
CFC will improve spatiotemporal stability.
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The clinical techniques to measure catheter drift, performed by Ullah et al. [18], can be
adopted in vivo within a thigh muscle preparation. Illustrated in Figure 5.7, a mapping
catheter can be introduced and suspended in the blood pool within femoral chamber
ensuring its position is not compromised by the moving tissue – this catheter will be used
as the reference position for accurate calculation of catheter drift. Several sets of RF
applications can be delivered to the tissue at different force levels and catheter-tissue
incident angles. The coordinates of the tip of both ablation and mapping catheters can be
recorded by the EAM system, which will be used to calculate the maximum relative drift.
Statistical analysis will determine if using the CFC provides improved spatiotemporal
stability over the manual approach and if either the set force level or incidence angle is
significant.

Figure 5.7. A secondary mapping catheter (in the form of a lasso),
affixed to ensure it is not influenced by tissue motion (yellow), is used
to track (green) the position of the RF electrode tip of the ablation
catheter. The maximum catheter drift (purple) can be then determined.
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It is hypothesized that CF control of the catheter tip will enhance spatiotemporal stability
of the catheter tip. Therefore, the CFC-assisted ablation will likely improve spatiotemporal
stability over the manual approach. The results from this experiment may suggest that
CFC-assisted intervention may provide ancillary benefit in improving RF lesion
production.

5.3.2.4

High-Power Short-Duration Ablation

Assessment of RF lesion production is a combination of CF, power, and duration. To this
end, emerging RF catheter ablation techniques include delivering high-power RF energy
(70-90 W) into the cardiac tissue for a short duration (4-8 seconds). The potential benefit
of high-power short-duration (HPSD) ablation is to reduce the effects of lesion-to-lesion
variability and catheter instability that cause partial-thickness lesion production. HPSD
ablation results in improved linear continuity, shorter ablation time, and a safety profile
comparable to conventional ablation. The less time the catheter is engaged with the tissue
during an RF application, the less potential variability in lesion production.

Figure 5.8. Overlay view of line drawings illustrating lesion geometries
resulting from different RF lesion settings: 30 W 30 s (red), 50 W 13 s
(purple), 60 W 10 s (green), 70 W 7 s (blue). The image was adapted
from the original paper, published by Bourier et al. [19].

In comparison to standard RF ablation settings (20-35 W for 30-60 seconds), HPSD
ablation results in similar lesion volumes but significantly different lesion geometries [19].
Illustrated in Figure 5.8, these lesions are generally shallower and with a larger diameter,
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which may contribute to the better encirclement of PVs by reducing gaps between adjacent
lesions and may suitable for PVI.
Successful ablation using HPSD application has been shown porcine models undergoing
PVI [20-23]. In one study, HPSD applications were delivered with 90 W for 4 seconds with
an average CF of 14 g ± 2.6 g, while maintaining an optimal CF range between 10 g and
20 g [20], resulting in successful ablation with no steam pops or adverse effects. In contrast,
in a different study, HPSD ablations were delivered in swine using the same ablation
settings and did experience steam pops [21]. In these events, HPSD applications delivered
in the right side of the heart had an average CF between 40 g and 60 g, causing an audible
steam pop within 3 seconds of RF application. Another group reported that achieving the
desired CF was of prime priority and maintained CF of 10.3 ± 1.4 g [23]. Nonetheless, the
group incurred steam pops in 11% of HPSD applications with settings of 80 W for 5
seconds. These preclinical studies suggest implications for HPSD in treating human
patients, primarily, that EPs would need to maintain and follow stringent CF guidelines.
However, as discussed in detail in the Introduction section of this thesis, EPs do not have
sufficient tools and techniques to maintain a stable CF and regularly exceed force levels
well beyond 40 g along a 4-second window. These studies also reported a range of lesion
depths between 1 mm and 8 mm, analyzed over hundreds of HPSD applications [21, 22].
Importantly the variability of lesion depths achieved in HPSD applications is comparable
to lesions delivered using standard RF settings. In an editorial written by Patel and
Padanilam [24], they report that large standard deviations in HPSD lesion sizes may result
in the same problems associated with conventional ablation therapy. Specifically, each
lesion should be sized for a particular anatomical site – meaning – shallow lesions should
be delivered to thin tissue, and deep lesions should be delivered to thick tissue. “The search
for the perfect burn must continue.” The results obtained in this thesis, specifically to the
CFC, suggests that this technology may assist in HPSD ablation techniques.
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No results have been reported, investigating CF variability in HPSD lesion production.
However, it is evident that CF variability plays a significant role in the successful delivery
of these lesions. To this end, we propose a final in vivo experiment to further investigate
CF control and its impact on HPSD lesion production. Using a thigh preparation, several
HPSD ablation sets can be delivered to moving tissue with and without the assistance of
the CFC. Discussed in detail in the previous sections, similar ablation parameters, lesion
measurement and analysis protocols can be followed to determine if CF variability plays a
significant role in HPSD application and if the incorporation of the CFC provides a solution
to ensuring reliable delivery of these lesions.

5.3.3

Clinical Evaluation of the CFC

The overarching goal to introduce the CFC to the clinic and perform the first-in-human
clinical evaluation. The purpose of the first trial is to demonstrate the safety and efficacy
of the CFC. A similar experimental protocol, outlined in Chapter 3 in vivo experiments,
will be followed. The tip of a force-sensing ablation catheter guided with a steerable sheath
will be navigated to targets in the RA. The CFC will then be employed at different set force
levels typically desired for RA ablation strategies. CF profiles will be recorded and
compared to the manual approach. In this first low-risk clinical trial, no RF applications
will be delivered. Additional data including spatiotemporal stability will be collected to
demonstrate the improved performance provided by the CFC.
To evaluate the CFC in a clinical setting, an authorization to perform investigational testing
(issued by Health Canada) is required. Acquiring approval includes demonstrating safety
and efficacy through extensive in vitro and in vivo experimentation. The preliminary data
collected in this thesis provides a strong foundation to aid in this application. The additional
preclinical experiments, proposed and outlined in the previous section, will provide further
validation demonstrating that the device is safe and effective in maintaining a stable CF
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between the catheter tip and moving tissue. These data will help meet the regulatory
requirements to secure authorization and bring the CFC technology to clinical evaluation.
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CFC Motor Requirements: Velocity, Acceleration, and Torque

It is critical that the motor used in the CFC can exceed peak speed and acceleration of
endocardial tissue. An abundant amount of information relating to this subject is available
in the literature [1-5]. Myocardial velocities have been shown – using tissue Doppler
imaging – not to exceed 10 cm/s, with less than 1000 cm/s2.

In addition to existing literature, I analyzed hundreds of contact-force profiles recorded
during RF ablation in patients. These profiles were converted to position profiles based on
Hooke’s law. Specifically, the force profiles were empirically scaled down until the
systolo-diastolic displacement matches those measured in human, typically between 3-6
mm peak-to-peak [6, 7]. The final “scaling” provided a conversion of 30 g to 1 cm. The
derivative and second-derivatives provided velocity and acceleration profiles. A
representative example is provided above; maximum displacement (top), velocity
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(middle), and acceleration (bottom) are similar to the ones reported in the literature. These
figures roughly provide maximum velocities and acceleration of tissue motion, and not
necessarily true minimum requirements for the motor. The velocity/acceleration
requirements for the motor should also consider the compliance of the catheter through the
sheath (as it is not entirely rigid). The motor selected and used in this thesis has a maximum
velocity of 230 cm/s and acceleration of 6570 cm/s2 exceeding the requirements
determined above.
For easy movement through the sheath, the motor must have torque capacity that
overcomes the friction between the catheter and hemostatic seal and between the catheter
shaft and the sheath itself. I used the setup, shown below, to measure the friction that must
be overcome between the catheter and sheath components.

In this experiment, a strain gauge was fixed to a linear carriage which glides along a rail.
The linear position of the carriage is detected using an encoder coupled to a rack and pinion
mechanism. The carriage was moved back and forth rapidly, and the friction and velocity
of the carriage were recorded by a microcontroller electronics system (not shown). Data
were recorded while the sheath was in the neutral position (not deflected) as well as
deflected to approximately 120°, illustrated below.
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With the sheath in the neutral position, the amount of force required to move the catheter
through the sheath did not exceed 250 g, illustrated below. While the sheath was deflected,
the amount of force increased to 400 g. If the sheath is fully deflected to a maximum of
180° (not likely used in clinic), the required force can climb to 550 g. The amount of force
required to translate the catheter through the sheath far exceeds the amount of force the
catheter pushes onto the tissue (less 40 g).
In the clinic, physiological 0.9% saline is introduced into the irrigation port of the steerable
sheath to provide passive irrigation to reduce the friction between the catheter and sheath.
The above experiment was performed with this condition as well as repeated in the absence
of any lubrication. In dry conditions, the maximum force increased by an additional 40 g.
This was performed to ensure that the selected motor of the CFC can withstand the highest
friction possible.

C.

CFC Control Systems

The CFC was integrated with a commercially available electro-anatomical catheter
mapping system (CARTO® 3, Biosense Webster, Irvine, CA) to receive real-time force
information from the tip of a force-sensing ablation catheter (THERMOCOOL®
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SMARTTOUCH™, Biosense Webster, Irvine, CA). A local area network connection was
used to establish communication between the mapping and CFC systems. Significant
degradation in the measurement of real-time CF (i.e. slow 20 Hz sampling rate, long timedelay, noise, et cetera) was discovered. Because of this, two control systems were
developed to provide compensation for a wide variety of variations in CF caused by cardiac
and respiratory tissue motion, or patient and catheter motion.
The following sections briefly describe two control systems used in the CFC system. The
adaptive and repetitive control systems were first implemented in MATLAB Simulink
(Mathworks, Natick, MA) and their response to changes in CF was evaluated in a simulated
environment. I implemented both control systems in the electronic hardware of the CFC as
software code processed on an ARM-based microcontroller (Arduino Due, Arduino, Turin,
Italy).

Adaptive Control System
The model reference adaptive control (MRAC) system is a direct adaptive strategy that
uses an adjustment mechanism to adjust the response of the controller [8]. In comparison
to standard simple-structured fixed-gain controllers, such as the proportional-integralderivative (PID) controllers, adaptive controllers are very useful in handling the unknown
variations in parameters and environmental changes (e.g. change in catheter angle, tissue
compliance, deflection of sheath tip).
The MRAC, illustrated in the block diagram below, consists of two loops, a standard
feedback loop and parameter adjustment loop. The adjustment mechanism uses the
constant gain to reduce the cost function to zero in an iterative process. This strategy works
on the principle of adjusting the controller parameters so that the output of the system plant
(measured force), P(s), tracks the output of a reference model, R(s), having the same
reference input (desired force). The reference input is first filtered by a low-pass filter, S(s).
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An adjustment mechanism uses a learning rate, γ, to reduce the cost function to zero. The
controller, C(s), takes the form of a standard integral (I) controller and generates a control
signal which is sent to the linear motor of the force controller. All models were
implemented as discrete-time transfer functions as software code on the microcontrollerbased electronic system of the CFC.

Through simulation, the MRAC was found to be an adequate controller to compensate for
gradual disturbances in CF changes, such as those caused by respiration, patient and
catheter motion. Additionally, this strategy is stable and does not increase the amplitude of
higher frequency components (i.e. cardiac motion); a common problem associated with
poorly sampled feedback closed-loop systems using standard PID controllers. The MRAC
strategy provides no attempt to compensate for changes in cardiac motion.

Repetitive Control System
To compensate for substantial variation in CF caused by the systolo-diastolic motion of the
heart, a repetitive control strategy was also implemented. The repetitive strategy is based
on a Smith predictor, which is a predictive controller commonly used for systems with
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significant time delay in the control loop [9, 10]. A Smith predictor is an appropriate
solution for processes that have a dead-time (or time-delay) longer than the time constant,
making it suitable for our force-control application, where the time constant is small
(measured to be less than 35 ms).
A standard Smith predictor alone cannot compensate for large rapid fluctuations in CF. To
address this, the standard Smith predictor was modified to enable repetitive control
designed to reject periodic disturbances [11]. Illustrated in the block diagram below, the
modified Smith predictor uses an added block to further delay the control loop by an
appropriate amount in order to synchronize the feedback loop with the periodic
disturbance. The known heart rate and modelled time-delay in the force sensor of the forcesensing ablation catheter are used to determine the additional delay required; this also can
be used to eliminate CF variation caused by respiration. In the current implementation, the
operator dials-in the desired frequency in beats per minute to eliminate CF fluctuations
caused by cardiac motion, or, breaths-per-minute to eliminate respiratory motion.

The modified Smith predictor, illustrated above, generates a control signal to the linear
motor based on the controller, C(s), which takes the form of a proportional-integral (PI)
controller. This is based on the difference between the feedback measured force signal and
the desired force, which is filtered by a low-pass filtered, S(s). A delay-less model of the
plant, Pm(s), is a second-order transfer function modelling the real system plant, P(s), to
predict the force measurement ahead of time. The force sensor delay is estimated, and the

Appendix C

150

amount of extra delay (shown in red) needed to synchronize the force controller with
periodic disturbance (cardiac or respiratory) is calculated by subtracting the estimated
delay from the period of the disturbance. All models were implemented as discrete-time
transfer functions as software code on the microcontroller-based electronic system of the
CFC.
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Comparison of Force Control: In Vitro to Simulation

The block diagram of the repetitive control loop illustrated in Appendix C (Repetitive
Control System) was implemented in MATLAB Simulink (Mathworks, Natick, MA) to
simulate the force control response of the SSC-RNS. A representative example comparing
a robotically assisted force control experiment performed in vitro with its simulation is
illustrated below.

The SSC-RNS employed force control on the 17.5-second mark. For this example, the
linear motion stage of the phantom was set to execute cardiac motion at 80 BPM and
respiratory motion at 20 BPM with a 3:8 amplitude ratio. The motion was prescribed as the
disturbance profile within the block diagram of the control loop (Appendix C, Repetitive
Control System, added to the output of the plant, P(s)). To compensate for the dominant
respiratory component, the SSC-RNS was set to respiratory gating, which synchronized
the controller by further delaying the control loop by approximately one respiratory cycles
period (20 BPM or 3 seconds). Respiratory gating was simulated by setting the extra delay
with the control loop (Appendix C, Repetitive Control System, extra delay block in red) to
the same amount. The measured CF profile and its simulated response demonstrated
complete elimination of the large swings in force caused by respiration. In comparison to
the simulation, the measured response demonstrated a slightly better CF control
performance in vitro.

153

Appendices

References
[1]

L. Thomas, K. Levett, A. Boyd, D. Y. Leung, N. B. Schiller, and D. L. Ross,
"Changes in regional left atrial function with aging: evaluation by Doppler tissue
imaging," Eur J Echocardiogr, vol. 4, no. 2, pp. 92-100, 2003

[2]

M. Duytschaever et al., "Transthoracic tissue Doppler imaging of the atria: a novel
method to determine the atrial fibrillation cycle length," J Cardiovasc
Electrophysiol, vol. 17, no. 11, pp. 1202-9, 2006

[3]

I. Limantoro et al., "Clinical correlates of echocardiographic tissue velocity
imaging abnormalities of the left atrial wall during atrial fibrillation," Europace,
vol. 16, no. 11, pp. 1546-53, 2014

[4]

N. Yoshida, M. Okamoto, and T. Fukuhara, "Left atrial wall motion velocity
measured by the velocity profile method with tissue Doppler echocardiography in
normal subjects: its relation to aging," J Med Ultrason (2001), vol. 31, no. 3, pp.
103-9, 2004

[5]

K. Mori, Y. Hayabuchi, Y. Kuroda, M. Nii, and T. Manabe, "Left ventricular wall
motion velocities in healthy children measured by pulsed wave Doppler tissue
echocardiography: normal values and relation to age and heart rate," J Am Soc
Echocardiogr, vol. 13, no. 11, pp. 1002-11, 2000

[6]

H. Skulstad et al., "Grading of myocardial dysfunction by tissue Doppler
echocardiography: a comparison between velocity, displacement, and strain
imaging in acute ischemia," J Am Coll Cardiol, vol. 47, no. 8, pp. 1672-82, 2006

[7]

A. Manouras et al., "Are measurements of systolic myocardial velocities and
displacement with colour and spectral Tissue Doppler compatible?," Cardiovasc
Ultrasound, vol. 7, p. 29, 2009

[8]

P. Jain and M. J. Nigam, "Design of a Model Reference Adaptive Controller Using
Modifited MIT Rule for a Second Order System," Advance in Electronic and
Electric Engineering, vol. 3, no. 4, pp. 477-484, 2013

[9]

O. J. M. Smith, "Closed Control of Loops with Dead Time," Chemical Engineering
Process, 1957

[10]

A. Ingimundarson and T. Hägglund, "Robust tuning procedures of dead-time
compensating controllers," Control Engineering Practice, vol. 9, no. 11, pp. 11951208, 2001

[11]

W. Qing-Guo, Z. Han-Qin, Y. Yong-Sheng, Z. Yong, and Z. Yu, "Modified Smith
predictor design for periodic disturbance rejection," in Asian Control Conference,
2004, vol. 2: IEEE, pp. 1145-50.

Curriculum Vitae

DANIEL GELMAN, PH.D

Robarts Research Institute
University of Western Ontario
1151 Richmond St. North
London, ON, Canada
N6A 5B7

EDUCATION
Doctor of Philosophy Candidate, School of Biomedical Engineering
Sept. 2012
Present

Sept. 2007
Apr. 2012

University of Western Ontario, London, ON, Canada
Supervisor: Maria Drangova, Ph.D.
Thesis: Remote Navigation and Contact-Force Control of Radiofrequency Ablation
Catheters

Bachelor of Engineering, Electrical and Biomedical Engineering
McMaster University, Hamilton, ON, Canada
Supervisor: Hubert de Bruin, Ph.D., P.Eng.
Thesis: Responsive EMG Static Progressive Knee Split

WORK EXPERIENCE
May 2017
Present

Aufero Medical Technologies, Inc.
President & CEO

May 2017
Aug. 2018

Electronics Design Engineer
Archetype Medical

Sept. 2015
Dec. 2015

Mechatronic Systems Engineer
Robarts Research Institute

May 2012
Sept. 2012

Instrumentation Control Systems Engineer
Brockhouse Institute for Materials Research

155

Curriculum Vitae

PUBLICATIONS & CONFERENCES
Refereed Journal Manuscripts
1. Gelman D, Skanes AC, Drangova M, "Remote Catheter Navigation and ContactForce Control: Design and Evaluation of a Novel Steerable Sheath and Catheter
Robotic Navigation System," IEEE Trans Biomed Eng, 2019. (In Preparation)
2. Gelman D, Skanes AC, Jones DL, Timofeyev M, Baron T, Drangova M,
"Eliminating the Effects of Motion during Radiofrequency Lesion Delivery using
a Novel Contact-Force Controller," J Cardiovasc Electrophysiol, 2019. (Accepted)
3. Gelman D, Skanes AC, Tavallaei MA, Drangova M, "Design and Evaluation of a
Catheter Contact-Force Controller for Cardiac Ablation Therapy," IEEE Trans
Biomed Eng, vol. 63, no. 11, pp. 2301-7, 2016.
4. Tavallaei MA, Gelman D, Lavdas MK, Skanes AC, Jones DL, Bax JS, Drangova
M, "Design, development and evaluation of a compact telerobotic catheter
navigation system," Int J Med Robot, vol. 12, no. 3, pp. 442-52, 2015.
5. Tavallaei MA, Lavdas MK, Gelman D, Drangova M, "Magnetic resonance
imaging compatible remote catheter navigation system with 3 degrees of freedom",
Int J Comput Assist Radiol Surg, vol. 11, no. 8, pp. 1537-45, 2015.
Peer-Reviewed Published Conference Abstracts
1. Gelman D, Skanes AC, Jones DL, Drangova M, "Catheter Contact-Force Control
during Cardiac Ablation Therapy: In Vivo Evaluation," Cardiac Arrhythmia
Network of Canada, Halifax, NS, Canada, 2017.
2. Gelman D, Skanes AC, Jones DL, Drangova M, "Catheter Contact-Force Control
during Cardiac Ablation Therapy: In Vivo Evaluation," Imaging Network of
Ontario, London, ON, Canada, 2017.
3. Gelman D, Skanes AC, Jones DL, Drangova M, " Catheter Contact-Force Control
during Cardiac Ablation Therapy: In Vivo Evaluation," London Health Research
Day, London, ON, Canada, 2017.
4. Tavallaei MA, Lavdas MK, Gelman D, Drangova M, "MRI-Compatible Remote
Catheter Navigation System", iMRI 2016, Baltimore, MD, USA, 2016.
5. Gelman D, Skanes AC, Tavallaei MA, Drangova M, "Catheter Contact-Force
Control during Cardiac Ablation Therapy: In Vitro Evaluation," Heart Rhythm, San
Fransico, CA, USA, 2016.
6. Gelman D, Skanes AC, Tavallaei MA, Drangova M, "Design and Evaluation of a
Catheter Contact-Force Controller for Cardiac Ablation Therapy," Imaging
Network of Ontario, Toronto, ON, Canada, 2016.
7. Tavallaei MA, Lavdas MK, Gelman D, Drangova M, "MRI-Compatible Remote
Catheter Navigation System with 3-Degrees-of-Freedom", Imaging Network of
Ontario, Toronto, ON, Canada, 2016.

Curriculum Vitae

156

8. Gelman D, Skanes AC, Tavallaei MA, Drangova M, "Design and Evaluation of a
Catheter Contact-Force Controller for Cardiac Ablation Therapy," London Health
Research Day, London, ON, Canada, 2016.
9. Gelman D, Lavdas MK, Drangova M, "Real-Time Three Degree-of-Freedom
Measurement of Catheter Motion for Input to a Robotic Catheter Navigation
System," IUPESM: World Congress of Medical Physics and Biomedical
Engineering, Toronto, ON, Canada, 2015.
10. Gelman D, Lavdas MK, Drangova M, "An Instinctive 3-Degree-of-Freedom
Master-Side Input Device to a Robotic Catheter Navigation System", Imaging
Network of Ontario, London, ON, Canada, 2015.
11. Tavallaei MA, Gelman D, Lavdas MK, Skanes AC, Jones DL, Drangova M,
"Design, Development and in vivo Evaluation of a Remote Catheter Navigation
System with 3-Degrees-of-Freedom", Imaging Network of Ontario, Toronto, ON,
Canada, 2015.
12. Gelman D, Tavallaei MA, Drangova M, "Towards Semi-Autonomous Remote
Cardiac Catheter Navigation," London Health Research Day, London, ON,
Canada, 2014.
Peer-Reviewed Oral Presentations (*presenting author)
1. Gelman D*, Skanes AC, Jones DL, Drangova M, "Catheter Contact-Force Control
for Cardiac Ablation Therapy," Society of Cardiac Robotic Navigation, Chicago,
IL, USA, 2017.
2. Gelman D*, Skanes AC, Jones DL, Drangova M, "Catheter Contact-Force Control
during Cardiac Ablation Therapy: In Vivo Evaluation," Imaging Network of
Ontario, London, ON, Canada, 2017.
3. Gelman D*, Skanes AC, Tavallaei MA, Drangova M, "Catheter Contact-Force
Control during Cardiac Ablation Therapy: In Vitro Evaluation," Cardiac
Arrhythmia Network of Canada, Calgary, AB, Canada, 2016.
4. Tavallaei MA, Lavdas MK, Gelman D*, Drangova M, "MRI-Compatible Remote
Catheter Navigation System with 3-Degrees-of-Freedom", Imaging Network of
Ontario, Toronto, ON, Canada, 2016.
5. Gelman D*, Lavdas MK, Drangova M, "Real-Time Three Degree-of-Freedom
Measurement of Catheter Motion for Input to a Robotic Catheter Navigation
System," IUPESM: World Congress of Medical Physics and Biomedical
Engineering, Toronto, ON, Canada, 2015.
6. Tavallaei MA*, Gelman D, Lavdas MK, Skanes AC, Jones DL, Drangova M,
"Design, Development and in vivo Evaluation of a Remote Catheter Navigation
System with 3-Degrees-of-Freedom", Imaging Network of Ontario, Toronto, ON,
Canada, 2015.

157

Curriculum Vitae

Peer-Reviewed Poster Presentations (*presenting author)
1. Gelman D*, Skanes AC, Jones DL, Drangova M, "Catheter Contact-Force Control
during Cardiac Ablation Therapy: In Vivo Evaluation," Cardiac Arrhythmia
Network of Canada, Halifax, NS, Canada, 2017.
2. Gelman D*, Skanes AC, Jones DL, Drangova M, " Catheter Contact-Force Control
during Cardiac Ablation Therapy: In Vivo Evaluation," London Health Research
Day, London, ON, Canada, 2017.
3. Gelman D*, Skanes AC, Tavallaei MA, Drangova M, "Catheter Contact-Force
Control during Cardiac Ablation Therapy: In Vitro Evaluation," Cardiac
Arrhythmia Network of Canada, Calgary, AB, Canada, 2016.
4. Gelman D*, Skanes AC, Tavallaei MA, Drangova M, "Catheter Contact-Force
Control during Cardiac Ablation Therapy: In Vitro Evaluation," Heart Rhythm, San
Francisco, CA, USA, 2016.
5. Gelman D*, Skanes AC, Tavallaei MA, Drangova M, "Catheter Contact-Force
Control during Cardiac Ablation Therapy: In Vitro Evaluation," Imaging Network
of Ontario, Toronto, ON, Canada, 2016.
6. Gelman D*, Skanes AC, Tavallaei MA, Drangova M, "Catheter Contact-Force
Control during Cardiac Ablation Therapy: In Vitro Evaluation," London Health
Research Day, London, ON, Canada, 2016.
7. Gelman D*, Lavdas MK, Drangova M, "An Instinctive 3-Degree-of-Freedom
Master-Side Input Device to a Robotic Catheter Navigation System", Imaging
Network of Ontario, London, ON, Canada, 2015.
8. Tavallaei MA*, Gelman D, Lavdas MK, Skanes AC, Jones DL, Drangova M,
"Design, Development and in vivo Evaluation of a Remote Catheter Navigation
System with 3-Degrees-of-Freedom", Imaging Network of Ontario, Toronto, ON,
Canada, 2015.
9. Gelman D*, Tavallaei MA, Drangova M, "Towards Semi-Autonomous Remote
Cardiac Catheter Navigation," London Health Research Day, London, ON,
Canada, 2014.

GRADUATE TEACHING ASSISTANTSHIP
University of Western Ontario, London, ON, Canada
Introduction to Electrical Instrumentation (MSE2201)
Mechatronics Engineering
Electrical Circuits and Electromechanics (ECE2274)
Electrical and Computer Engineering
Introduction to Medical Imaging (BME9513)
Biomedical Engineering

Curriculum Vitae

158

Introduction to Electronics for Mechanical Engineering (ECE3374)
Electrical and Computer Engineering
Programming Fundamentals for Engineers (ES1036)
Engineering Science
Introductory Engineering Design and Innovation Studio (ES1050)
Engineering Science

GRANTS
Commercialization Grant – $300,000
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CANet Annual Scientific Meeting.
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Catheter Contact-Force Control Device
National Phase Submission
CA3013270A
US16/074,753
EP17746678.6A
CN201780020658.0A
JP2018558456A

Feb. 2017

Catheter Contact-Force Control Device
PCT Application
PCT/CA2017/050119

Feb. 2016

Catheter Contact-Force Control Device
US Provisional
US62/290,243

TECHNOLOGY TRANSFER
July 2018

Licensing Agreement; Catheter Contact-Force Control
Aufero Medical

May 2017

Aufero Medical Technologies, Inc.
Incorporation

